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Abstract	  	   The	  dermonecrotic	  toxin	  family	  consists	  of	  the	  dermonecrotic	  toxin	  from	  
Bordetella	  spp.	  (DNT),	  the	  cytotoxic	  necrotizing	  factors	  from	  Escherichia	  coli	  (CNF1,	  CNF2	  and	  CNF3)	  and	  Yersinia	  pseudotuberculosis	  (CNFY),	  and	  the	  mitogenic	  toxin	  from	  Pasteurella	  multocida	  (PMT).	  These	  relatively	  large	  (100-­‐160	  kDa),	  single	  polypeptide	  protein	  toxins	  share	  some	  regions	  of	  homology	  with	  one	  another	  in	  their	  protein	  sequence,	  which	  may	  account	  for	  some	  of	  their	  similar	  biological	  activities.	  Though	  much	  effort	  has	  been	  directed	  toward	  understanding	  the	  mode	  of	  toxin	  entry	  and	  their	  molecular	  determinants,	  we	  still	  lack	  sufficient	  evidence	  to	  fully	  comprehend	  the	  intoxication	  process.	  The	  focus	  of	  this	  thesis	  is	  therefore	  to	  address	  two	  major	  aspects	  of	  the	  toxin’s	  mode	  of	  action:	  (1)	  The	  involvement	  of	  the	  dermonecrotic	  toxin	  in	  adipogenesis	  and	  the	  effects	  on	  adipocyte	  differentiation,	  and	  (2)	  PMT-­‐mediated	  delivery	  of	  its	  cargo.	  In	  this	  work	  we	  demonstrate	  the	  involvement	  of	  dermonecrotic	  toxins	  in	  adipogenesis.	  We	  show	  that	  treatment	  with	  any	  one	  of	  the	  dermonecrotic	  toxins	  blocked	  adipogenesis	  and	  inhibited	  adipocyte	  differentiation	  through	  Rho/ROCK-­‐dependent	  pathway,	  suggesting	  an	  important	  role	  of	  the	  Rho/ROCK	  pathway	  in	  the	  regulation	  of	  adipocyte	  differentiation	  and	  adipogenesis.	  CNF1-­‐	  and	  DNT-­‐	  mediated	  inhibition	  of	  Rho/ROCK	  signaling	  displayed	  stronger	  effects	  compared	  to	  that	  of	  PMT,	  indicating	  that	  additional	  pathways	  mediate	  the	  action	  of	  PMT.	  Knockdown	  studies	  confirm	  that	  PMT-­‐mediated	  downregulation	  of	  Notch1	  does	  not	  occur	  through	  Rho/ROCK	  or	  Gαq	  but	  through	  G12/13	  signaling.	  We	  present	  herein	  a	  better-­‐defined	  trafficking	  pathway	  of	  PMT	  and	  mechanism	  by	  which	  the	  toxin	  delivers	  the	  activity	  domain	  into	  host	  cell.	  Using	  an	  HA-­‐tagged	  PMT	  (PMT-­‐HA),	  we	  show	  the	  subcellular	  localization	  and	  nature	  of	  the	  protein	  after	  internalization	  in	  Swiss	  3T3	  cells.	  Our	  experiments	  reveal	  an	  internalized	  intact	  moiety	  corresponding	  to	  the	  activity	  domain,	  providing	  the	  first	  evidence	  that	  delivery	  of	  C-­‐terminus	  takes	  place	  from	  late	  endosomes	  and	  involves	  the	  release	  of	  endogenous	  cargo.	  We	  also	  probe	  the	  early	  steps	  of	  intoxication	  using	  an	  N-­‐terminal	  mutant	  of	  PMT	  (1-­‐568)	  fused	  to	  GFP	  and	  the	  later	  stages	  of	  the	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process	  using	  a	  biotinylated	  full-­‐length	  toxin	  and	  truncated	  mutants.	  This	  investigation	  reveals	  the	  initial	  localization	  of	  the	  toxin	  in	  early	  endosomes	  and	  its	  subsequent	  localization	  to	  other	  subcellular	  vesicular	  compartments,	  such	  as	  lysosomes.	  Moreover,	  upon	  the	  delivery	  of	  cargo,	  the	  N-­‐terminal	  fragment	  of	  the	  toxin	  remains	  in	  the	  vesicle.	  Both	  full-­‐length	  and	  N-­‐terminal	  toxins	  transfer	  most	  of	  the	  cargo	  (GFP,	  PMT-­‐C)	  intact	  into	  the	  cytosol,	  and	  the	  N-­‐terminal	  portion	  of	  the	  toxin	  gets	  further	  processed	  into	  multiple,	  smaller	  fragments,	  which	  remain	  associated	  with	  vesicles.	  	  Taken	  together,	  we	  outline	  a	  mechanism	  whereby	  after	  uptake	  and	  trafficking	  to	  endosomes,	  PMT	  is	  proteolytically	  processed	  and	  subsequently	  translocates	  and	  releases	  its	  C-­‐terminal	  cargo	  (endogenous	  or	  exogenous)	  as	  an	  intact	  moiety	  into	  the	  cell	  cytosol.	  This	  cargo	  would	  then	  presumably	  target	  the	  plasma	  membrane	  via	  its	  membrane	  localization	  subdomain	  to	  bring	  the	  glutamine	  deamidase	  domain	  to	  the	  membrane-­‐bound	  heterotrimeric	  G-­‐protein	  substrate.	  This	  thesis	  provides	  new	  insights	  in	  toxin	  translocation	  and	  the	  understanding	  of	  the	  toxin	  mode	  of	  action.	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Chapter	  1:	  	  Introduction	  
1.1.	  Bacterial	  Toxins	  
1.1.1.	  Toxins	  as	  Biological	  Significance	  	   Bacterial	  and	  other	  infectious	  diseases	  have	  a	  significant	  health	  and	  economic	  impact	  on	  our	  lives.	  In	  the	  early	  years	  of	  pathogenic	  microbe	  research,	  identifying	  the	  factors	  that	  caused	  a	  disease	  seemed	  simpler.	  However,	  as	  new	  pathogenic	  organisms	  are	  being	  discovered,	  the	  complexity	  of	  the	  biology	  involved	  in	  disease	  progression	  has	  increased	  tremendously.	  Pathogenic	  bacteria	  often	  produce	  virulence	  factor(s)	  or	  toxins	  that	  directly	  cause	  the	  disease	  in	  host	  organisms.	  Toxins	  are	  able	  to	  circumvent	  host	  immune	  systems	  to	  gain	  access	  to	  host	  cells,	  where	  they	  effectively	  cause	  the	  disease	  symptoms,	  as	  well	  as	  regulate	  immune	  suppressive	  signaling	  processes.	  Toxins	  are	  highly	  diverse,	  yet	  they	  often	  show	  specificity	  with	  regard	  to	  the	  types	  of	  organs,	  cells,	  and	  even	  intracellular	  targets	  they	  attack.	  	  	   Since	  the	  discovery	  of	  Helicobacter	  pylori	  infection	  and	  its	  association	  with	  gastric	  cancer,	  many	  other	  chronic	  bacterial	  infections	  have	  been	  implicated	  in	  cancer	  development.	  Due	  to	  the	  chronic	  exposure	  to	  bacteria	  effector	  proteins/toxins	  as	  a	  consequence,	  bacterial	  infections	  are	  now	  implicated	  as	  a	  reason	  for	  cancer	  development.	  These	  effector	  proteins	  and	  toxins	  directly	  and	  specifically	  disrupt	  normal	  cellular	  signaling	  pathways	  to	  cause	  dysregulation	  of	  cell	  growth	  by	  altering	  cell	  cycle	  progression	  or	  by	  facilitating	  anti-­‐apoptotic	  processes,	  and	  increased	  inflammation,	  including	  DNA	  damage.	  The	  cell	  cycle	  is	  an	  important	  program	  for	  cell	  division	  and	  growth,	  and	  control	  over	  the	  process	  is	  key	  for	  many	  biological	  processes.	  Uncontrolled	  cell	  proliferation	  may	  lead	  to	  tumorigenesis.	  These	  characteristics	  point	  towards	  an	  ability	  of	  these	  toxins	  to	  function	  as	  biological	  carcinogens	  or	  risk	  factors	  for	  cancer	  progression	  [29,	  75,	  76,	  107,	  155].	  Some	  bacterial	  toxins	  that	  are	  implicated	  in	  causing	  these	  effects	  in	  hosts	  are	  the	  topics	  of	  this	  thesis.	  	  Bacterial	  toxins	  have	  been	  used	  as	  tools	  to	  study	  cellular	  signaling	  pathways	  [131,	  152].	  ADP-­‐ribosylation	  of	  Gs	  by	  cholera	  toxin	  (CT)	  [44]	  and	  Go,	  Gi,	  or	  Gt	  by	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pertussis	  toxin	  (PT)	  [57,	  159]	  is	  an	  example	  of	  how	  different	  toxins	  can	  specifically	  target	  host	  molecules	  that	  affect	  the	  same	  signaling	  pathway	  with	  opposite	  effects.	  The	  ADP-­‐ribosylation	  of	  Gs	  by	  CT	  blocks	  GTP	  hydrolysis,	  causing	  constitutive	  activation.	  This	  leads	  to	  an	  increase	  in	  adenylate	  cyclase	  activity,	  and	  in	  turn	  increases	  the	  intracellular	  concentration	  of	  cAMP	  [44].	  On	  the	  other	  hand,	  ADP-­‐ribosylation	  by	  PT	  blocks	  intracellular-­‐signaling	  by	  preventing	  the	  G-­‐proteins	  from	  interacting	  with	  G	  protein-­‐coupled	  receptors.	  This	  causes	  the	  subunits	  of	  G-­‐proteins	  to	  remain	  locked	  in	  their	  inactive	  states,	  unable	  to	  inhibit	  adenylate	  cyclase	  activity,	  leading	  to	  an	  increase	  in	  cAMP	  level	  [57,	  159].	  Due	  to	  the	  specificity	  that	  toxins	  exhibit,	  we	  can	  use	  them	  as	  molecular	  tools	  to	  study	  signal	  transduction	  pathways.	  Studying	  toxin	  action	  will	  help	  us	  define	  the	  cellular	  targets	  and	  subsequent	  effects	  on	  host	  signaling	  pathways,	  thereby	  giving	  us	  valuable	  information	  on	  signaling	  as	  a	  study	  tool.	  It	  will	  also	  help	  us	  understand	  the	  entry	  pathway	  and	  route	  by	  which	  toxins	  gain	  access	  to	  the	  host.	  This	  will	  allow	  us	  to	  design	  and	  establish	  a	  connection	  with	  novel	  therapeutics	  to	  prevent	  exposure	  to	  the	  toxins,	  the	  causative	  agents	  of	  the	  disease	  itself.	  However,	  one	  of	  the	  most	  difficult	  aspects	  of	  designing	  therapeutics	  is	  to	  generate	  reagents	  that	  can	  be	  internalized	  by	  targeted	  cells	  efficiently.	  Utilization	  of	  toxin-­‐based	  therapeutics	  would	  be	  beneficial	  since	  toxins	  have	  specificity	  for	  the	  cell	  types	  that	  they	  exploit.	  Because	  of	  the	  utility	  of	  the	  toxin	  as	  a	  research	  tool	  and	  the	  specificity	  that	  they	  possess,	  toxins	  then	  can	  be	  used	  as	  a	  delivery	  vehicle.	  In	  this	  thesis,	  this	  aspect	  of	  toxin	  action	  is	  explored.	  	  	  
1.1.2.	  Bacterial	  Toxins	  	   Bacterial	  toxins	  that	  cause	  host	  cytotoxicity	  may	  be	  classified	  based	  on	  their	  mechanism	  of	  action,	  their	  intracellular	  target(s)	  in	  the	  host	  cells,	  and/or	  how	  the	  toxins	  are	  released	  from	  bacteria.	  The	  list	  of	  bacterial	  toxins	  that	  cause	  diseases	  seems	  to	  be	  growing,	  as	  a	  number	  of	  new	  or	  re-­‐emerging	  infectious	  diseases	  have	  come	  to	  surface	  at	  an	  alarming	  rate	  [157].	  As	  we	  learn	  more	  about	  these	  toxins,	  the	  number	  of	  toxins	  that	  fall	  into	  each	  category	  is	  expanding	  and	  the	  mode	  of	  action	  by	  which	  they	  reach	  their	  intracellular	  targets	  seems	  to	  be	  more	  complex.	  Here,	  toxins	  are	  classified	  broadly,	  based	  on	  their	  general	  mechanism	  of	  action;	  type	  I	  through	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III.	  Generally,	  the	  first	  step	  of	  toxin	  action	  is	  to	  bind	  to	  the	  cell	  surface,	  which	  may	  or	  may	  not	  be	  followed	  by	  internalization	  of	  the	  toxin	  and	  entry	  into	  the	  cytosol	  to	  elicit	  the	  cytotoxic	  effects.	  	  	   Type	  I	  toxins	  function	  at	  the	  membrane	  surface	  of	  the	  host	  cell,	  mimicking	  normal	  signaling	  transduction	  processes,	  i.e.	  the	  toxins	  do	  not	  get	  transported	  across	  a	  host	  cell	  membrane,	  but	  elicit	  cellular	  responses	  by	  binding	  to	  a	  receptor	  that	  transduces	  a	  signal	  like	  heat-­‐stable	  enterotoxins	  (HST)	  [14].	  HST	  binding	  to	  a	  guanylate	  cyclase	  receptor	  causes	  an	  increase	  in	  cGMP,	  leading	  to	  electrolyte	  flux	  [14].	  Type	  II	  toxins	  elicit	  their	  cytotoxicity	  by	  targeting	  the	  membrane	  of	  host	  cells.	  They	  exploit	  membrane	  insertion	  to	  form	  pores,	  e.g.	  pore-­‐forming	  toxins	  [92],	  or	  cause	  membrane	  destruction,	  e.g.	  phospholipases	  [71].	  Type	  III	  toxins	  act	  on	  eukaryotic	  intracellular	  targets	  and	  possess	  a	  means	  to	  enter	  the	  host	  cell	  and	  cross	  the	  cell	  membrane	  to	  gain	  access	  to	  their	  targets.	  These	  toxins	  are	  known	  as	  AB	  toxins,	  where	  a	  binding	  domain	  (B	  component)	  recognizes	  a	  receptor	  on	  the	  host	  cell	  surface	  and	  initiates	  internalization	  of	  the	  A	  component,	  which	  subsequently	  is	  delivered	  into	  the	  cytosol	  and	  carries	  out	  its	  catalytic	  activity.	  In	  addition	  to	  these	  exotoxins,	  some	  bacteria	  produce	  toxic	  effector	  proteins	  that	  have	  intracellular	  targets,	  but	  are	  injected	  directly	  into	  the	  host	  cell	  cytosol	  via	  specialized	  bacterial	  secretion	  systems	  [144].	  This	  thesis	  focuses	  on	  a	  family	  of	  AB	  toxins.	  	  
1.1.3.	  AB	  Toxins	  Internalization	  of	  Type	  III	  AB	  toxins	  typically	  occurs	  in	  three	  steps	  that	  involve	  different	  functional	  domains:	  (1)	  a	  receptor-­‐binding	  domain	  that	  binds	  to	  a	  receptor	  on	  the	  cell	  surface.	  This	  event	  triggers	  uptake	  via	  endocytosis	  and	  transport	  of	  the	  complex	  to	  intracellular	  organelles,	  (2)	  a	  translocation	  domain	  that	  mediates	  transport	  of	  the	  toxic	  activity	  domain	  across	  the	  vesicle	  membrane,	  and	  (3)	  a	  catalytic	  activity	  domain	  that	  modifies	  the	  intracellular	  target	  substrate	  and	  causes	  cytotoxicity	  (Figure	  1).	  	  The	  simplest	  AB	  toxins	  are	  synthesized	  as	  a	  single	  polypeptide	  that	  contains	  a	  single	  binding	  domain,	  a	  single	  translocation	  domain,	  and	  a	  single	  catalytic	  activity	  domain.	  An	  example	  is	  diphtheria	  toxin	  (DT),	  which	  is	  secreted	  as	  a	  single	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polypeptide	  chain,	  comprised	  of	  an	  activity	  domain	  at	  its	  N	  terminus,	  followed	  by	  a	  translocation	  domain	  and	  then	  a	  binding	  domain	  at	  its	  C	  terminus	  [23].	  More	  complex	  forms	  of	  AB	  toxins	  are	  produced	  as	  multi-­‐subunit	  complexes	  (AB5	  or	  A3B7	  toxins),	  consisting	  of	  multiple	  B	  subunits	  and	  one	  or	  more	  A	  subunits,	  which	  are	  expressed	  as	  separate	  proteins	  that	  subsequently	  form	  an	  active	  complex.	  	  For	  instance,	  cholera	  toxin	  (CT)	  has	  a	  single	  A	  subunit	  plus	  5	  B	  subunits	  (AB5),	  and	  anthrax	  toxin	  is	  comprised	  of	  two	  A	  subunits	  (lethal	  factor	  and	  edema	  factor)	  and	  7	  B	  subunits	  (protective	  antigen)	  that	  come	  together	  to	  form	  an	  A3B7	  complex	  [Reviewed	  in	  97].	  This	  thesis	  will	  focus	  on	  a	  group	  of	  AB	  toxins	  that	  are	  produced	  as	  a	  single	  polypeptide	  comprised	  of	  multiple	  domains	  that	  carry	  out	  the	  AB	  functions.	  The	  exotoxins	  have	  to	  cross	  the	  host	  cell	  membrane	  in	  order	  to	  find	  their	  targets	  intracellularly.	  To	  do	  this,	  the	  toxins	  use	  the	  host	  cell’s	  surface	  receptors.	  Different	  toxins	  utilize	  different	  receptors	  at	  the	  host	  cell	  membrane.	  For	  example,	  low-­‐density	  lipoprotein	  receptor-­‐related	  protein	  1	  (LRP1)	  and	  LRP1B	  function	  as	  receptors	  for	  exotoxin	  A	  from	  Pseudomonas	  aeruginosa	  [70,	  110].	  DT,	  on	  the	  other	  hand,	  binds	  to	  heparin-­‐binding	  epidermal	  growth	  factor-­‐like	  growth	  factor	  (HB-­‐EGF)	  to	  gain	  access	  to	  host	  cells	  [Reviewed	  in	  146].	  Another	  example	  would	  be	  botulinum	  neurotoxin	  [Reviewed	  in	  61].	  Different	  serotypes	  seem	  to	  have	  a	  distinct	  binding	  partner	  in	  addition	  to	  gangliosides	  as	  a	  co-­‐receptor;	  synaptic	  vesicle	  glycoprotein	  2	  (SV2)	  for	  serotype	  A,	  and	  synaptotagmin	  for	  serotype	  B	  [61]	  and	  G	  [27,	  126].	  Toxin	  internalization	  is	  initiated	  when	  the	  toxin	  binds	  to	  a	  cell	  surface	  receptor	  of	  the	  host	  cell,	  triggering	  uptake	  by	  endocytosis.	  Endocytosis	  is	  distinguished	  based	  on	  the	  size	  of	  the	  endocytic	  vesicles	  formed;	  the	  uptake	  of	  large	  particles	  (>250	  nm)	  (phagocytosis)	  or	  the	  ingestion	  of	  fluid	  and	  solutes	  through	  small	  vesicles	  (<200	  nm)	  (pinocytosis).	  In	  mammalian	  cells,	  receptor-­‐ligand	  complexes	  are	  endocytosed	  via	  clathrin-­‐coated	  pits,	  clathrin-­‐independent	  pathways	  (i.e.	  lipid-­‐raft-­‐dependent	  pathway)	  [78],	  or	  caveolae,	  all	  of	  which	  are	  forms	  of	  pinocytosis.	  A	  number	  of	  toxins	  use	  one	  or	  more	  of	  these	  mechanisms	  to	  gain	  access	  to	  the	  host	  targets.	  For	  instance,	  Shiga	  toxin	  (ST)	  uses	  clathrin-­‐dependent	  and/or	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clathrin-­‐independent	  pathways	  [130]	  for	  internalization,	  while	  CT	  uses	  only	  a	  clathrin-­‐dependent	  pathway	  [96,	  137,	  143].	  	  	  Once	  a	  toxin	  is	  internalized,	  it	  is	  trafficked	  to	  particular	  intracellular	  compartments,	  where	  translocation	  occurs.	  Trafficking	  pathways	  of	  toxins	  are	  divided	  into	  two	  major	  categories:	  endocytic	  pathways	  or	  retrograde	  trafficking	  pathways	  (Figure	  1).	  The	  endocytic	  pathway	  involves	  transport	  of	  the	  activity	  component	  of	  the	  toxin	  from	  the	  endosome	  to	  the	  cytosol	  through	  a	  pH-­‐dependent	  step,	  as	  shown	  for	  DT.	  DT	  appears	  to	  contain	  a	  translocation	  domain	  in	  which	  the	  acidity	  (protonation	  of	  the	  helical	  loop	  residues	  in	  the	  translocation	  domain)	  is	  a	  critical	  part	  of	  the	  translocation	  process	  [33].	  Other	  toxins,	  such	  as	  CT,	  follow	  the	  retrograde	  trafficking	  pathway.	  It	  travels	  through	  the	  trans-­‐Golgi	  Network	  (TGN)	  and	  Golgi	  organelles	  prior	  to	  the	  translocation	  of	  the	  activity	  domain	  from	  the	  endoplasmic	  reticulum	  (ER).	  	  The	  translocation	  process	  via	  the	  endocytic	  pathway	  is	  extensively	  studied	  in	  the	  case	  of	  DT	  [Reviewed	  in	  23].	  It	  forms	  a	  pore	  in	  the	  endocytic	  vesicles	  through	  which	  partially	  unfolded	  toxin	  translocates	  the	  activity	  domain,	  followed	  by	  refolding	  in	  the	  cytosol	  [Reviewed	  in	  23].	  On	  the	  other	  hand,	  toxins	  that	  use	  the	  retrograde	  pathway	  do	  not	  possess	  a	  translocation	  domain,	  but	  rather	  use	  a	  host	  system	  to	  transport	  the	  activity	  domain	  into	  the	  cytosol	  as	  shown	  in	  CT	  [Reviewed	  in	  150].	  Trafficking	  through	  TGN	  and	  Golgi	  to	  reach	  ER,	  CT	  acts	  as	  a	  misfolded	  protein	  to	  hijack	  the	  ER	  associated	  degradation	  (ERAD)	  pathway	  to	  cross	  the	  ER	  membrane.	  The	  activity	  domain	  also	  undergoes	  an	  unfolding	  event	  by	  protein	  disulfide	  isomerase	  (PDI)	  before	  crossing	  the	  ER	  membrane.	  Upon	  entering	  the	  cytosol,	  the	  activity	  domain	  refolds	  quickly	  to	  avoid	  degradation	  [Reviewed	  in	  150].	  	  Upon	  the	  delivery	  of	  the	  activity	  domain	  into	  the	  cytosol,	  AB	  toxins	  act	  on	  a	  variety	  of	  host	  targets.	  Toxicity	  elicited	  by	  these	  toxins	  is	  divided	  in	  four	  categories,	  based	  on	  the	  cellular	  process	  that	  they	  affect:	  (1)	  protein	  synthesis,	  (2)	  signal	  transduction,	  (3)	  cytoskeleton	  structure,	  or	  (3)	  intracellular	  trafficking.	  ADP-­‐ribosylation	  of	  elongation	  factor	  2	  (EF-­‐2)	  by	  DT,	  which	  leads	  to	  cell	  death,	  is	  an	  example	  of	  a	  toxin	  affecting	  protein	  synthesis	  [36].	  An	  example	  of	  a	  toxin	  that	  affects	  signal	  transduction	  is	  the	  anthrax	  edema	  factor	  (EF)	  from	  Bacillus	  anthracis,	  which	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upon	  binding	  to	  calmodulin	  converts	  ATP	  to	  cAMP,	  leading	  to	  increased	  cellular	  cAMP	  levels	  and	  activation	  of	  a	  number	  of	  cAMP-­‐dependent	  protein	  kinases	  [91].	  Toxin	  C2	  from	  Clostridium	  botulinum	  affects	  actin	  cytoskeletal	  function	  by	  ADP-­‐ribosylation	  of	  monomeric	  G	  actin,	  preventing	  actin	  polymerization	  and	  causing	  cell	  rounding	  [1].	  Botulinum	  neurotoxin	  serotype	  A	  (BoNT/A)	  from	  C.	  botulinum	  cleaves	  SNAP-­‐25,	  a	  protein	  involved	  in	  synaptic	  vesicle	  fusion	  with	  plasma	  membranes	  to	  prevent	  exocytosis	  and	  release	  of	  acetylcholine,	  leading	  to	  flaccid	  paralysis	  [149].	  	  	  
1.2.	  Dermonecrotic	  Toxin	  Family	  The	  dermonecrotic	  toxins	  are	  a	  family	  of	  AB	  toxins	  that	  include	  the	  dermonecrotic	  toxin	  from	  Bordetella	  spp.	  (DNT),	  the	  cytotoxic	  necrotizing	  factors	  from	  Escherichia	  coli	  (CNF1,	  CNF2	  and	  CNF3)	  and	  Yersinia	  pseudotuberculosis	  (CNFY),	  and	  the	  mitogenic	  toxin	  from	  Pasteurella	  multocida	  (PMT)	  [90,	  116,	  152,	  156].	  The	  name	  comes	  from	  the	  fact	  that	  all	  of	  these	  toxins	  show	  a	  characteristic	  dermonecrotic	  lesion	  when	  injected	  intradermally	  into	  rabbits	  [83,	  109].	  These	  relatively	  large	  (100-­‐160	  kDa),	  single	  polypeptide	  protein	  toxins	  share	  some	  regions	  of	  homology	  with	  one	  another	  in	  their	  protein	  structure,	  which	  may	  account	  for	  some	  of	  their	  similar	  biological	  activities	  [Reviewed	  in	  51,	  69,	  154,	  155,	  156].	  All	  of	  these	  dermonecrotic	  toxins	  are	  known	  to	  act	  intracellularly	  [Reviewed	  in	  154,	  156],	  causing	  cytopathic	  effects	  in	  epithelial	  cultured	  cells	  and	  promoting	  cytoskeletal	  rearrangements	  [Reviewed	  in	  156]	  via	  their	  C-­‐terminal	  activity	  domain.	  	  Sequence	  similarity	  is	  found	  among	  the	  family	  members.	  PMT	  and	  CNFs	  share	  approximately	  48%	  sequence	  similarity	  at	  the	  N-­‐terminus	  (Figure	  2),	  which	  might	  account	  for	  similar	  aspect	  of	  entry	  pathway	  (i.e.	  utilization	  of	  endocytic	  pathway)	  [122].	  In	  addition,	  sequence	  is	  most	  conserved	  among	  CNFs	  with	  at	  least	  78%	  similarity.	  Furthermore,	  CNF	  and	  DNT	  share	  51%	  sequence	  similarity	  in	  their	  C-­‐terminal	  300	  amino	  acids	  (Figure	  2),	  which	  might	  explain	  how	  they	  direct	  towards	  the	  same	  cellular	  targets.	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1.3.	  Bordetella	  Dermonecrotic	  Toxin	  (DNT)	  
1.3.1.	  DNT	  and	  Diseases	  
Bordetella	  species	  are	  associated	  with	  a	  variety	  of	  upper	  respiratory	  diseases	  in	  their	  natural	  hosts,	  including	  whooping	  cough	  in	  humans	  (B.	  pertussis	  and	  in	  some	  cases	  B.	  parapertussis),	  kennel	  cough	  in	  dogs	  (B.	  bronchiseptica)	  [46],	  pneumonia	  and	  atrophic	  rhinitis	  in	  swine	  (B.	  bronchiseptica)	  [15,	  128]	  and	  bordetellosis	  (turkey	  corzyza)	  in	  birds	  (B.	  avium)	  [119,	  123].	  Bordetella	  dermonecrotic	  toxin	  (DNT)	  is	  produced	  by	  Bordetella	  species.	  Southern-­‐blot	  analyses	  show	  that	  genes	  encoding	  for	  DNTs	  from	  B.	  bronchiseptica,	  B.	  parapertussis,	  and	  B.	  pertussis	  are	  nearly	  identical	  and	  show	  similar	  biological	  activities,	  but	  DNT	  from	  B.	  avium	  is	  genetically	  and	  biologically	  distinct	  [147].	  	  	   DNT	  is	  first	  described	  in	  1909	  associated	  with	  a	  whooping	  cough	  case	  caused	  by	  B.	  pertussis.	  Since	  then,	  other	  Bordetella	  species	  have	  been	  shown	  to	  produce	  DNT.	  Besides	  demonecrosis,	  other	  pathological	  changes	  happen	  in	  the	  upper	  respiratory	  tract;	  indeed,	  DNT	  is	  lethal	  in	  mice	  [60].	  The	  toxin	  can	  also	  cause	  spleen	  atrophy	  [60].	  	  	  
1.3.2.	  Structural	  Architecture	  and	  Intoxication	  Process	  	   DNT	  is	  chromosomally	  encoded	  and	  produced	  as	  a	  single-­‐chain	  polypeptide	  toxin,	  consisting	  of	  1464	  amino	  acids.	  Sequence	  analysis	  and	  functional	  studies	  have	  identified	  putative	  binding,	  translocation	  and	  activity	  domains	  of	  DNT	  (Figure	  3)	  [41,	  63,	  88].	  The	  binding	  domain	  is	  located	  within	  the	  first	  30	  amino	  acids	  of	  N-­‐terminus	  [41],	  and	  the	  activity	  domain	  is	  located	  in	  the	  last	  300	  amino	  acids	  of	  C-­‐terminus	  [63].	  The	  region	  spanning	  residues	  45-­‐166	  is	  important	  for	  translocation	  [41].	  	   The	  toxin	  entry	  is	  divided	  into	  five	  steps	  (Figure	  4):	  (1)	  toxin	  binding	  to	  a	  currently	  unidentified	  host	  cell	  surface	  receptor,	  (2)	  uptake	  via	  dynamin-­‐dependent	  endocytosis	  [88,	  Reviewed	  in	  40],	  (3)	  proteolytic	  cleavage	  of	  toxin	  at	  the	  C-­‐terminal	  end	  of	  the	  binding	  domain	  [87,	  Reviewed	  in	  40],	  (4)	  pH-­‐independent	  translocation	  of	  the	  activity	  domain	  across	  the	  endosomal	  membrane	  [87,	  Reviewed	  in	  40],	  and	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(5)	  cytotoxicity	  mediated	  through	  the	  deamidase	  activity	  domain	  at	  the	  C-­‐terminus	  [87,	  Reviewed	  in	  40].	  	  	   Although	  cellular	  receptor(s)	  for	  DNT	  have	  not	  yet	  been	  identified,	  DNT	  has	  specificity	  towards	  the	  cell	  types	  that	  it	  affects,	  indicating	  that	  the	  receptor(s)	  confers	  some	  host	  cell	  specificity	  to	  the	  toxin	  [88].	  In	  one	  study,	  DNT	  showed	  toxicity	  towards	  sensitive	  cells	  such	  as	  MC3T3-­‐E1,	  C3H10T1/2,	  Swiss3T3,	  and	  NIH3T3	  cells	  but	  not	  to	  resistant	  cells	  like	  COS7,	  Balb3T3,	  L929,	  PAE,	  and	  K562	  cells	  [88].	  Additionally,	  DNT	  binding	  to	  the	  cell	  surface	  receptor	  through	  residues	  2-­‐30	  at	  the	  N-­‐terminus	  shows	  very	  low	  affinity	  to	  receptors,	  making	  it	  difficult	  to	  identify	  its	  receptor	  [41].	  After	  interaction	  with	  host	  receptors	  at	  the	  membrane,	  DNT	  enters	  the	  cell	  through	  dynamin-­‐mediated	  endocytosis	  [88].	  In	  addition,	  DNT	  uptake	  most	  likely	  does	  not	  require	  actin	  dependent	  endocytosis	  since	  cytochalasin	  D	  shows	  no	  effects	  on	  DNT	  uptake	  [88].	  	   Similar	  to	  other	  bacterial	  toxins,	  DNT	  appears	  to	  undergo	  proteolytic	  cleavage	  at	  Arg44	  by	  furin	  prior	  to	  translocation	  into	  the	  host	  cytosol	  [145].	  This	  proteolytic	  cleavage	  is	  essential	  for	  the	  toxin	  activity,	  and	  this	  appears	  to	  be	  the	  rate-­‐limiting	  step	  [88].	  The	  intracellular	  Rho	  modification	  takes	  place	  immediately	  after	  addition	  of	  the	  toxin	  when	  nicked	  DNT	  is	  used.	  On	  the	  other	  hand,	  the	  intact	  DNT	  requires	  a	  30-­‐minute	  lag	  time	  before	  DNT-­‐mediated	  Rho	  modification	  is	  observed	  [88].	  Delivery	  of	  the	  activity	  domain	  into	  the	  cytosol	  occurs	  through	  a	  change	  in	  conformation,	  followed	  by	  membrane	  insertion	  through	  the	  putative	  translocation	  domain.	  Unlike	  other	  dermonecrotic	  toxins,	  translocation	  of	  DNT	  does	  not	  appear	  to	  require	  the	  acidification	  of	  endosomes	  [reviewed	  in	  88,	  41],	  as	  shown	  by	  the	  inability	  of	  bafilomycin	  A1	  or	  NH4Cl	  to	  prevent	  DNT	  intoxication	  [88].	  Furthermore,	  DNT	  unlikely	  uses	  the	  retrograde	  pathway	  because	  brefeldin	  A	  and	  nocodazole	  also	  do	  not	  affect	  toxin	  activity	  [88].	  Alas,	  the	  mechanism	  of	  DNT	  translocation	  remains	  unclear.	  	  
1.3.3.	  Intracellular	  Effects	  At	  a	  cellular	  level,	  DNT	  stimulates	  protein	  and	  DNA	  synthesis	  [55,	  56].	  The	  DNT-­‐treated	  cells	  show	  multinucleation	  and	  enlargement,	  indicating	  inhibition	  of	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cytokinesis	  and	  effects	  on	  the	  cytoskeletal	  system.	  DNT	  also	  affects	  the	  formation	  of	  actin	  stress	  fibers	  and	  focal	  adhesions	  through	  direct	  activation	  on	  RhoA	  [52,	  54],	  causing	  changes	  in	  cell	  morphology.	  In	  addition,	  DNT	  induces	  membrane	  organelle	  proliferation	  and	  caveolae	  formation	  [135].	  Moreover,	  DNT	  inhibits	  osteoblastic	  differentiation	  in	  MC3T3-­‐E1	  cultured	  cells	  [53].	  	   DNT	  activates	  intracellular	  Rho	  GTPase	  through	  its	  transglutaminase	  activity,	  resulting	  in	  the	  constitutive	  activation	  of	  cellular	  targets	  [132]	  (Figure	  5).	  The	  toxin	  deamidates	  or	  polyaminates	  RhoA	  at	  Gln63,	  and	  Rac	  and	  Cdc42	  at	  Gln61	  residue	  [52,	  86]	  (Figure	  6).	  Members	  of	  the	  Rho	  family	  of	  GTPases	  belong	  to	  the	  Ras	  superfamily.	  They	  function	  as	  molecular	  switches,	  shuttling	  between	  the	  inactive,	  GDP-­‐bound	  and	  the	  active,	  GTP-­‐bound	  form.	  When	  induced,	  the	  GTPases	  exchange	  GDP	  with	  GTP,	  triggering	  downstream	  signals,	  and	  return	  to	  the	  inactive	  GDP-­‐bound	  form	  by	  hydrolyzing	  the	  GTP.	  Guanine	  nucleotide	  exchange	  factors	  (GEFs)	  catalyze	  the	  exchange	  of	  GDP	  to	  GTP,	  thereby	  activating	  Rho	  GTPases.	  GTPase-­‐activating	  proteins	  (GAPs)	  are	  responsible	  for	  GTP	  hydrolysis	  induction,	  effectively	  returning	  GTPases	  to	  the	  inactive	  GDP	  form.	  GAP-­‐mediated	  GTP	  hydrolysis	  is	  transient	  in	  nature	  [124].	  Guanine	  nucleotide	  dissociation	  inhibitors	  (GDIs)	  bind	  to	  and	  maintain	  this	  inactive	  form	  of	  GTPases,	  while	  preventing	  localization	  of	  the	  complex	  to	  the	  membrane	  (Figure	  5).	  DNT	  blocks	  GAP	  activity,	  thereby	  causing	  GTPases	  to	  remain	  in	  their	  active,	  GTP-­‐bound	  state.	  Although	  DNT	  targets	  all	  of	  these	  Rho	  family	  members,	  RhoA	  and	  Rac	  are	  preferentially	  activated,	  and	  Cdc42	  shows	  less	  sensitivity	  than	  the	  others	  [52,	  86].	  At	  the	  molecular	  level,	  DNT	  causes	  a	  covalent	  modification	  on	  RhoA	  that	  can	  be	  detected	  by	  using	  electrophoretic	  mobility	  shift	  assay	  [52].	  The	  activation	  of	  RhoA	  through	  polyamination	  seems	  to	  be	  more	  favorable	  than	  the	  deamidation	  [86].	  The	  DNT-­‐mediated	  modification	  of	  Rho	  inhibits	  induction	  of	  GTP	  hydrolysis	  by	  GAP,	  generating	  a	  constitutively	  active	  form.	  The	  glutamine	  residue	  that	  gets	  modified	  by	  DNT	  is	  located	  in	  the	  common	  switch	  II	  region	  of	  GTPases,	  which	  plays	  a	  crucial	  role	  in	  the	  GTP	  hydrolysis	  activity,	  leading	  to	  constitutive	  activation	  and	  upregulation	  of	  downstream	  signaling	  pathways	  [52].	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1.4.	  Cytotoxic	  Necrotizing	  Factors	  (CNFs)	  
1.4.1.	  Cytotoxic	  Necrotizing	  Factor	  1	  (CNF1)	  
1.4.1.1.	  CNF1	  and	  Diseases	  	   Pathogenic	  Escherichia	  coli	  cause	  a	  wide	  variety	  of	  diseases	  in	  humans	  and	  animals.	  In	  addition	  to	  intestinal	  infection	  that	  presents	  with	  diarrhea,	  it	  can	  cause	  extraintestinal	  infections,	  such	  as	  acute	  pyelonephritis,	  cystitis,	  asymptomatic	  bacteriuria	  [48],	  urinary	  tract	  infection	  [58],	  septicemia,	  neonatal	  meningitis	  and	  pneumonia	  [11,	  20].	  CNF1	  has	  been	  identified	  in	  E.	  coli	  strains	  isolated	  from	  neonatal	  meningitis	  [11].	  CNF1	  is	  one	  of	  the	  virulence	  factors	  of	  uropathogenic	  E.	  
coli	  (UPEC)	  [9,	  74],	  where	  cnf1	  is	  encoded	  on	  the	  chromosome	  [32].	  Furthermore,	  activation	  of	  RhoA	  by	  CNF1	  is	  associated	  with	  central	  nervous	  system	  invasion	  by	  E.	  
coli	  [64].	  	  
1.4.1.2.	  Structural	  Architecture	  and	  Intoxication	  Process	  	   CNF1	  is	  produced	  as	  a	  single-­‐chain	  polypeptide	  toxin	  that	  has	  a	  molecular	  mass	  of	  114-­‐kDa.	  It	  is	  an	  AB	  toxin	  containing	  an	  N-­‐terminal	  receptor-­‐binding	  domain	  (residues	  53-­‐190)	  [31,	  79]	  and	  a	  C-­‐terminal	  catalytic	  domain	  (residues	  720-­‐1014)	  [79,	  134]	  (Figure	  7).	  Residues	  350-­‐412	  make	  up	  a	  helix-­‐loop-­‐helix	  transmembrane	  region	  that	  appears	  to	  be	  critical	  for	  delivering	  the	  activity	  domain	  into	  the	  cytosol	  [113].	  There	  is	  also	  a	  cleavage	  site	  located	  between	  residues	  536-­‐542	  that	  is	  critical	  for	  successful	  translocation	  to	  occur,	  delivering	  a	  55-­‐kDa	  fragment	  into	  the	  cytosol	  [68].	  	   CNF1	  enters	  and	  shows	  cytotoxicity	  in	  a	  wide	  variety	  of	  cells,	  indicating	  CNF1	  uses	  a	  receptor	  that	  is	  commonly	  expressed	  in	  most	  cells.	  Recently,	  laminin	  receptor	  precursor	  (LPRp67)	  was	  suggested	  to	  be	  the	  receptor	  for	  CNF1	  [21,	  66].	  Competition	  studies	  showed	  that	  RhoA	  activation	  by	  CNF	  and	  uptake	  of	  CNF	  producing	  bacteria	  were	  inhibited	  when	  external	  laminin	  receptor	  precursor	  was	  added	  [21].	  A	  second	  receptor	  (co-­‐receptor)	  for	  CNF1	  has	  also	  been	  identified	  as	  heparan	  sulfate	  proteoglycan	  (HSPG)	  [10,	  89].	  In	  this	  study,	  a	  second	  receptor-­‐binding	  site	  in	  the	  C-­‐terminal	  region	  was	  identified	  (residues	  683-­‐730),	  which	  was	  necessary	  for	  binding	  to	  Hep-­‐2	  cells	  [89].	  Additionally,	  three	  important	  residues	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(591,	  593	  and	  661)	  in	  the	  C-­‐terminal	  region	  of	  the	  toxin	  are	  known	  to	  be	  important	  for	  toxin	  binding	  to	  Hep-­‐2	  cells	  [47].	  These	  residues	  are	  not	  conserved	  in	  all	  CNFs.	  However,	  this	  difference	  may	  explain	  the	  observed	  preferential	  receptor	  binding	  of	  CNFs.	  Because	  p67	  and	  HSPG	  form	  a	  complex	  with	  each	  other,	  HSPG	  is	  proposed	  as	  a	  co-­‐receptor	  for	  CNF1	  [10,	  140].	  Thus,	  CNF1	  may	  bind	  preferentially	  to	  this	  LPRp67-­‐HSPG	  complex,	  and	  other	  CNFs,	  such	  as	  CNF3	  and	  CNFy,	  may	  bind	  only	  to	  HSPG.	  This	  difference	  also	  explains	  perhaps	  why	  inactive	  CNF3	  and	  CNFy	  can	  inhibit	  partial	  uptake	  of	  CNF1	  [140].	  More	  recently,	  Lutheran	  (Lu)	  adhesion	  glycoprotein/basal	  cell	  adhesion	  molecule	  (BCAM)	  was	  identified	  as	  a	  receptor	  for	  CNF1	  [115].	  Interaction	  between	  CNF1	  and	  Lu/BCAM	  was	  assessed	  using	  direct	  protein-­‐protein	  interaction	  as	  well	  as	  competition	  assays.	  This	  study	  showed	  that	  the	  secondary	  binding	  domain	  is	  located	  directly	  adjacent	  to	  the	  activity	  domain	  (within	  the	  predicted	  activity	  domain,	  residues	  720-­‐1014).	  This	  region	  is	  important	  for	  toxin	  uptake,	  as	  Lu/BCAM	  deficient	  cells	  did	  not	  show	  toxin	  binding	  to	  the	  cells	  [115].	  	   After	  uptake	  by	  the	  host,	  CNF1	  goes	  through	  the	  clathrin-­‐	  and	  caveolin-­‐	  independent	  endocytosis	  to	  deliver	  the	  activity	  domain	  into	  the	  cytosol	  [22].	  During	  the	  translocation	  step,	  two	  hydrophobic	  helices	  (helix-­‐loop-­‐helix)	  play	  a	  crucial	  role	  in	  membrane	  crossing	  [113].	  A	  low	  pH	  causes	  unfolding	  of	  the	  toxin	  and	  protonation	  of	  acidic	  residues,	  and	  this	  facilitates	  the	  insertion	  of	  the	  toxin	  into	  the	  endosomal	  membrane	  [113].	  Hence,	  a	  mutation	  in	  the	  acidic	  residues	  of	  this	  region	  prevents	  toxin	  from	  getting	  across	  the	  endosomal	  membrane	  [113].	  In	  addition,	  CNF1	  has	  been	  shown	  to	  possess	  a	  putative	  activity-­‐modulating	  domain,	  attributing	  to	  the	  differential	  toxin	  responses	  to	  acidification	  inhibitors	  [122].	  When	  cells	  were	  treated	  with	  moderate	  amounts	  of	  acidification	  inhibitors	  such	  as	  a	  weak	  base	  NH4Cl,	  a	  v-­‐ATPase	  pump	  inhibitor	  bafilomycin	  A1,	  and	  the	  two	  ionophores	  monensin	  and	  nigericin,	  an	  enhancement	  of	  toxin-­‐mediated	  SRE-­‐luciferase	  activity	  was	  observed	  [122].	  This	  effect	  was	  overcome	  at	  higher	  concentration	  of	  inhibitors	  [122].	  Taken	  together,	  translocation	  of	  CNF1	  requires	  some	  acidification	  of	  the	  endosomes	  but	  moderate	  inhibition	  of	  the	  acidification	  promotes	  the	  translocation	  of	  CNF1,	  leading	  to	  enhancement	  of	  the	  toxin	  activity.	  After	  crossing	  the	  endosomal	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membrane,	  the	  activity	  domain	  is	  cleaved	  off	  the	  toxin	  by	  a	  host	  factor	  and	  the	  released	  activity	  domain	  finds	  its	  target	  in	  the	  cytosol	  (Figure	  8)	  [68].	  	  
1.4.1.3.	  Intracellular	  Effects	  	   CNF1	  facilitates	  DNA	  synthesis	  [73],	  and	  causes	  multinucleation	  and	  enlargement	  of	  various	  culture	  cells.	  Toxin	  treatment	  also	  leads	  to	  formation	  of	  actin	  stress	  fibers,	  filopodia,	  lamellipodia	  and	  membrane	  ruffling	  [35,	  81,	  133].	  These	  cellular	  effects	  are	  indicative	  of	  Rho	  GTPase	  activation	  [35].	  Like	  DNT,	  CNF1	  deamidates	  Gln63	  of	  RhoA	  [133],	  leading	  to	  stress	  fiber	  formation,	  and	  Gln61	  of	  Rac	  and	  Cdc42,	  causing	  lamellipodia	  and	  filopodia,	  respectively	  [81]	  (Figure	  6).	  CNF1,	  through	  its	  catalytic	  core,	  activates	  RhoA,	  with	  specificity	  conferred	  by	  the	  switch	  II	  region	  of	  RhoA	  (Asp59-­‐Asp78)	  [17,	  37,	  82].	  	   Although	  CNF1	  can	  act	  as	  a	  transglutaminase	  [134],	  it	  acts	  preferentially	  as	  a	  deamidase.	  The	  activation	  and	  covalent	  modification	  of	  Rho	  can	  be	  observed	  by	  gel	  mobility	  shift	  assay	  [108].	  In	  addition,	  persistent	  activation	  of	  Rho	  leads	  to	  degradation	  through	  polyubiquitylation	  and	  proteasomal	  degradation	  [13,	  29,	  80,	  94],	  perhaps	  limiting	  the	  magnitude	  of	  host	  immune	  responses.	  	  
1.4.2.	  Cytotoxic	  Necrotizing	  Factor	  2	  (CNF2)	  	   CNF2	  was	  initially	  detected	  in	  calves	  with	  enteritis	  [25],	  and	  later	  classified	  as	  a	  second	  type	  of	  CNF	  [24].	  CNF2	  is	  produced	  by	  enterotoxigenic	  E.	  coli	  (ETEC),	  and	  unlike	  CNF1,	  CNF2	  is	  encoded	  by	  a	  transmissible	  Vir	  plasmid	  [24,	  105,	  106].	  CNF2	  shares	  86%	  amino	  acid	  identity	  with	  CNF1.	  CNF2-­‐treated	  cultured	  cells	  also	  show	  multinucleation	  [19,	  25,	  106].	  Although	  CNF2	  targets	  RhoA	  just	  like	  CNF1,	  causing	  stress	  fiber	  formation	  and	  mobility	  shift	  in	  RhoA	  in	  SDS-­‐PAGE	  [108],	  CNF2	  preferentially	  activates	  RhoA	  and	  Rac	  and	  has	  a	  little	  to	  no	  effect	  on	  Cdc42	  [141].	  This	  was	  confirmed	  by	  an	  accumulation	  of	  the	  GTP-­‐bound	  RhoA	  and	  Rac	  in	  Cos7	  cells	  upon	  CNF2-­‐mediated	  induction	  [141].	  	   Although	  the	  receptor	  for	  CNF2	  has	  not	  been	  identified,	  it	  is	  predicted	  to	  share	  the	  same	  or	  similar	  receptors	  as	  CNF1	  due	  to	  their	  sequence	  homology	  [89].	  CNF2	  shows	  binding	  capability	  to	  LRP,	  when	  exposed	  to	  exogenous	  LRP	  or	  to	  surface	  
	   13	  
exposed	  LRP	  [89].	  However,	  the	  degree	  of	  CNF2	  bound	  to	  LRP	  is	  less	  than	  that	  of	  CNF1	  [89].	  Furthermore,	  when	  neutralizing	  antibody	  or	  exogenous	  LRP	  is	  present,	  the	  CNF2	  binding	  ability	  to	  host	  cells	  is	  not	  significantly	  altered	  [89],	  indicating	  that	  LRP	  can	  act	  as	  a	  binding	  partner	  of	  CNF2,	  but	  there	  might	  be	  involvement	  of	  other	  receptor(s)	  as	  well.	  CNF2	  is	  predicted	  to	  use	  the	  endocytic	  pathway,	  because	  the	  toxin	  entry	  is	  inhibited	  when	  cells	  are	  pretreated	  with	  methylamine	  chloride,	  which	  increases	  endosomal	  and	  lysosomal	  pH,	  thereby	  inhibiting	  membrane	  translocation	  of	  toxins	  [108].	  Like	  CNF1,	  CNF2	  showed	  differential	  toxin	  responses	  to	  acidification	  inhibitors,	  when	  cells	  were	  treated	  with	  moderate	  amounts	  of	  inhibitors,	  causing	  an	  enhancement	  of	  toxin-­‐mediated	  SRE-­‐luciferase	  activity	  [122].	  It	  follows	  that	  the	  translocation	  of	  CNF2	  also	  requires	  some	  acidification	  of	  the	  endosomes	  but	  moderate	  inhibition	  of	  the	  acidification	  promotes	  the	  translocation	  of	  CNF2,	  leading	  to	  enhancement	  of	  the	  toxin	  activity.	  	  	  
1.4.3.	  Cytotoxic	  Necrotizing	  Factor	  3	  (CNF3)	  	   CNF3	  is	  the	  most	  recently	  identified	  member	  of	  this	  family.	  It	  was	  isolated	  from	  necrotoxic	  Escherichia	  coli	  (NTEC)	  in	  sheep	  and	  goats	  [98].	  CNF3	  shares	  70%	  of	  sequence	  identity	  with	  CNF1/2,	  and	  68%	  with	  CNFy.	  In	  addition,	  the	  conserved	  active	  site	  residues	  essential	  for	  activity	  in	  the	  other	  CNFs	  (C866	  and	  H881)	  are	  also	  found	  in	  CNF3	  (C865	  and	  H880).	  Like	  CNF1,	  CNF3	  activates	  RhoA,	  Rac	  and	  Cdc42,	  though	  the	  activation	  of	  Rho	  A	  by	  CNF3	  is	  5-­‐10	  times	  greater	  than	  that	  of	  CNF1	  [140].	  Furthermore,	  CNF3	  and	  CNFy	  appear	  to	  enter	  the	  same	  cell	  lines,	  implicating	  they	  use	  the	  same	  receptors	  to	  gain	  access	  to	  their	  targets	  [140].	  This	  observation	  is	  further	  highlighted	  by	  a	  phylogenetic	  tree	  analysis	  (Figure	  2D),	  showing	  that	  CNFy	  is	  most	  closely	  related	  to	  CNF3.	  CNF3	  is	  also	  closely	  related	  to	  CNF1/2.	  As	  CNF1,	  2	  and	  3	  are	  identified	  in	  different	  strains	  of	  E.	  coli,	  homology	  between	  them	  is	  expected.	  Interestingly,	  the	  relationship	  between	  CNF3	  and	  CNFy	  further	  alludes	  to	  similar	  mode	  of	  action	  by	  these	  two	  toxins.	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1.4.4.	  Cytotoxic	  Necrotizing	  Factor	  from	  Yersinia	  pseudotuberculosis	  (CNFy)	  	   CNFy	  was	  first	  identified	  in	  cell	  extracts	  from	  Yersinia	  pseudotuberculosis,	  where	  it	  caused	  multinucleation	  in	  cells	  in	  a	  similar	  manner	  to	  that	  of	  CNF1	  [84].	  A	  gene	  responsible	  for	  this	  activity	  was	  encoded	  on	  the	  bacterial	  chromosome,	  producing	  a	  1,013	  amino	  acid	  protein	  toxin	  (CNFy)	  that	  shares	  61%	  amino	  acid	  sequence	  identity	  with	  CNF1	  [84].	  Unlike	  the	  other	  CNFs	  from	  E.	  coli,	  CNFy	  activates	  selectively	  Rho	  A,	  but	  not	  Rac	  or	  Cdc42	  [50],	  since	  it	  caused	  RhoA-­‐mediated	  stress	  fiber	  formation,	  but	  no	  membrane	  ruffling	  or	  formation	  of	  filopodia	  or	  lamellipodia,	  which	  would	  be	  indicative	  of	  Rac	  or	  Cdc42	  activation.	  CNFy	  induced	  morphological	  changes	  in	  cultured	  cells	  and	  showed	  RhoA	  mobility	  shift	  by	  SDS-­‐PAGE,	  similar	  to	  CNF1	  and	  CNF2	  [50].	  Activation	  of	  RhoA	  by	  deamidation	  at	  Glu63	  was	  confirmed	  by	  mass	  spectroscopy	  [50].	  	  	   Although	  CNF1	  and	  CNFy	  share	  homology	  in	  their	  binding	  domains,	  they	  appear	  to	  bind	  to	  different	  host	  cell	  receptors	  [10].	  While	  CNF1	  enters	  Caco2	  and	  CHO-­‐K1	  cells,	  CNFy	  does	  not	  [10].	  CNFy	  uptake	  is	  not	  inhibited	  by	  pretreatment	  of	  HeLa	  cells	  with	  catalytically	  inactive	  CNF1,	  while	  in	  the	  reverse	  experiment,	  CNFy	  affects	  CNF1	  uptake	  (i.e.	  preincubation	  of	  HeLa	  cells	  with	  catalytically	  inactive	  CNFy),	  indicating	  partial	  receptor	  overlap	  between	  the	  two	  toxins	  [10].	  More	  recently,	  CNFy	  was	  shown	  to	  use	  the	  same	  receptor	  as	  CNF3	  [140].	  Both	  CNF1	  and	  CNFy	  are	  taken	  up	  into	  cells	  via	  clathrin/caveolin-­‐independent	  pathways,	  and	  membrane	  translocation	  occurs	  from	  acidified	  endosomes	  [10].	  Unlike	  CNF1	  and	  CNF2,	  whose	  activity	  increased	  in	  the	  presence	  of	  acidification	  inhibitors	  at	  moderate	  concentrations,	  CNFy	  did	  not	  show	  this	  differential	  response	  to	  acidification	  inhibitors.	  This	  difference	  might	  be	  due	  to	  differences	  in	  the	  acid-­‐base	  properties	  of	  the	  toxin,	  specifically	  between	  residues	  119-­‐267	  [122].	  	  
1.5.	  Pasteurella	  multocida	  Toxin	  (PMT)	  
1.5.1.	  PMT	  and	  Diseases	  Atrophic	  rhinitis	  (AR)	  is	  a	  disease	  of	  the	  upper	  respiratory	  tract	  found	  most	  commonly	  in	  pigs	  and	  other	  domestic	  animals	  [26,	  38,	  39].	  AR	  causes	  degeneration	  and	  atrophy	  of	  the	  nasal	  turbinate	  bones	  in	  piglets,	  which	  leads	  to	  abnormally	  small	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or	  irregularly-­‐shaped	  snouts	  [34,	  93].	  The	  primary	  cause	  of	  AR	  is	  associated	  with	  toxigenic	  strains	  of	  Pasteurella	  multocida	  and	  Bordetella	  bronchiseptica	  [49,	  111,	  112,	  127].	  Symptoms	  of	  infection	  may	  include	  pneumonia-­‐like	  respiratory	  dysfunction	  in	  swine	  and	  cattle	  [65,	  153]	  and	  dermonecrosis	  in	  both	  humans	  and	  animals	  from	  bite	  wounds	  [Reviewed	  in	  157].	  Because	  of	  the	  ability	  of	  P.	  multocida	  to	  infect	  a	  wide	  range	  of	  animal	  species,	  it	  can	  have	  a	  significant	  health	  and	  economic	  impact.	  	  	  The	  toxigenic	  type	  D	  and	  some	  A	  strains	  of	  P.	  multocida	  strains	  produce	  a	  major	  virulence	  factor	  responsible	  for	  AR,	  an	  intracellularly-­‐acting	  mitogenic	  toxin	  (PMT)	  that	  is	  potent	  and	  heat-­‐labile	  [77,	  117].	  Exposure	  to	  PMT	  can	  cause	  progressive	  AR,	  with	  cases	  ranging	  from	  moderate	  to	  severe	  (Figure	  9).	  PMT	  induces	  localized	  osteolysis	  in	  the	  nasal	  turbinates	  and	  causes	  bone	  destruction	  through	  increased	  osteoclastic	  bone	  resorption	  [34,	  59,	  93].	  Purified	  PMT	  alone	  can	  cause	  many	  of	  the	  same	  physiological	  effects	  as	  the	  bacterium.	  Although	  B.	  
bronchiseptica,	  which	  is	  spread	  widely	  through	  herds	  of	  swine,	  leads	  to	  mild,	  non-­‐progressive	  cases	  of	  AR,	  it	  can	  also	  act	  synergistically	  with	  PMT	  to	  cause	  severe	  AR	  disease	  [15].	  	  
1.5.2.	  Structural	  Architecture	  and	  Intoxication	  Process	  PMT	  is	  a	  1,285	  amino	  acid	  single-­‐chain	  polypeptide	  protein	  toxin	  of	  146-­‐kDa	  that	  has	  domain	  architecture	  similar	  to	  the	  other	  dermonecrotic	  toxins.	  The	  functional	  domains	  of	  PMT	  are	  located	  in	  the	  N-­‐terminus	  for	  binding	  and	  translocation	  and	  the	  C-­‐terminus	  for	  catalytic	  activity	  [18,	  67,	  118,	  156].	  Specifically,	  the	  N-­‐terminal	  region	  comprised	  of	  residues	  1-­‐505	  has	  been	  shown	  to	  contain	  the	  binding	  and	  translocation	  domain,	  as	  evidenced	  by	  the	  ability	  of	  a	  chimeric	  PMT-­‐DTa	  (catalytic	  A	  domain	  of	  DT)	  to	  deliver	  DTa	  to	  the	  cytosol	  [8].	  The	  C-­‐terminal	  activity	  domain	  (residues	  575-­‐1285)	  consists	  of	  three	  subdomains,	  namely	  C1,	  C2	  and	  C3	  [67].	  The	  C1	  domain	  harbors	  a	  membrane-­‐targeting	  motif	  [62]	  that	  consists	  of	  a	  four	  helical	  bundle	  (residues	  590-­‐670)	  that	  recruits	  the	  rest	  of	  the	  C-­‐terminal	  portion	  of	  PMT	  to	  the	  plasma	  membrane	  [43,	  62].	  The	  function	  of	  the	  C2	  domain	  has	  yet	  to	  be	  determined,	  but	  it	  is	  suggested	  to	  have	  a	  secondary	  enzymatic	  function	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[67].	  The	  C3	  domain	  is	  the	  minimum	  catalytic	  domain	  [2]	  that	  contains	  a	  fold	  reminiscent	  of	  a	  cysteine	  protease	  and	  a	  catalytic	  triad:	  an	  essential	  cysteine	  residue	  (position	  at	  1165)	  [18,	  148],	  a	  histidine	  residue	  (position	  at	  1205)	  [100],	  and	  an	  aspartic	  acid	  (position	  at	  1220)	  [67]	  (Figure	  10).	  	  Much	  work	  has	  been	  focused	  on	  deciphering	  toxin	  activity	  and	  cellular	  effects	  on	  the	  host,	  and	  very	  little	  is	  known	  about	  cellular	  uptake,	  intracellular	  trafficking,	  and	  the	  process	  of	  translocation.	  It	  has	  been	  suggested	  that	  PMT	  might	  use	  a	  ganglioside	  as	  a	  receptor	  to	  gain	  access	  to	  host	  cells	  [30,	  114].	  However,	  recent	  studies	  suggest	  this	  may	  not	  be	  the	  case	  and	  indeed	  have	  shown	  that	  PMT	  binds	  directly	  to	  membrane	  phospholipids	  rather	  than	  gangliosides	  [16].	  When	  the	  binding	  ability	  of	  PMT	  was	  examined	  using	  TLC-­‐overlay	  binding	  or	  pull-­‐down	  experiments	  with	  reconstituted	  membrane	  lipids	  or	  liposomes,	  full-­‐length	  PMT	  and	  the	  N-­‐terminal	  fragment	  (PMT-­‐N)	  did	  not	  bind	  to	  gangliosides	  (GM1,	  GM2	  or	  GM3),	  but	  instead	  bound	  to	  membrane	  phospholipids	  [16].	  The	  primary	  binding	  partner	  was	  found	  to	  be	  sphingomyelin	  along	  with	  phosphatidylcholine	  and	  other	  lipid	  components.	  It	  was	  also	  suggested	  that	  PMT	  has	  a	  protein	  co-­‐receptor	  [16].	  Although	  the	  detailed	  mechanism	  by	  which	  PMT	  gains	  entry	  into	  the	  host	  cytosols	  is	  still	  incomplete,	  several	  lines	  of	  evidence	  suggest	  that	  after	  uptake	  by	  the	  host,	  PMT	  goes	  through	  the	  endocytic	  pathway	  to	  deliver	  the	  activity	  domain	  into	  the	  cytosol.	  Upon	  interaction	  with	  the	  host	  receptor	  at	  the	  membrane,	  PMT	  was	  shown	  to	  enter	  the	  cell	  through	  Arf6-­‐dependent	  endocytosis	  [121].	  PMT	  trafficking	  from	  early	  to	  late	  endosome	  was	  also	  shown	  to	  be	  important	  for	  toxin	  delivery	  [121].	  The	  disassembly	  of	  microtubules	  and	  the	  disruption	  of	  actin	  polymerization	  inhibit	  the	  mitogenic	  activity	  of	  PMT	  [121].	  Toxin	  activity	  was	  blocked	  when	  a	  weak	  base,	  such	  as	  NH4Cl,	  chloroquine	  or	  methylamine,	  was	  used	  to	  buffer	  endosomal	  acidification	  [121,	  125]	  or	  when	  a	  specific	  inhibitor	  for	  H+-­‐ATPase,	  Bafilomycin	  A1,	  was	  used	  [7,	  121].	  Additionally,	  low	  pH-­‐dependent	  translocation	  at	  the	  cell	  membrane	  was	  observed,	  even	  in	  the	  presence	  of	  bafilomycin	  A1	  [7].	  All	  of	  these	  results	  point	  towards	  an	  acidic	  compartment,	  i.e.	  late	  endosomes,	  as	  the	  site	  of	  translocation	  for	  PMT	  (Figure	  11).	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Residues	  402-­‐457	  make	  up	  a	  putative	  helix-­‐loop-­‐helix	  transmembrane	  region	  that	  is	  predicted	  to	  play	  an	  important	  role	  in	  the	  translocation	  of	  PMT	  [7].	  The	  loop	  region	  (residues	  424-­‐436)	  contains	  three	  acidic	  residues	  (D425,	  D431	  and	  E434),	  which	  were	  proposed	  to	  play	  a	  similar	  role	  as	  that	  found	  in	  CNF1	  (D373,	  D379	  and	  E382/383)	  [7].	  However,	  a	  mutation	  at	  D401	  just	  outside	  of	  the	  helix-­‐loop-­‐helix	  motif	  abolished	  PMT	  activity	  completely	  [7].	  This	  result	  suggests	  PMT	  might	  use	  a	  slightly	  different	  mechanism	  than	  CNF1	  to	  gain	  access	  to	  the	  cytosol.	  	  	  
1.5.3.	  Intracellular	  Effects	  Once	  inside	  the	  host	  cell,	  PMT	  is	  known	  to	  cause	  pleiotropic	  effects	  [Reviewed	  in	  156].	  Global	  and	  local	  effects	  of	  host	  molecular	  processes	  caused	  by	  PMT	  have	  mitogenic	  traits.	  In	  addition,	  PMT	  displays	  characteristics	  of	  a	  negative	  regulator	  of	  signaling	  pathways	  involved	  in	  differentiation	  [Reviewed	  in	  156].	  All	  of	  these	  diverse	  effects	  have	  been	  attributed	  to	  the	  action	  of	  PMT	  on	  its	  target	  heterotrimeric	  G-­‐protein	  substrates.	  The	  heterotrimeric	  G	  protein	  family	  is	  comprised	  of	  four	  main	  family	  members	  that	  are	  further	  divided	  into	  subgroups,	  each	  of	  which	  regulates	  downstream	  signaling	  pathways	  through	  their	  cognate	  effector	  proteins	  [reviewed	  in	  28].	  Inactive,	  GDP-­‐bound	  heterotrimeric	  G	  proteins	  (α	  subunit	  and	  βγ	  subunits)	  are	  complexed	  with	  their	  cognate	  G-­‐protein-­‐coupled	  receptors	  (GPCR).	  Once	  activated,	  the	  GPCR	  acts	  as	  a	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  to	  cause	  a	  conformational	  change	  that	  promotes	  GTP	  exchange	  of	  the	  GDP	  by	  the	  G-­‐protein	  α	  subunit	  [45,	  120,	  151].	  The	  active,	  GTP-­‐bound	  α	  subunit	  dissociates	  from	  the	  complex,	  releasing	  the	  βγ	  subunit.	  Both	  α	  and	  βγ	  subunits	  interact	  with	  their	  cognate	  effector	  proteins	  to	  elicit	  signal	  transduction	  (Figure	  12).	  PMT	  targets	  specifically	  the	  α	  subunits	  of	  the	  Gq,	  Gi,	  G11,	  and	  G12/13	  proteins	  [6,	  99,	  102,	  104],	  where	  it	  deamidates	  an	  active	  site	  glutamine	  residue	  in	  the	  switch	  II	  region	  of	  the	  α	  subunit	  [104]	  (Figure	  13).	  This	  causes	  persistent	  activation	  of	  the	  G	  proteins	  [6,	  99,	  102,	  104].	  Activation	  of	  Gq	  by	  PMT	  leads	  to	  the	  activation	  of	  phospholipase	  Cβ	  (PLCβ1),	  causing	  an	  increase	  in	  intracellular	  Ca2+,	  diacylglycerol	  (DAG),	  and	  inositoltrisphosphate	  (IP3)	  levels	  [2,	  3,	  85,	  95,	  125,	  138,	  159,	  160].	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Activation	  of	  Gq	  and	  G12/13	  causes	  cytoskeletal	  changes	  via	  Rho-­‐dependent	  actin	  signaling	  [72,	  103,	  129,	  160].	  Activation	  of	  Gi	  causes	  inhibition	  of	  adenylyl	  cyclase	  activity	  [101],	  causing	  downregulation	  of	  cAMP-­‐dependent	  signaling	  pathways	  (Figure	  14).	  It	  is,	  therefore	  expected	  that	  the	  outcomes	  of	  PMT	  action	  on	  these	  G-­‐proteins	  are	  diverse.	  These	  include:	  (1)	  stimulation	  of	  mitogenic	  effects,	  including	  initiation	  of	  DNA	  synthesis	  [125],	  MAPK	  activation	  [136]	  and	  increased	  tyrosine	  phosphorylation	  [72];	  (2)	  stimulation	  of	  calcium	  signaling,	  including	  calcineurin-­‐dependent	  activation	  of	  the	  nuclear	  factor	  of	  activated	  T	  cells	  (NFAT)	  [3];	  (3)	  stimulation	  of	  kinase	  signaling,	  including	  increased	  protein	  kinase	  C-­‐dependent	  phosphorylation	  [139];	  and	  (4)	  stimulation	  of	  cytoskeletal	  rearrangement	  and	  changes	  in	  cell	  morphology	  [30,	  72].	  	  
1.5.4.	  Signal	  Transduction	  Pathways	  As	  mentioned	  above,	  PMT	  is	  involved	  in	  many	  cellular	  signaling	  pathways,	  causing	  a	  variety	  of	  disease	  symptoms.	  In	  this	  section,	  adipogenesis	  is	  discussed	  in	  more	  detail	  as	  an	  example	  of	  pathways	  affected	  by	  the	  activation	  of	  G-­‐proteins	  due	  to	  PMT	  intoxication.	  	  
1.5.4.1.	  Adipogenesis	  PMT	  prevents	  adipocyte	  differentiation	  and	  blocks	  adipogenesis	  under	  differentiation-­‐inducing	  conditions	  in	  a	  cell	  culture	  model	  using	  NIH	  3T3-­‐L1	  cells	  [3].	  PMT	  inhibits	  the	  expression	  of	  adipocyte	  specific	  markers,	  namely	  peroxisome-­‐proliferator-­‐activated	  receptor	  γ	  (PPARγ)	  and	  CAATT	  enhancer-­‐binding	  protein	  α	  (C/EBPα),	  in	  preadipocytes	  and	  completely	  downregulates	  the	  expression	  of	  these	  markers	  in	  mature	  adipocytes	  [3].	  Adipocyte	  differentiation	  requires	  β-­‐catenin	  degradation,	  suppression	  of	  preadipocyte	  factor	  1	  (Pref1)	  [12,	  42,	  142],	  and	  Wnt	  signaling.	  PMT	  has	  opposing	  effects	  on	  the	  abundance	  of	  these	  proteins,	  maintaining	  Pref1	  and	  β-­‐catenin	  protein	  levels	  [3].	  Furthermore,	  PMT	  is	  shown	  to	  downregulate	  Notch	  1	  expression	  [3].	  Notch	  1	  and	  Wnt/β-­‐catenin	  pathways	  play	  a	  key	  role	  in	  cell	  fate	  decisions	  [4].	  Interestingly,	  these	  PMT	  effects	  on	  adipocytes	  and	  adipogenesis	  appear	  to	  occur	  not	  just	  through	  Gq-­‐dependent	  signaling.	  Evidence	  in	  support	  is	  the	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inability	  of	  cyclosporine	  A	  (CsA),	  an	  inhibitor	  of	  calcineurin,	  to	  rescue	  PMT-­‐mediated	  cellular	  effects	  [3],	  suggesting	  the	  involvement	  of	  other	  G-­‐protein	  signaling	  pathways.	  	  
1.6.	  Aims	  The	  purpose	  of	  this	  thesis	  is	  to	  address	  two	  major	  questions	  regarding	  toxin	  action:	  (1)	  What	  additional	  signal	  transduction	  pathways	  involved	  in	  adipogenesis	  are	  affected	  by	  PMT	  and	  the	  other	  dermonecrotic	  toxins?	  and	  (2)	  What	  are	  the	  determinants	  involved	  in	  PMT	  trafficking	  and	  translocation	  of	  the	  C-­‐terminal	  activity	  domain(s)?	  Chapter	  2	  deals	  with	  the	  involvement	  of	  dermonecrotic	  toxins	  in	  adipogenesis.	  We	  previously	  demonstrated	  that	  PMT	  blocks	  adipogenesis	  and	  adipocyte	  differentiation	  through	  suppression	  of	  Notch1	  and	  stabilization	  of	  β-­‐catenin	  and	  Pref1/Dlk1	  [3].	  My	  overall	  goal	  for	  this	  project	  is	  to	  investigate	  the	  role	  of	  other	  dermonecrotic	  toxins,	  specifically	  DNT	  and	  CNF1,	  in	  adipogenesis	  and	  adipocyte	  differentiation,	  in	  comparison	  with	  PMT,	  as	  well	  as	  to	  explore	  which	  G-­‐protein	  signaling	  pathways	  are	  used	  for	  PMT-­‐mediated	  notch1	  downregulation.	  To	  investigate	  association	  of	  other	  dermonecrotic	  toxins	  in	  adipogenesis	  and	  adipocyte	  differentiation	  in	  collaboration	  with	  Dr.	  Leila	  Aminova,	  I	  studied	  the	  effects	  of	  PMT,	  CNF1	  and	  DNT	  on	  murine	  NIH	  3T3-­‐L1	  cell	  differentiation	  and	  adipogenesis.	  The	  3T3-­‐L1	  cell	  line	  is	  a	  culture	  model	  for	  adipocyte	  differentiation	  [5].	  Temporary	  exposure	  to	  differentiation	  inducing	  culture	  conditions	  triggers	  adipogenesis,	  thereby	  changing	  the	  expression	  of	  many	  downstream	  adipogenesis	  genes	  and	  transcription	  factors.	  Contact	  inhibition	  stops	  preadipocyte	  proliferation	  and	  cells	  undergo	  terminal	  differentiation	  upon	  stimulation	  with	  differentiation	  inducers.	  I	  examined	  whether	  the	  dermonecrotic	  toxin-­‐induced	  inhibition	  of	  adipogenesis	  and	  adipocyte	  differentiation	  occur	  through	  Rho/ROCK	  signaling.	  In	  addition,	  I	  investigated	  whether	  PMT-­‐mediated	  notch1	  downregulation	  is	  through	  the	  Gq	  or	  G12/13	  signaling	  pathway.	  Since	  PMT	  activates	  Rho/ROCK	  pathway	  indirectly,	  I	  wanted	  to	  see	  which	  of	  these	  G-­‐protein	  pathways	  is	  the	  target	  of	  PMT-­‐induced	  inhibition	  of	  adipogenesis.	  As	  shown	  previously	  with	  PMT,	  I	  expected	  the	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other	  dermonecrotic	  toxins	  (DNT	  and	  CNF1)	  to	  behave	  similarly	  due	  to	  their	  similar	  cytotoxic	  activities	  in	  blocking	  adipogenesis	  and	  adipocyte	  differentiation.	  Results	  from	  these	  experiments	  helped	  us	  gain	  a	  better	  understanding	  of	  adipogenesis	  and	  adipocyte	  differentiation,	  improving	  our	  definition	  of	  the	  role	  of	  Rho/ROCK	  and	  Notch1	  signaling.	  Identifying	  and	  defining	  these	  molecular	  players	  in	  signal	  transduction	  pathways	  also	  helped	  us	  better	  understand	  the	  molecular	  dynamics	  of	  cellular	  processes	  in	  cells.	  	  My	  overall	  goal	  of	  the	  second	  project	  was	  to	  further	  define	  the	  trafficking	  pathway	  and	  the	  translocation	  process	  of	  PMT,	  which	  is	  discussed	  in	  chapter	  3.	  As	  mentioned	  above,	  a	  picture	  of	  the	  trafficking	  pathway	  for	  PMT	  is	  slowly	  emerging,	  yet	  there	  is	  still	  some	  evidence	  missing	  to	  completely	  define	  the	  pathway.	  In	  order	  to	  gain	  a	  better	  understanding	  of	  the	  mode	  of	  toxin	  action,	  I	  focused	  on	  translocation	  steps	  utilized	  by	  PMT	  and	  how	  PMT	  delivers	  its	  C-­‐terminus	  into	  host	  cytosol.	  Specifically,	  I	  intended	  to	  first	  identify	  the	  region(s)/sequences	  of	  PMT	  that	  get	  translocated	  into	  the	  host	  cytosol.	  Next,	  I	  aimed	  to	  determine	  the	  cellular	  and	  protein	  determinants	  that	  facilitate	  cargo	  delivery.	  Lastly,	  I	  wanted	  to	  address	  what	  happens	  to	  the	  N-­‐terminus	  of	  the	  toxin	  after	  the	  delivery	  of	  its	  C-­‐terminus.	  	  To	  examine	  the	  region(s)	  or	  sequences	  that	  get	  translocated	  into	  the	  cytosol,	  I	  used	  an	  HA-­‐tagged	  full-­‐length	  PMT	  to	  track	  localization	  of	  the	  intact	  toxin	  protein	  and	  intracellularly	  track	  fragments	  of	  the	  toxin	  after	  internalization.	  This	  would	  help	  us	  ascertain	  how	  the	  translocation	  process	  occurs	  and	  whether	  or	  not	  the	  delivery	  of	  the	  activity	  domain	  is	  associated	  with	  its	  release	  or	  some	  other	  mechanism	  such	  as	  tethering.	  	  To	  investigate	  the	  cellular	  and	  protein	  determinants	  that	  initiate	  delivery,	  I	  used	  an	  N-­‐terminal	  mutant	  with	  an	  exogenous	  cargo	  (GFP),	  PMT-­‐N-­‐GFP	  (N	  =	  residues	  1-­‐568),	  to	  examine	  toxin	  trafficking	  inside	  the	  host	  cells	  by	  fluorescence	  confocal	  microscopy.	  Organelle	  specific	  markers	  expressing	  DsRed	  were	  employed	  to	  visualize	  co-­‐localization	  of	  PMT	  (GFP)	  with	  a	  specific	  organelle.	  Next,	  I	  examined	  dose	  and	  time	  dependency	  of	  the	  toxin	  entry	  using	  PMT-­‐N-­‐GFP	  by	  Western	  blot.	  I	  further	  studied	  the	  localization	  of	  the	  toxin	  and	  toxin	  fragments	  by	  using	  subcellular	  fractionation,	  which	  I	  expect	  to	  be	  a	  useful	  method	  to	  assess	  toxin	  uptake	  and	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processing	  by	  host	  cells.	  By	  using	  a	  density	  gradient	  to	  separate	  cellular	  compartments,	  I	  confirmed	  localization	  of	  PMT	  inside	  the	  host	  during	  intoxication.	  This	  helped	  define	  the	  trafficking	  pathway	  used	  by	  PMT,	  as	  well	  as	  the	  site(s)	  of	  toxin	  processing	  and/or	  translocation.	  	  Lastly,	  I	  aimed	  to	  delineate	  the	  fate	  of	  the	  N-­‐terminus	  of	  the	  toxin.	  Upon	  delivery	  of	  the	  cargo,	  the	  toxin	  could	  remain	  in	  vesicles,	  localize	  to	  lysosome	  to	  follow	  degradation	  pathway,	  or	  traffic	  back	  to	  extracellular	  space	  by	  a	  recycling	  mechanism.	  To	  address	  this	  issue,	  I	  used	  biotinylated	  N-­‐terminal	  mutants	  (PMT-­‐N-­‐GFP	  and	  PMT-­‐N)	  and	  full-­‐length	  PMT	  (PMT-­‐GFP)	  to	  examine	  toxin	  processing	  inside	  the	  host.	  Until	  now,	  we	  were	  unable	  to	  probe	  the	  fate	  of	  the	  N-­‐terminus	  after	  the	  translocation	  event	  but	  I	  was	  able	  to	  visualize	  whether	  or	  not	  further	  processing	  of	  the	  toxin	  occurs	  by	  taking	  advantage	  of	  biotin.	  Results	  from	  these	  experiments	  further	  defined	  the	  trafficking	  pathway	  for	  PMT.	  	  Identifying	  and	  refining	  the	  trafficking	  pathway	  of	  PMT	  will	  help	  us	  gain	  a	  better	  understanding	  of	  bacterial	  toxin	  entry	  mechanisms,	  which	  could	  aid	  in	  elucidating	  the	  molecular	  dynamics	  of	  cellular	  processes	  in	  cells.	  This	  will	  aid	  us	  designing	  inhibitors	  to	  block	  intoxication	  by	  these	  toxins,	  as	  well	  as	  further	  exploring	  possibility	  of	  using	  them	  as	  a	  delivery	  vehicles	  to	  transport	  new	  therapeutics	  into	  targeted	  cells.	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1.7.	  Figures	  
	  
Figure	  1.1.	  A	  schematic	  diagram	  of	  general	  AB	  toxin	  entry.	  	  The	   retrograde	   transport	   involves	   (1)	   binding	   of	   toxin	   at	   the	   cell	   surface,	   (2)	  internalization	  of	   the	   toxin	   through	   receptor-­‐mediated	   endocytosis,	   (3)	   trafficking	  through	   endosomes,	   golgi	   and	   ER,	   and	   (4)	   release	   of	   the	   activity	   domain	   into	   the	  cytosol.	   The	   endocytic	   pathway	   involves	   (1)	   toxin	   binding	   to	   the	   receptor,	   (2)	  uptake	  via	  receptor-­‐mediated	  endocytosis,	  (3)	  conformational	  change	  triggered	  by	  a	  low	  pH	  in	  the	  late	  endosome	  to	  translocate	  activity	  domain	  through	  the	  endosomal	  membrane,	  and	  (4)	  release	  of	  the	  activity	  domain	  into	  the	  cytosol.	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Figure	  1.2.	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Figure	  1.2.	  continued	  	  
B	  
	  
	  	  	  
(B)	  N-­‐terminal	  sequence	  (residues	  1-­‐500)	  alignment	  of	  CNFs	  and	  PMT.	  	  Clustalw	  was	  used	  to	  perform	  multiple	  sequence	  alignment.	  An	  *(asterisk)	  indicates	  positions	   which	   have	   a	   single,	   fully	   conserved	   residue.	   Red	   indicates	   small	   and	  hydrophobic	  amino	  acids,	  blue	  indicates	  acidic	  amino	  acids,	  magenta	  indicates	  basic	  amino	  acids,	  green	  indicates	  hydroxyl,	  sulfhydryl,	  amine,	  and	  glycine.	  	  	  Sequences	  used	  to	  generate	  alignment	  (PMT:	  GenBank:	  CAA01892.1;	  CNF1GenBank:	  CAA50007.1;	   CNF2GenBank:	   AAA18229.1;	   CNF3GenBank:	   CAK19001.1;	  CNFyGenBank:	  AAG45433.1).	  
!"
	   25	  
Figure	  1.2.	  continued	  	  
C	  
	  
(C)	  C-­‐terminal	  sequence	  (last	  300	  amino	  acids)	  alignment	  of	  CNFs	  and	  DNT.	  Clustalw	  was	  used	  to	  perform	  multiple	  sequence	  alignment.	  An	  *(asterisk)	  indicates	  positions	   which	   have	   a	   single,	   fully	   conserved	   residue.	   Red	   indicates	   small	   and	  hydrophobic	  amino	  acids,	  blue	  indicates	  acidic	  amino	  acids,	  magenta	  indicates	  basic	  amino	  acids,	  green	  indicates	  hydroxyl,	  sulfhydryl,	  amine,	  and	  glycine.	  	  	  Sequences	  used	  to	  generate	  alignment	  (CNF1GenBank:	  CAA50007.1;	  CNF2GenBank:	  AAA18229.1;	   CNF3GenBank:	   CAK19001.1;	   CNFyGenBank:	   AAG45433.1;	   DNTNCBI	  Reference	  Sequence:	  NP_881965.1).	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Figure	  1.2.	  continued	  	  
	  
D	  
	  	  	  	  
(D)	  Phylogenetic	  tree	  highlighting	  the	  relationship	  among	  the	  dermonecrotic	  
toxins.	  CNF1	   and	   CNF2	   are	   closely	   related,	   while	   CNF3,	   CNFy,	   DNT	   and	   PMT	   are	   more	  distantly	  related.	  Branch	  length	  (the	  indicated	  numbers)	  equates	  substitution	  rates.	  Clustalw	  was	  used	  to	  generate	  the	  map.	  Sequences	  used	  to	  generate	  the	  map	  (PMT:	  GenBank:	   CAA01892.1;	   CNF1GenBank:	   CAA50007.1;	   CNF2GenBank:	   AAA18229.1;	  CNF3GenBank:	   CAK19001.1;	   CNFyGenBank:	   AAG45433.1;	   DNTNCBI	   Reference	  Sequence:	  NP_881965.1).	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Figure	  1.3.	  Schematic	  representation	  of	  DNT	  structure.	  	  The	  binding	  domain	   (2-­‐30),	   transmembrane	   region	   (45-­‐166),	   and	   activity	   domain	  (1176-­‐1464)	   are	   indicated	   along	   with	   predicted	   secondary	   structure	   of	   the	   cell-­‐binding	  domain	  (adapted	   from	  Fuyuki-­‐Miyazawa	  2011).	  The	  numbers	   indicate	   the	  amino	   acid	   positions,	   the	   underlined	   region	   represents	   the	   furin-­‐recognition	  sequence	   in	  which	  the	  circled	  residues	  are	  critical,	  and	  the	  triangle	  represents	   the	  furin	  cleavage	  site.	  	  




Cell-binding region of DNT
Fig. 5. The amino acid sequence and predicted secondary struc-
ture of the cell-binding domain of DNT. The numbers show the amino
acid positions. The underline indicates the furin-recognition site, in which
residues labeled with circles constitute the motif recognized by furin.
presence or type of the tagged peptide. The minimum
binding unit does not contain the furin-recognition site,
indicating that the binding of DNT occurs independently
of the intramolecular cleavage by furin or furin-like en-
doproteases. The Chou–Fasman analysis predicted that
DNT forms a helix-turn-helix structure at theN-terminus
of approximately 40 amino acids (Fig. 5). Therefore, the
DNT2–30 peptide should consist of the first helix and
half of the second helix, whereas DNT2–25, which failed
to compete with the full-length DNT, lacks almost all of
the second helix. These predictions imply that the steric
structure, helix-turn-helix, may be required for DNT to
recognize and bind to its specific receptor.
The functional receptor forDNT is still unknown. Iden-
tifying the receptor and elucidating the mode of action of
DNT is important for understanding how the toxin specif-
ically and effectively affects target cells. In this study, we
found that DNT2–30 encompasses the minimum unit re-
sponsible for binding to the receptor; using this fragment,
we are now conducting further work to identify the recep-
tor for the toxin.
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Figure	  1.4.	  A	  schematic	  diagram	  depicting	  proposed	  DNT	  entry.	  (1)	  DNT	  binds	   to	   its	   receptor,	  which	   triggers	  dynamin-­‐dependent	  endocytosis.	   (2)	  Upon	  entry	  to	  the	  endosome,	  the	  toxin	  gets	  cleaved	  by	  furin	  or	  a	  furin-­‐like	  protease,	  after	  which	  the	  toxin	  remains	  associated	  non-­‐covalently.	  (3)	  The	  activity	  domain	  is	  released	  into	  the	  cytosol.	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Figure	  1.6.	  Small	  GTPase	  regulation	  as	  a	  molecular	  switch.	  	  Inactive	   form,	  Rho	   is	  GDP-­‐bound.	  Rho	   is	  activated	  once	  GEF	  comes	   in	   to	  exchange	  GDP	  with	  GTP,	  and	  cause	  downstream	  signaling	  effects.	  GAP	  comes	  in	  to	  inactivate	  Rho,	  hence	  bringing	  cycle	  back	  to	  inactive	  form.	  DNT	  activates	  Rho	  and	  inhibits	  the	  activity	  of	  GAP,	  generating	  constitutive	  activation	  of	  Rho.	  GDI:	   GDP	   dissociation	   inhibitor,	   GEF:	   GDP/GTP	   exchange	   factor,	   GAP:	   GTPase-­‐activating	  protein.	  	  	  **include	  Rac	  Gln61	  and	  Cdc	  Gln61	  *polyamidation	  Putrescine:	  NH2(CH2)4NH2	  Spermidine:	  NH2(CH2)3NH(CH2)4NH2	  Spermine:	  NH2(CH2)3NH(CH2)4NH(CH2)3NH2	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Figure	  1.7.	  Schematic	  representation	  of	  CNF1	  structure.	  	  The	  binding	  domain	  (53-­‐190),	  transmembrane	  region	  (350-­‐412),	  secondary	  binding	  site	   (683-­‐730),	   and	   secondary	   binding	   site/activity	   domain	   (720-­‐1014)	   are	  indicated	  along	  with	  the	  cleavage	  site	  and	  catalytic	  triad	  (C866,	  H881,	  and	  V833).	  The	   secondary	   binding	   site	   has	   been	   demonstrated	   by	   two	   groups:	   *indicates	  secondary	  site	  shown	  by	  McNichol	  (2007)	  and	  **	  indicates	  secondary	  site	  shown	  by	  Piteau	  (2014).	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Figure	  1.8.	  A	  schematic	  diagram	  depicting	  proposed	  CNF1	  entry.	  	  (1)	  CNF1	  binds	  to	  its	  receptor,	  laminin,	  which	  triggers	  the	  uptake.	  (2)	  Upon	  entry	  to	  late	   endosome,	   conformational	   changes	   occur	   due	   to	   the	   low	   pH.	   (3)	   The	  translocated	  activity	  domain	   is	  cleaved	  by	  a	  host	   factor,	  and	  (4)	  gets	  released	   into	  cytosol.	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Figure	  1.9.	  PMT	  is	  the	  major	  causative	  agent	  for	  atrophic	  rhinitis.	  	  Pathological	   changes	   in	   nasal	   turbinate	   bones	   as	   well	   as	   exterior	   phenotype	   as	   a	  result	   of	   AR	   are	   shown.	   The	   various	   stages	   of	   atrophic	   rhinitis	   are	   depicted	   in	   a	  cross-­‐section	  of	  snout.	  Mild-­‐severe	  AR:	  the	  progression	  of	  bone	  destruction,	  causing	  complete	  loss	  of	  the	  nasal	  turbinate	  bones.	  Infection	  with	  PMT	  causes	  an	  imbalance	  between	   osteoblasts	   and	   osteoclasts	   and	   subsequent	   bone	   resorption,	   leading	   to	  degeneration	   of	   the	   nasal	   turbinate	   bones.	   This	   also	   causes	   an	   irregularly	   shaped	  snout.	  Copyright	   ©	   Cross-­‐section	   image	   (Wilson	   &	   Ho	   2006)	   and	   exterior	   phenotype	  (www.ThePigSite.com)	  -­‐	  Reproduced	  with	  Permission.	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Figure	  1.10.	  Schematic	  representation	  of	  PMT	  structure.	  	  The	   putative	   binding	   domain	   (1-­‐505),	   transmembrane	   region	   (402-­‐457),	   and	  activity	   domain	   (C1-­‐3:	   575-­‐1285)	   are	   indicated	   along	   with	   the	   catalytic	   triad	  (C1165,	  H1205,	  and	  D1220).	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Figure	  1.11.	  A	  schematic	  diagram	  depicting	  proposed	  mode	  of	  PMT	  entry.	  	  (1)	   PMT	   binds	   to	   its	   receptor.	   (2)	   Upon	   entry	   to	   late	   endosome,	   conformational	  changes	  occur	  due	   to	   the	   low	  pH.	   (3)	  The	   translocated	  activity	  domain	   is	   released	  into	  cytosol.	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Figure	  1.12.	  Regulation	  of	  the	  heterotrimeric	  GTPases.	  	  The	   activation	   of	   the	   GPCR	   through	   the	   exchange	   of	   GDP	   to	   GDP	   causes	  conformational	  change	  of	  the	  complex,	  releases	  the	  Gαβγ	  subunits,	  which	  stimulate	  the	  appropriate	  downstream	  signaling	  cascade.	  The	  G-­‐protein	  is	  inactivated	  through	  the	  action	  of	  GAP,	  and	  once	  again,	  forms	  a	  complex.	  When	   the	   heterotrimeric	   G	   proteins	   are	   activated	   by	   PMT,	   the	   GTPase	   cycle	   is	  inhibited.	   The	   toxin	   acts	   on	   the	   Gq/11-­‐,	   G12/13-­‐	   and	   Gi-­‐family	   to	   induce	   their	   signal	  transduction	  via	  their	  respective	  effectors.	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Figure	   1.13.	   Molecular	   mechanism	   of	   PMT	   activation	   of	   heterotrimeric	   G	  
proteins.	  	  The	  toxin	  deamidates	  a	  specific	  glutamine	  residue	  in	  the	  α-­‐subunit	  of	  heterotrimeric	  G	  proteins,	  converting	  it	  to	  a	  glutamic	  acid	  residue.	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Figure	   1.14.	   Summary	   of	   signaling	   pathways	   modulated	   by	   PMT	   and	   their	  
cellular	  outcomes.	  	  The	  diagram	  depicts	  pathways	   that	  PMT	  has	  effects	  on.	  The	  downstream	  outcome	  due	   to	  PMT	  action	   can	  be	   activation	   or	   inhibition	  depending	   on	   the	  pathway	   that	  PMT	  acts	  on.	  Schematic	  is	  adapted	  from	  [153].	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Chapter	  2:	  	  Rho/ROCK-­‐Dependent	  Inhibition	  of	  3T3-­‐L1	  
Adipogenesis	  by	  G-­‐Protein-­‐Deamidating	  Dermonecrotic	  Toxins:	  
Differential	  Regulation	  of	  Notch1,	  Pref1/Dlk1,	  and	  β-­‐Catenin	  
Signaling	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2.2.	  Introduction	  Bone	  resorption	  and	  subsequent	  atrophic	  rhinitis	  are	  characteristic	  outcomes	  attributed	  to	  the	  actions	  of	  PMT	  and	  DNT	  on	  differentiation	  and/or	  proliferation	  of	  osteoblasts	  and	  osteoclasts	  during	  respiratory	  infections	  in	  animals	  with	  their	  respective	  bacterial	  pathogens	  [1,	  2,	  10,	  18,	  19,	  20,	  33,	  43].	  Since	  bone-­‐forming	  osteoblasts	  and	  marrow	  adipocytes	  share	  a	  common	  mesenchymal	  stem	  cell	  origin,	  it	  is	  anticipated	  that	  these	  dermonecrotic	  toxins	  might	  also	  affect	  adipocyte	  differentiation.	  Indeed,	  there	  is	  some	  evidence	  that	  PMT	  exposure	  results	  in	  reduced	  body	  weight	  and	  fat	  in	  experimental	  animals	  [1,	  2,	  11,	  45].	  In	  support	  of	  this,	  we	  previously	  demonstrated	  that	  PMT	  treatment	  prevents	  adipocyte	  differentiation	  and	  blocks	  adipogenesis	  in	  cultured	  3T3-­‐L1	  cells	  [6].	  We	  showed	  that	  PMT	  prevents	  expression	  of	  key	  adipocyte-­‐specific	  markers	  C/EBPα	  and	  PPARγ	  in	  3T3-­‐L1	  preadipocytes,	  and	  downregulates	  these	  markers	  in	  mature	  adipocytes.	  PMT	  also	  prevented	  the	  downregulation	  of	  Pref1	  (also	  called	  Dlk1),	  an	  EGF-­‐like	  transmembrane	  protein	  that	  is	  highly	  expressed	  in	  certain	  tumors	  and	  carcinomas	  [12,	  25,	  26,	  50,	  51]	  and	  that	  is	  strongly	  downregulated	  in	  adipocytes	  [9,	  16,	  44].	  Furthermore,	  PMT	  completely	  downregulated	  Notch1	  mRNA	  and	  protein	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expression,	  while	  stabilizing	  β-­‐catenin	  protein	  levels	  [6].	  Notch1	  and	  Wnt/β-­‐catenin	  signaling	  pathways	  are	  involved	  in	  pivotal	  cell	  fate	  decisions	  [7].	  	  Gq-­‐PLCβ1	  activation	  of	  calcium	  signaling	  is	  known	  to	  block	  adipogenesis	  through	  activation	  of	  Ca2+-­‐calmodulin-­‐dependent	  calcineurin	  signaling	  [31,	  34].	  However,	  we	  previously	  found	  that	  the	  inhibitory	  effects	  of	  PMT	  on	  adipocyte	  differentiation	  and	  Notch1	  could	  not	  be	  reversed	  by	  treatment	  with	  the	  calcineurin	  inhibitor	  cyclosporine	  A	  (CsA)	  [6],	  suggesting	  that	  PMT-­‐induced	  Gq-­‐PLCβ1	  activation	  of	  calcium	  signaling	  is	  not	  the	  only	  signaling	  pathway	  employed	  by	  PMT	  to	  block	  adipocyte	  differentiation.	  	  This	  thesis	  chapter	  aims	  to	  further	  characterize	  the	  pathway	  that	  PMT	  utilizes	  to	  block	  adipocyte	  differentiation	  and	  adipogenesis,	  as	  well	  as	  the	  role	  of	  other	  dermonecrotic	  toxins	  (DNT	  and	  CNF1)	  in	  adipogenesis	  and	  adipocyte	  differentiation,	  in	  comparison	  with	  PMT.	  Although	  the	  connection	  between	  G-­‐protein	  signaling	  and	  Notch1	  signaling	  in	  adipogenesis	  is	  not	  fully	  understood,	  we	  considered	  the	  possibility	  that	  PMT-­‐induced	  blockade	  of	  adipocyte	  differentiation	  and	  adipogenesis	  might	  occur	  due	  to	  its	  indirect	  action	  on	  Rho-­‐GTPases	  through	  other	  heterotrimeric	  G	  proteins,	  such	  as	  G12/13.	  To	  explore	  this	  possibility,	  we	  first	  examined	  whether	  the	  other	  dermonecrotic	  toxins,	  DNT	  and	  CNF1,	  might	  also	  inhibit	  3T3-­‐L1	  differentiation	  and	  adipogenesis,	  and	  if	  so,	  whether	  they	  modulate	  Notch1	  and	  β-­‐catenin	  levels	  similar	  to	  PMT.	  As	  opposed	  to	  PMT,	  CNF	  and	  DNT	  directly	  modify	  and	  activate	  Rho-­‐GTPases	  and	  do	  not	  act	  on	  heterotrimeric	  G	  proteins.	  We	  first	  assessed	  whether	  or	  not	  preadipocytes	  can	  differentiate	  into	  mature	  adipocytes	  in	  the	  presence	  of	  the	  toxins,	  and	  the	  toxin	  effects	  on	  differentiation	  can	  be	  inhibited	  in	  the	  presence	  of	  ROCK	  inhibitor.	  Two	  isoforms	  of	  Rho-­‐associated	  kinases	  (ROCK1	  and	  ROCK2)	  mediate	  downstream	  signaling	  of	  Rho	  proteins,	  leading	  to	  actin	  reorganization,	  formation	  of	  actin	  filaments	  and	  focal	  adhesions	  as	  well	  as	  contractility	  [4].	  Since	  inhibition	  of	  ROCK	  signaling	  is	  known	  to	  enhance	  adipogenesis	  [35],	  we	  examined	  whether	  inhibition	  of	  Rho/ROCK	  signaling	  might	  counteract	  the	  toxic	  effects	  on	  3T3-­‐L1	  cells.	  Furthermore,	  we	  addressed	  the	  toxin	  effects	  on	  adipocyte	  differentiation	  by	  examining	  expression	  levels	  of	  known	  adipocyte	  markers	  (PPARγ,	  C/EBPα,	  Pref1/Dlk1	  and	  β-­‐catenin).	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Results	  from	  these	  experiments	  will	  help	  us	  gain	  a	  better	  understanding	  of	  adipogenesis	  and	  adipocyte	  differentiation,	  in	  particular	  a	  better	  definition	  of	  the	  role	  of	  Rho/ROCK	  and	  Notch1	  signaling.	  Identifying	  and	  characterizing	  these	  molecular	  players	  in	  signal	  transduction	  pathways	  will	  also	  help	  us	  better	  understand	  the	  molecular	  dynamics	  of	  cellular	  processes	  in	  cells.	  	  	  
2.3.	  Materials	  and	  Methods	  
2.3.1.	  Recombinant	  Toxins	  The	  pQE-­‐CNF1	  vector	  was	  provided	  kindly	  from	  Dr.	  Alison	  D.	  O’Brien	  at	  the	  Uniformed	  Services	  University	  [32].	  The	  pTHB-­‐DNT	  vector	  was	  constructed	  by	  subcloning	  the	  DNT	  gene	  into	  the	  BamHI	  and	  KpnI	  sites	  of	  the	  expression	  vector	  pTrcHisB	  (Invitrogen).	  The	  DNT	  gene	  was	  generated	  by	  PCR	  and	  subcloning	  using	  two	  overlapping	  DNT	  gene	  fragments	  from	  plasmids	  pDNT103	  and	  pDNT115,	  kindly	  obtained	  from	  Dr.	  Alison	  A.	  Weiss	  at	  the	  University	  of	  Cincinnati	  [46].	  His6-­‐tagged	  recombinant	  toxin	  proteins	  (rCNF1,	  rDNT	  and	  rPMT)	  were	  purified	  using	  methods	  similar	  to	  those	  previously	  described	  for	  rPMT	  [6],	  except	  rCNF1	  and	  rDNT	  were	  expressed	  in	  Escherichia	  coli	  XL1-­‐Blue	  cells	  under	  the	  induction	  of	  IPTG.	  Toxin	  concentrations	  were	  determined	  by	  NIH	  Image	  J	  digital	  image	  analysis	  of	  Pierce	  GelCode	  Blue-­‐stained	  SDS-­‐PAGE	  gels,	  using	  BSA	  as	  the	  standard.	  The	  toxins	  were	  stored	  at	  -­‐80°C	  until	  use.	  Biological	  activity	  of	  rPMT,	  rDNT	  and	  rCNF	  were	  confirmed	  by	  cell	  morphology	  assay,	  as	  previously	  described	  for	  rPMT	  [38,	  48],	  and	  by	  NFAT-­‐luciferase	  activation	  assay,	  as	  previously	  described	  for	  rPMT	  [5].	  	  
2.3.2.	  Cell	  Culture	  Murine	  3T3-­‐L1	  preadipocytes	  (ATCC,	  CL-­‐173)	  were	  maintained	  at	  37°C	  and	  5%	  carbon	  dioxide	  in	  10%	  fetal	  bovine	  serum	  (FBS,	  Atlanta	  Biologicals)-­‐medium,	  consisting	  of	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM,	  Invitrogen)	  supplemented	  with	  10%	  heat-­‐inactivated	  FBS,	  pH	  7.4,	  100	  units/mL	  penicillin	  G,	  and	  100	  µg/mL	  streptomycin.	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2.3.3.	  Fluorescence	  Microscopy	  3T3-­‐L1	  cells	  were	  treated	  overnight	  with	  the	  indicated	  amount	  of	  toxins	  in	  the	  presence	  or	  absence	  of	  10	  µM	  ROCK	  inhibitor,	  Y-­‐27632	  (Sigma,	  cat	  #Y0503).	  Cells	  were	  then	  washed	  3	  times	  with	  phosphate-­‐buffered	  saline	  (PBS)	  and	  treated	  with	  0.5	  %	  formaldehyde	  for	  15	  min.	  Cells	  were	  washed	  3	  times	  with	  PBS,	  treated	  with	  0.1	  %	  Triton	  X-­‐100,	  washed	  again	  with	  PBS	  and	  treated	  with	  TRITC-­‐phalloidin	  (Sigma,	  cat	  #P1951)	  to	  stain	  F-­‐actin	  and	  DAPI	  (Sigma,	  cat	  #D9564)	  to	  stain	  nuclei	  before	  washing	  and	  visualizing	  with	  fluorescence	  microscope.	  Images	  were	  taken	  using	  an	  Olympus	  IX-­‐70	  inverted	  fluorescence	  microscope	  equipped	  with	  a	  digital	  camera	  (Olympus	  DP70).	  	  
2.3.4.	  3T3-­‐L1	  Cell	  Differentiation	  Differentiation	  studies	  using	  3T3-­‐L1	  cells	  were	  done	  essentially	  as	  previously	  described	  with	  slight	  modifications	  [6].	  In	  brief,	  3T3-­‐L1	  cells	  were	  plated	  onto	  a	  6-­‐well	  plate	  and	  grown	  for	  5-­‐6	  days	  until	  confluence,	  changing	  the	  medium	  every	  two	  days.	  Two	  days	  post-­‐confluence,	  denoted	  as	  day	  0,	  the	  cells	  were	  induced	  to	  differentiate	  in	  the	  presence	  or	  absence	  of	  1	  nM	  of	  the	  indicated	  toxin	  in	  normal	  10%	  FBS-­‐DMEM	  or	  in	  differentiation	  medium	  (DM),	  consisting	  of	  normal	  10%	  FBS-­‐DMEM	  with	  1	  mM	  dexamethasone	  (Sigma,	  cat	  #D2915),	  0.5	  mM	  3-­‐isobutyl-­‐1-­‐methylxanthine	  (Sigma,	  cat	  #I5879),	  and	  10	  mg/mL	  of	  bovine	  insulin	  (Sigma,	  cat	  #I6634).	  Two	  days	  after	  differentiation	  induction,	  the	  medium	  was	  changed	  to	  post-­‐DM,	  consisting	  of	  normal	  10%	  FBS-­‐DMEM	  with	  10	  µg/mL	  of	  insulin.	  In	  the	  case	  of	  experiments	  involving	  treatment	  with	  ROCK	  inhibitor,	  Y-­‐27632,	  cells	  were	  induced	  to	  differentiate	  in	  the	  presence	  or	  absence	  of	  10	  µM	  Y-­‐27632	  and	  1	  nM	  of	  the	  indicated	  toxin.	  Toxins	  were	  removed	  on	  day	  2,	  but	  Y-­‐27632	  was	  maintained	  throughout	  the	  differentiation	  process.	  	  
2.3.5.	  Oil	  Red	  O	  Staining	  and	  Lipid	  Quantification	  Accumulation	  of	  oil	  droplets	  during	  adipogenesis	  was	  visualized	  by	  Oil	  Red	  O	  staining,	  as	  previously	  described	  [6].	  Phase-­‐contrast	  microscopy	  images	  were	  taken	  using	  an	  Olympus	  IX-­‐70	  inverted	  microscope	  equipped	  with	  a	  digital	  camera	  
	   58	  
(Olympus	  DP70).	  Lipid	  accumulation	  was	  measured	  by	  absorbance	  at	  490	  nm	  using	  a	  microplate	  reader	  (BioTek	  Synergy	  HT).	  In	  the	  case	  of	  toxin	  dose	  experiments,	  the	  reading	  for	  oil	  accumulation	  was	  expressed	  as	  a	  percentage	  of	  that	  observed	  for	  fully	  differentiated	  cells.	  The	  experiments	  were	  repeated	  at	  least	  three	  times.	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2.3.7.	  shRNA	  Knockdown	  Short	  hairpin	  RNAs	  (shRNA),	  corresponding	  to	  the	  Gα	  and	  GFP	  genes	  were	  designed	  according	  to	  the	  manufacturer’s	  instructions.	  Target	  sequences	  for	  shRNA	  against	  Gαq:	  5'-­‐	  GGAAGCCCGGAGGATCAAC-­‐3';	  Gα12:	  5'-­‐GCGACACCATCTTCGACAACA-­‐3';	  Gα13:	  5'-­‐TGGGTGAGTCTGTAAAGTATT-­‐3';	  and	  GFP:	  5'-­‐GCAAGCTGACCCTGAAGTTC-­‐3'.	  	  shRNAs	  were	  cloned	  into	  the	  pSuperRetro	  vector	  (OligoEngine,	  WA)	  under	  the	  control	  of	  polymerase-­‐III	  H1-­‐RNA	  gene	  promoter.	  Oligonucleotides	  were	  annealed	  and	  cloned	  into	  the	  BglII/HindIII	  site	  of	  the	  vector.	  The	  MLV-­‐based	  viruses	  were	  generated	  by	  tripartite	  transfection	  of	  HEK-­‐293T	  cells	  using	  packing	  plasmids	  from	  Harvard	  Gene	  Therapy	  Initiative,	  Boston.	  Virus	  titer	  was	  estimated	  by	  quantifying	  the	  number	  of	  HEK-­‐293T	  cells	  surviving	  after	  incubation	  in	  medium	  containing	  puromycin	  (4	  mg/mL;	  Sigma,	  cat#P8833).	  3T3-­‐L1	  cells,	  maintained	  as	  above,	  were	  plated	  onto	  12-­‐well	  plates	  at	  the	  density	  of	  5x104	  cells/mL	  for	  16	  hrs.	  Cells	  were	  then	  infected	  with	  retroviruses	  at	  a	  titer	  of	  109/mL	  in	  the	  presence	  of	  4	  mg/mL	  Polybrene	  (Sigma,	  cat#AL-­‐118)	  at	  an	  MOI	  of	  10	  and,	  after	  incubation	  for	  24	  hrs	  virus-­‐infected	  cells	  were	  selected	  by	  treatment	  for	  at	  least	  1	  week	  with	  puromycin	  (4	  mg/mL).	  
	  
2.3.8.	  RT-­‐PCR	  3T3-­‐L1	  cells	  in	  60-­‐mm	  culture	  dishes	  were	  treated	  as	  described	  above.	  Total	  RNA	  was	  prepared	  using	  RNeasy	  Miniprep	  Kit	  (Qiagen),	  was	  quantified	  using	  a	  Genesys	  2	  UV-­‐Vis	  spectrophotometer	  (Spectronics),	  and	  samples	  were	  stored	  at	  -­‐80°C	  until	  analysis.	  The	  levels	  of	  mRNA	  expression	  were	  determined	  by	  RT-­‐PCR	  using	  Reverse-­‐iT	  RT-­‐PCR	  kit	  (ABgene).	  Reverse	  transcription	  was	  performed	  at	  55˚C	  for	  30	  min,	  followed	  by	  PCR	  in	  the	  same	  tube.	  To	  determine	  the	  linear	  range	  of	  cycle	  numbers	  for	  each	  primer	  set,	  RT-­‐PCR	  was	  performed	  with	  different	  RNA	  amounts	  from	  untreated	  cells	  at	  day	  0	  (for	  genes	  with	  maximum	  expression	  level	  in	  preadipocytes)	  and	  in	  mature	  adipocytes	  at	  day	  7	  (no	  treatment	  with	  the	  toxin).	  RT-­‐PCR	  products	  were	  analyzed	  using	  ethidium	  bromide-­‐stained	  agarose	  gel	  electrophoresis.	  The	  mRNA	  levels	  of	  Notch1	  and	  the	  housekeeping	  gene	  for	  GAPDH	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were	  determined	  by	  using	  published	  primer	  sets	  [17].	  The	  mRNA	  levels	  of	  Gαq,	  Gα11,	  Gα12,	  and	  Gα13	  were	  determined	  by	  using	  the	  following	  primer	  sets:	  Gαq:	  forward-­‐AGGCTCATGCACAATTGGTTCG,	  reverse-­‐GATAGGAAGGGTCGGCTACACG;	  Gα11:	  forward-­‐GGCCAATGCACTCCTGATCCG,	  reverse-­‐GGTAGCCTACTGTGGCGATG;	  Gα12:	  forward-­‐CGGCTGGTCAAGATCCTGCT,	  reverse-­‐AGAGTGCTGCCAGGGAATGC;	  Gα13:	  forward-­‐TCCGTGCTGTCCGTGTGCTT,	  reverse-­‐GGTTTTTGTTATCTCCCCAGGG.	  
	  
2.3.9.	  Statistics	  All	  data	  shown	  are	  representative	  of	  at	  least	  three	  independent	  experiments	  performed	  in	  triplicate	  and	  are	  presented	  as	  the	  mean	  ±	  standard	  deviation.	  Comparisons	  between	  groups	  were	  made	  using	  the	  Student’s	  paired	  t-­‐test	  (Excel	  statistics	  package),	  where	  statistical	  significance	  was	  defined	  as	  P	  <	  0.05.	  
	  
2.4.	  Results	  
2.4.1.	  Effect	  of	  Toxins	  on	  Murine	  3T3-­‐L1	  Cell	  Morphology	  and	  Stress	  Fiber	  Formation	  Undifferentiated	  murine	  3T3-­‐L1	  preadipocytes	  treated	  with	  0.5	  nM	  rPMT	  or	  rDNT	  formed	  a	  dense	  monolayer	  with	  cells	  clustering	  into	  discrete	  patches	  or	  "foci"	  (Figure	  1A),	  similar	  to	  what	  was	  reported	  before	  for	  rPMT-­‐treated	  or	  rDNT-­‐treated	  fibroblasts	  [6,	  13,	  23,	  24,	  28,	  48].	  rCNF1-­‐treated	  3T3-­‐L1	  cells,	  on	  the	  other	  hand,	  showed	  cell	  spreading	  and	  enlargement	  with	  multi-­‐nucleation	  but	  without	  proliferation,	  similar	  to	  what	  was	  reported	  before	  for	  rCNF1-­‐treated	  fibroblasts	  [14,	  15].	  These	  changes	  were	  accompanied	  in	  each	  case	  by	  increased	  formation	  of	  actin	  stress	  fibers	  (Figure	  1B,	  upper	  panel),	  similar	  to	  that	  reported	  previously	  [6,	  13,	  14,	  15,	  23,	  24,	  28,	  48].	  Formation	  of	  stress	  fibers,	  however,	  was	  blocked	  when	  cells	  were	  treated	  with	  the	  toxin	  in	  the	  presence	  of	  the	  Rho-­‐associated	  protein	  kinase	  (ROCK)	  inhibitor,	  Y-­‐27632	  (Figure	  1B,	  lower	  panel).	  
	  
2.4.2.	  Effect	  of	  Toxins	  on	  3T3-­‐L1	  Differentiation	  and	  Adipogenesis	  3T3-­‐L1	  cell	  differentiation	  was	  induced	  in	  the	  absence	  or	  presence	  of	  0.1	  nM	  of	  rPMT,	  rDNT	  or	  rCNF1.	  Lipid	  accumulation	  was	  visualized	  7	  days	  after	  induction	  of	  differentiation	  by	  Oil	  Red	  O	  staining	  of	  the	  lipid	  droplets.	  As	  shown	  in	  Figure	  2A,	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after	  induction	  of	  differentiation,	  3T3-­‐L1	  cells	  developed	  into	  round	  adipocytes	  containing	  abundant	  lipid	  droplets	  that	  stained	  red	  (control,	  no	  toxin).	  In	  contrast,	  3T3-­‐L1	  cells	  treated	  with	  rPMT,	  rDNT	  or	  rCNF1	  at	  the	  time	  of	  differentiation	  induction,	  failed	  to	  differentiate	  into	  adipocytes,	  in	  agreement	  with	  what	  was	  reported	  previously	  for	  PMT	  [6].	  Instead,	  in	  all	  three	  cases,	  the	  cells	  formed	  a	  dense	  monolayer	  with	  little	  (≤20%)	  accumulation	  of	  lipids	  (Figure	  2B).	  This	  inhibition	  of	  adipogenesis	  was	  dose-­‐dependent	  (Figure	  2C),	  with	  DNT	  and	  CNF1	  effecting	  70-­‐80%	  inhibition	  at	  50	  pM,	  while	  PMT	  was	  more	  potent,	  better	  exhibiting	  >80%	  inhibition	  at	  10	  pM.	  	  	  
	  
2.4.3.	  Effect	  of	  ROCK	  Inhibitor	  Y-­‐27632	  on	  Toxin-­‐Mediated	  Blockade	  of	  Adipogenesis	  To	  determine	  whether	  toxin-­‐mediated	  inhibition	  of	  adipogenesis	  could	  be	  rescued	  by	  inhibiting	  Rho/ROCK	  signaling,	  3T3-­‐L1	  cells	  were	  treated	  with	  Y-­‐27632	  in	  the	  presence	  of	  toxins.	  Y-­‐27632	  co-­‐treatment	  resulted	  in	  partial	  override	  of	  the	  toxin-­‐induced	  blockade	  of	  differentiation	  and	  lipid	  accumulation	  for	  the	  case	  of	  rPMT	  and	  rDNT	  (30%	  and	  53%,	  respectively)	  and	  a	  76%	  override	  in	  the	  case	  of	  rCNF1	  (Figure	  2A	  and	  2B),	  even	  at	  toxin	  concentrations	  up	  to	  100-­‐fold	  higher	  than	  needed	  to	  block	  adipogenesis.	  
	  
2.4.4.	  Effect	  of	  Toxins	  on	  Adipogenesis	  Marker	  Expression	  During	  3T3-­‐L1	  
Differentiation	  Protein	  level	  patterns	  of	  adipogenesis	  markers	  were	  monitored	  over	  the	  course	  of	  3T3-­‐L1	  differentiation	  in	  the	  presence	  or	  absence	  of	  1	  nM	  of	  rPMT,	  rDNT	  or	  rCNF1.	  As	  expected	  during	  normal	  differentiation	  (Figure	  3,	  far	  left	  panels),	  preadipocytes	  had	  high	  levels	  of	  Pref1/Dlk1	  protein	  at	  the	  onset	  of	  differentiation	  induction,	  but	  Pref1/Dlk1	  were	  absent	  by	  day	  4	  and	  remained	  undetectable	  in	  mature	  adipocytes.	  PPARγ	  and	  C/EBPα	  protein	  levels,	  on	  the	  other	  hand,	  were	  upregulated	  by	  day	  4	  and	  remained	  high	  in	  mature	  adipocytes.	  In	  contrast,	  while	  Pref1/Dlk1	  protein	  levels	  decreased	  by	  about	  half	  on	  day	  2,	  similar	  to	  the	  control,	  in	  the	  presence	  of	  any	  of	  the	  toxins	  the	  levels	  were	  restored	  by	  day	  4	  and	  were	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maintained	  high	  thereafter	  (Figure	  3,	  right	  panels).	  Toxin	  treatment	  completely	  blocked	  induction	  of	  the	  two	  major	  adipocyte	  markers,	  PPARγ	  and	  C/EBPα.	  	  
2.4.5.	  Effect	  of	  ROCK	  Inhibitor	  Y-­‐27632	  on	  Toxin-­‐Mediated	  Blockade	  of	  Adipogenesis	  Since	  Y-­‐27632	  treatment	  appeared	  to	  counteract	  the	  toxin-­‐mediated	  blockade	  of	  adipogenesis	  (Figure	  2),	  we	  next	  examined	  whether	  inhibition	  of	  Rho/ROCK	  signaling	  could	  overcome	  toxin-­‐mediated	  downregulation	  of	  adipocyte	  markers,	  PPARγ	  and	  C/EBPα,	  upon	  differentiation	  induction	  in	  3T3-­‐L1	  preadipocytes.	  As	  shown	  in	  Figure	  4,	  Y-­‐27632	  was	  able	  to	  partially	  prevent	  the	  downregulation	  of	  PPARγ	  and	  C/EBPα	  by	  all	  three	  toxins,	  but	  more	  so	  in	  the	  case	  of	  CNF1.	  Y-­‐27632	  was	  also	  able	  to	  dampen	  the	  toxin-­‐mediated	  upregulation	  of	  Pref1/Dlk1	  in	  all	  cases,	  although	  again	  more	  so	  for	  CNF1	  than	  PMT	  or	  DNT.	  In	  contrast,	  Y-­‐27632	  was	  not	  able	  to	  counteract	  the	  downregulation	  of	  PPARγ	  and	  C/EBPα	  levels	  by	  any	  of	  the	  toxins	  in	  mature	  adipocytes	  (Figure	  5).	  	  
2.4.6.	  Effects	  of	  Toxins	  on	  Notch1	  and	  β-­‐Catenin	  Signaling	  in	  3T3-­‐L1	  Cells	  We	  previously	  showed	  that	  PMT	  downregulated	  Notch1	  expression,	  while	  maintaining	  Pref1/Dlk1	  and	  β-­‐catenin	  levels	  in	  3T3-­‐L1	  cells	  during	  differentiation	  [6].	  We	  next	  determined	  whether	  a	  similar	  effect	  might	  be	  observed	  for	  the	  other	  dermonecrotic	  toxins,	  DNT	  and	  CNF1.	  In	  control	  cells,	  both	  Pref1/Dlk1	  and	  β-­‐catenin	  levels	  declined	  during	  differentiation.	  As	  was	  previously	  observed	  for	  PMT,	  β-­‐catenin	  protein	  levels	  were	  maintained	  through	  day	  7	  of	  differentiation	  in	  the	  presence	  of	  either	  of	  the	  other	  toxins	  (Figure	  4).	  For	  each	  of	  the	  toxins,	  Y-­‐27632	  partially	  blocked	  the	  effect	  of	  the	  toxins	  on	  β-­‐catenin	  levels.	  	  In	  undifferentiated	  3T3-­‐L1	  preadipocytes,	  Notch1	  protein	  levels	  decreased	  after	  one	  day	  of	  treatment	  with	  any	  of	  the	  three	  toxins	  (Figure	  6A).	  For	  PMT	  and	  DNT	  this	  decrease	  in	  protein	  levels	  could	  be	  partially	  prevented	  by	  Y-­‐27632,	  but	  apparently	  through	  a	  mechanism	  independent	  of	  toxin	  action,	  since	  Y-­‐27632	  treatment	  also	  caused	  an	  increase	  in	  Notch1	  levels	  in	  control	  cells.	  Y-­‐27632	  also	  caused	  a	  partial	  increase	  in	  Notch1	  mRNA	  levels	  in	  the	  case	  of	  PMT	  and	  to	  a	  lesser	  extent	  DNT,	  but	  again	  Y-­‐27632	  also	  caused	  a	  noticeable,	  presumably	  independent	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increase	  in	  Notch1	  mRNA	  levels	  in	  control	  cells	  (Figure	  6B).	  These	  results	  suggest	  that	  while	  toxin-­‐mediated	  modulation	  of	  C/EBPα,	  PPARγ,	  Pref1/Dlk1	  and	  β-­‐catenin	  protein	  levels	  occurs	  through	  activation	  of	  Rho/ROCK	  signaling,	  toxin-­‐mediated	  downregulation	  of	  Notch1	  does	  not.	  	  
2.4.7.	  Involvement	  of	  Gq	  and	  G12/13	  in	  PMT-­‐Mediated	  Downregulation	  of	  Notch1	  in	  3T3-­‐
L1	  Cells	  The	  involvement	  of	  Rho/ROCK	  signaling	  in	  dermonecrotic	  toxin	  action	  on	  Notch1	  and	  β-­‐catenin	  signaling	  and	  on	  adipogenesis	  was	  completely	  in	  keeping	  with	  Rho	  proteins	  being	  direct	  targets	  of	  DNT	  and	  CNF1	  [3,	  21,	  22]	  and	  as	  indirect	  targets	  of	  PMT	  [49].	  Since	  PMT	  activates	  Rho	  proteins	  indirectly	  through	  activation	  of	  Gαq	  or	  Gα12/13	  signaling	  [36,	  40,	  52],	  we	  next	  considered	  which	  of	  these	  pathways	  was	  involved	  in	  PMT-­‐induced	  downregulation	  of	  Notch1.	  Gαq,	  Gα12,	  and	  Gα13	  were	  knocked	  down	  in	  3T3-­‐L1	  cells	  by	  using	  shRNA	  against	  their	  respective	  shRNAs	  (Figure	  7A).	  Specificity	  of	  shRNA	  against	  Gαq	  was	  also	  confirmed	  by	  knockdown	  of	  Gαq,	  but	  not	  the	  closely	  related	  Gα11	  (Figure	  7A).	  In	  the	  absence	  of	  PMT,	  knockdown	  of	  Gαq,	  Gα12,	  or	  Gα13	  alone	  in	  3T3-­‐L1	  cells	  had	  no	  effect	  on	  Notch1	  mRNA	  levels	  (Figure	  7B),	  but	  in	  all	  cases,	  PMT	  treatment	  diminished	  Notch1	  mRNA	  levels	  (Figure	  7B),	  suggesting	  that	  PMT	  activates	  multiple	  pathways	  to	  cause	  Notch1	  mRNA	  downregulation.	  PMT	  treatment	  also	  reduced	  Notch1	  protein	  levels	  in	  3T3-­‐L1	  cells	  knocked	  down	  in	  Gαq	  (Figure	  7C).	  Y-­‐27632	  only	  partially	  blocked	  PMT-­‐induced	  downregulation	  of	  Notch1	  in	  3T3-­‐L1	  cells	  Gαq	  knockdowns	  (Figure	  7D),	  supporting	  that	  PMT	  downregulation	  of	  Notch1	  does	  not	  occur	  through	  Rho/ROCK	  or	  Gαq	  signaling.	  On	  the	  other	  hand,	  knockdown	  of	  Gα12	  or	  Gα13	  blocked	  the	  downregulation	  of	  Notch1	  protein	  levels	  by	  PMT	  (Figure	  7C).	  These	  results	  suggested	  that	  Gαq	  was	  not	  the	  mediator	  of	  PMT-­‐downregulation	  of	  Notch1,	  and	  instead	  this	  occurs	  through	  PMT	  activation	  of	  Gα12	  and	  Gα13.	  	  
	  
2.5.	  Discussion	  The	  3T3-­‐L1	  cell	  line	  is	  a	  well-­‐established	  in	  vitro	  model	  of	  adipocyte	  differentiation,	  which	  is	  characterized	  by	  expression	  of	  adipocyte-­‐specific	  markers,	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such	  as	  PPARγ	  and	  C/EBPα	  [37,	  39],	  and	  downregulation	  of	  pre-­‐adipocyte-­‐specific	  markers,	  such	  as	  Pref1/Dlk1	  [47].	  Our	  data	  revealed	  that	  treatment	  of	  3T3-­‐L1	  cells	  during	  differentiation	  with	  any	  one	  of	  the	  dermonecrotic	  toxins	  resulted	  in	  blockade	  of	  adipogenesis,	  as	  evidenced	  by	  the	  lack	  of	  lipid	  accumulation.	  Toxin	  treatment	  in	  all	  three	  cases	  also	  inhibited	  adipocyte	  differentiation	  as	  evidenced	  by	  the	  downregulation	  of	  PPARγ	  and	  C/EBPα	  levels	  and	  stabilization	  of	  Pref1.	  Moreover,	  the	  toxin’s	  effects	  on	  adipogenesis	  and	  adipocyte	  differentiation	  were	  Rho/ROCK-­‐dependent,	  since	  treatment	  with	  the	  ROCK	  inhibitor	  Y-­‐27632	  countered	  toxin	  action	  by	  all	  three	  toxins.	  These	  results	  point	  to	  a	  pivotal	  role	  of	  Rho/ROCK	  signaling	  in	  the	  regulation	  of	  adipocyte	  differentiation	  and	  adipogenesis.	  DNT	  and	  the	  CNFs	  act	  directly	  on	  Rho	  proteins,	  while	  PMT	  acts	  on	  heterotrimeric	  G	  proteins	  that	  are	  upstream	  of	  the	  Rho	  proteins.	  Consistent	  with	  this,	  inhibition	  of	  Rho/ROCK	  signaling	  was	  able	  to	  prevent	  76%	  of	  the	  inhibition	  by	  CNF1	  and	  53%	  of	  that	  of	  DNT,	  but	  to	  a	  much	  lesser	  extent	  that	  of	  PMT	  (30%),	  suggesting	  that	  additional	  pathways	  are	  involved	  in	  the	  action	  of	  PMT.	  We	  therefore	  wanted	  to	  determine	  which	  of	  the	  upstream	  Gα	  protein	  targets	  of	  PMT	  were	  responsible	  for	  mediating	  PMT	  action	  on	  Rho/ROCK-­‐dependent	  inhibition	  of	  adipogenesis.	  The	  several	  earlier	  studies	  had	  demonstrated	  that	  stimulators	  of	  calcium	  signaling,	  such	  as	  calcium	  ionophores,	  thapsigargin	  and	  prostaglandin	  (PGF2α),	  block	  adipogenesis	  through	  activation	  of	  calcineurin	  such	  activation	  can	  be	  reversed	  by	  calcineurin	  inhibitors	  [31,	  34,	  41],	  we	  had	  previously	  considered	  the	  possibility	  that	  PMT-­‐mediated	  inhibition	  of	  adipogenesis	  occurs	  through	  its	  known	  activation	  of	  Gq-­‐PLCβ1-­‐dependent	  calcium	  signaling	  [6].	  However,	  from	  those	  studies	  we	  determined	  that	  inhibition	  of	  calcineurin	  with	  CsA	  did	  not	  prevent	  the	  PMT-­‐mediated	  blockade	  of	  adipogenesis	  or	  the	  effects	  of	  PMT	  on	  expression	  of	  PPARγ,	  C/EBPα,	  or	  Pref1	  proteins,	  suggesting	  that	  PMT	  blockade	  of	  adipocyte	  differentiation	  occurs	  through	  other	  pathways	  in	  addition	  to	  the	  Gq-­‐PLC-­‐calcium-­‐calcineurin	  signaling	  pathway.	  The	  partial	  recovery	  of	  differentiation	  observed	  for	  PMT	  in	  the	  presence	  of	  Y-­‐27632	  in	  this	  study	  supports	  the	  notion	  that	  Rho/ROCK	  signaling	  mediates	  at	  least	  part	  of	  the	  inhibitory	  effect	  of	  PMT	  on	  differentiation.	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Wnt/β-­‐catenin	  and	  Notch1	  signaling	  pathways	  are	  differentially	  expressed	  during	  adipocyte	  differentiation	  [8,	  17,	  27],	  with	  Wnt/β-­‐catenin	  levels	  decreasing	  and	  Notch1	  levels	  increasing	  during	  conversion	  of	  preadipocytes	  into	  adipocytes.	  Consistent	  with	  the	  opposing	  roles	  of	  Wnt/β-­‐catenin	  and	  Notch1	  signaling	  in	  adipogenesis	  as	  well	  as	  our	  previous	  observations	  for	  PMT	  [6],	  treatment	  with	  any	  one	  of	  the	  dermonecrotic	  toxins	  maintained	  β-­‐catenin	  levels,	  while	  downregulating	  Notch1.	  In	  this	  study,	  we	  further	  investigated	  the	  role	  of	  Rho/ROCK	  signaling	  in	  toxin-­‐mediated	  effects	  on	  β-­‐catenin	  and	  Notch1	  levels	  by	  using	  Y-­‐17632.	  Although	  the	  β-­‐catenin	  protein	  levels	  were	  maintained	  through	  day	  7	  of	  differentiation	  in	  the	  presence	  of	  any	  of	  the	  dermonecrotic	  toxins,	  the	  presence	  of	  Y-­‐27632	  dampened	  this	  effect,	  supporting	  at	  least	  a	  partial	  role	  for	  Rho/ROCK	  signaling	  in	  maintaining	  the	  predifferentiated	  state.	  We	  next	  explored	  the	  potential	  role	  of	  Rho/ROCK	  signaling	  in	  mediating	  the	  toxin-­‐induced	  downregulation	  of	  Notch1.	  In	  agreement	  with	  previously	  reported	  findings	  for	  PMT	  [6],	  Notch1	  protein	  levels	  decreased	  after	  one	  day	  of	  treatment	  with	  any	  one	  of	  the	  dermonecrotic	  toxins	  in	  undifferentiated	  3T3-­‐L1	  preadipocytes.	  This	  decrease	  in	  Notch1	  protein	  levels	  could	  be	  partially	  prevented	  by	  Y-­‐27632	  in	  the	  case	  of	  PMT	  and	  DNT,	  but	  not	  CNF1.	  However,	  this	  partial	  recovery	  of	  Notch1	  expression	  apparently	  occurred	  through	  a	  mechanism	  independent	  of	  toxin	  action,	  since	  Y-­‐27632	  treatment	  caused	  an	  increase	  in	  Notch1	  levels	  in	  our	  control.	  Similar	  results	  were	  observed	  for	  Notch1	  mRNA	  levels	  in	  the	  presence	  of	  Y-­‐27632.	  In	  all,	  these	  results	  suggest	  that	  toxin-­‐induced	  Notch1	  downregulation	  does	  not	  occur	  through	  activation	  of	  Rho/ROCK	  signaling.	  In	  this	  study,	  we	  further	  considered	  the	  possible	  involvement	  of	  G12	  and/or	  G13	  in	  mediating	  PMT	  downregulation	  of	  Notch1.	  Results	  using	  shRNA	  knockdowns	  of	  Gαq,	  G12	  or	  G13	  confirmed	  our	  previous	  findings	  that	  Gαq	  is	  not	  involved	  and	  instead	  support	  the	  model	  of	  both	  G12	  and	  G13	  mediating	  the	  action	  of	  PMT	  on	  Notch1.	  Although	  we	  cannot	  rule	  out	  the	  possibility	  that	  the	  observed	  inhibitory	  action	  of	  PMT	  on	  adipocyte	  differentiation	  was	  mediated	  at	  least	  in	  part	  through	  PMT-­‐activation	  of	  Gi	  signaling,	  our	  results	  with	  knockdowns	  of	  G12	  and	  G13	  clearly	  show	  that	  PMT-­‐mediated	  downregulation	  of	  Notch1	  could	  be	  attributed	  almost	  fully	  to	  the	  presence	  of	  G12	  and	  G13.	  Our	  results	  are	  also	  consistent	  with	  the	  connection	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between	  Rho/ROCK	  signaling	  and	  the	  action	  of	  lysophosphatidic	  acid	  (LPA).	  LPA	  is	  a	  known	  bioactive	  phospholipid	  ligand	  of	  Gi/q/12/13-­‐protein-­‐coupled	  receptors	  that	  activates	  Rho	  signaling	  [29].	  This	  evidence	  suggests	  that	  the	  activation	  of	  Rho/ROCK	  by	  LPA	  might	  be	  mediated	  primarily	  through	  G12/13	  and	  not	  Gq	  or	  Gi.	  LPA	  is	  known	  to	  inhibit	  adipogenesis	  through	  downregulation	  of	  PPARγ	  [42]	  and	  upregulation	  of	  Wnt/β-­‐catenin	  signaling	  through	  activation	  of	  the	  Rho/ROCK	  pathway	  [30].	  A	  summary	  of	  the	  adipogenic	  signaling	  pathways	  involved	  in	  dermonecrotic	  toxin	  action	  is	  depicted	  in	  Figure	  8.	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2.6.	  Figures	  
	  
Figure	   2.1.	   Effect	   of	   dermonecrotic	   toxins	   on	   3T3-­‐L1	   preadipocyte	   cell	  
morphology	  and	  stress	  fiber	  formation.	  	  (A)	   Phase-­‐contrast	   images	   of	   confluent,	   undifferentiated	   3T3-­‐L1	   cell	   monolayers	  treated	  continuously	  for	  5	  days	  with	  0.5	  nM	  of	  the	  indicated	  toxin.	  (B)	  Fluorescence	  microscopy	  images	  of	  undifferentiated	  3T3-­‐L1	  cells	  treated	  for	  16	  hrs	  with	  1	  nM	  of	  the	   indicated	   toxin	   in	   the	  absence	   (top	  panels)	  or	  presence	   (bottom	  panels)	  of	  10	  µM	   Y-­‐27632.	   Red,	   TRITC-­‐phalloidin	   staining	   of	   F-­‐actin,	   showing	   stress	   fibers	  resulting	   from	   toxin	   treatment.	   Blue,	   DAPI	   staining	   of	   cell	   nuclei.	   Bar,	   50	   µm.	  Experiments	  performed	  by	  Leila	  Aminova.	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Figure	  2.2.	  
	  
(A) Blocking	   of	   3T3-­‐L1	   cell	   differentiation	   and	   lipid	   accumulation	   by	  
dermonecrotic	  toxins.	  	  Confluent	   3T3-­‐L1	   cells	   were	   induced	   to	   differentiate	   in	   DM	   in	   the	   absence	   or	  presence	   of	   0.5	   nM	   of	   the	   indicated	   toxin,	   as	   described	   in	   Methods.	   (A)	   Phase-­‐contrast	   images	   of	   Oil	   Red	   O-­‐stained	   3T3-­‐L1	   cells	   on	   day	   7	   after	   induction	   of	  differentiation	  in	  the	  absence	  (top	  panels)	  or	  presence	  (bottom	  panels)	  of	  10	  µM	  Y-­‐27632.	  Bar,	  200	  µm.	  Red	  color	  indicates	  Oil	  Red	  O	  staining	  of	  lipid	  droplets.	  Below	  each	  panel	  are	  macro-­‐view	  light	  images	  of	  corresponding	  Oil	  Red	  O-­‐stained	  3T3-­‐L1	  monolayers	  on	  tissue	  culture	  plates.	  Experiments	  performed	  by	  Leila	  Aminova.	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Figure	  2.2.	  continued	  	  
	  	  
(B,	   C)	   Blocking	   of	   3T3-­‐L1	   cell	   differentiation	   and	   lipid	   accumulation	   by	  
dermonecrotic	  toxins.	  	  Confluent	   3T3-­‐L1	   cells	   were	   induced	   to	   differentiate	   in	   DM	   in	   the	   absence	   or	  presence	   of	   0.5	   nM	   of	   the	   indicated	   toxin,	   as	   described	   in	   Methods.	   (B)	  Quantification	   of	   lipid	   accumulation	   based	   on	  Oil	   Red	  O	   staining	   on	   day	   7	   for	   the	  indicated	   toxins,	  measured	   as	   described	   in	  Methods.	  White	   bar,	  without	   Y-­‐27632;	  black	   bar,	   with	   Y-­‐27632;	   P	   values	   <	   0.01.	   (C)	   Toxin	   dose-­‐response	   of	   lipid	  accumulation	  based	  on	  Oil	  Red	  O	  staining.	  White	  bar,	  PMT;	  grey	  bar,	  DNT;	  black	  bar,	  CNF1;	  P	  values	  <	  0.01.	  Experiments	  performed	  and	  figure	  generated	  in	  collaboration	  with	  Leila	  Aminova.	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Figure	   2.3.	   Effect	   of	   dermonecrotic	   toxins	   on	   adipocyte	   marker	   expression	  
profiles	  during	  differentiation.	  	  Confluent	  3T3-­‐L1	  preadipocytes	  were	   induced	  to	  differentiate	   in	  DM,	  as	  described	  in	   Methods.	   On	   the	   indicated	   days,	   cell	   lysates	   were	   subjected	   to	   SDS-­‐PAGE	   and	  immunoblot	   analysis	   using	   antibodies	   against	   β-­‐catenin,	   Pref1/Dlk1,	   PPARγ,	  C/EBPα,	   or	   β-­‐actin.	   Time-­‐course	   of	   differentiation	   in	   the	   absence	   (control)	   or	  presence	  of	  1	  nM	  of	  the	  indicated	  toxin.	  Experiments	  performed	  by	  Leila	  Aminova.	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Figure	   2.4.	   Effect	   of	   dermonecrotic	   toxins	   on	   adipocyte	   marker	   expression	  
profiles	  during	  differentiation.	  	  Confluent	  3T3-­‐L1	  preadipocytes	  were	   induced	  to	  differentiate	   in	  DM,	  as	  described	  in	  Methods.	  Cell	  lysates	  were	  subjected	  to	  SDS-­‐PAGE	  and	  immunoblot	  analysis	  using	  antibodies	  against	  β-­‐catenin,	  Pref1/Dlk1,	  PPARγ,	  C/EBPα,	  or	  β-­‐actin.	  Effect	  of	  10	  µM	  Y-­‐27632	  on	   adipocyte	  marker	   expression	  profiles	   in	  preadipocytes	   on	  day	  7	   after	  differentiation	   induction	   in	   the	   absence	   (control)	   or	   presence	   of	   1	   nM	   of	   the	  indicated	  toxin.	  Experiments	  performed	  by	  Leila	  Aminova.	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Figure	   2.5.	   Effect	   of	   dermonecrotic	   toxins	   on	   adipocyte	   marker	   expression	  
profiles	  during	  differentiation.	  	  Confluent	  3T3-­‐L1	  preadipocytes	  were	   induced	  to	  differentiate	   in	  DM,	  as	  described	  in	  Methods.	  Cell	  lysates	  were	  subjected	  to	  SDS-­‐PAGE	  and	  immunoblot	  analysis	  using	  antibodies	  against	  β-­‐catenin,	  Pref1/Dlk1,	  PPARγ,	  C/EBPα,	  or	  β-­‐actin.	  Effect	  of	  10	  µM	  Y-­‐27632	  on	  adipocyte	  marker	  expression	  profiles	   in	  mature	  adipocytes	   treated	  on	  day	  7	  after	  differentiation	  induction	  without	  (control)	  or	  with	  1	  nM	  of	  the	  indicated	  toxin	  and	  analyzed	  on	  day	  8.	  Experiments	  performed	  by	  Leila	  Aminova.	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Figure	  2.6.	  Effect	  of	  dermonecrotic	  toxins	  on	  Notch1	  signaling	  in	  3T3-­‐L1	  cells.	  Confluent	  3T3-­‐L1	  preadipocytes	  were	  treated	  for	  1	  day	  without	  (control)	  or	  with	  1	  nM	   of	   the	   indicated	   toxin	   in	   the	   absence	   or	   presence	   of	   10	   µM	   Y-­‐27632.	   (A)	   Cell	  lysates	   were	   subjected	   to	   SDS-­‐PAGE	   and	   immunoblot	   analysis	   using	   antibodies	  against	  Notch1	  or	  β-­‐actin	  (as	  control).	  (B)	  Cell	  lysates	  analyzed	  for	  mRNA	  levels	  for	  Notch1	   or	   GAPDH	   (as	   control)	   by	   RT-­‐PCR.	   Experiments	   performed	   by	   Leila	  Aminova.	  
	  
	   	  





Figure	  2.7.	  Involvement	  of	  Gαq	  and	  Gα12/13-­‐dependent	  Rho/ROCK	  signaling	  in	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Figure	   2.8.	   Proposed	   model	   of	   dermonecrotic	   toxin	   action	   on	   pathways	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Chapter	  3:	  	  Pasteurella	  multocida	  Toxin	  Mediates	  Delivery	  of	  Intact	  
Cargos	  into	  Host	  Cell	  Cytosol	  via	  the	  Endocytic	  Pathway	  	  
3.1.	  Introduction	  As	  discussed	  in	  section	  1.5.2	  of	  chapter	  1,	  PMT	  is	  comprised	  of	  multiple	  discrete	  functional	  domains	  (also	  viewed	  as	  modules)	  that	  are	  responsible	  for	  each	  of	  the	  intoxication	  steps	  involved	  in	  toxin	  action	  (reviewed	  in	  [13,	  19,	  20,	  21]).	  Although	  there	  are	  no	  structures	  available	  for	  the	  N-­‐terminus	  of	  PMT	  (PMT-­‐N,	  residues	  1-­‐575),	  several	  biochemical	  and	  mutagenesis	  studies	  have	  shown	  that	  the	  PMT-­‐N	  harbors	  the	  domains	  responsible	  for	  binding	  to	  cell	  receptors,	  cellular	  uptake,	  membrane	  translocation	  and	  delivery	  of	  the	  intracellular	  activity	  cargo	  modules	  into	  the	  cytosol	  [2,	  3,	  5,	  14,	  15]:	  PMT	  utilizes	  sphingomyelin,	  phosphatidylcholine	  and	  an	  unknown	  protein	  as	  co-­‐receptors	  for	  cell	  binding	  and	  entry	  [5].	  Mutations	  of	  residues	  in	  a	  predicted	  helix-­‐loop-­‐helix	  motif	  (residues	  402-­‐457)	  blocked	  pH-­‐dependent	  entry	  into	  the	  cytoplasm,	  suggesting	  involvement	  of	  this	  region	  in	  the	  translocation	  of	  the	  activity	  domain	  [2].	  	  We,	  and	  others,	  have	  shown	  that	  PMT-­‐N	  can	  serve	  as	  a	  transporter	  of	  not	  only	  its	  cognate	  toxic	  activity	  modules,	  but	  also	  other	  cargos,	  such	  as	  green	  fluorescence	  protein	  (GFP)	  [15]	  or	  the	  catalytic	  domains	  of	  other	  toxins	  (i.e.,	  diphtheria	  toxin)	  [3].	  We	  are	  only	  beginning	  to	  gain	  some	  insights	  into	  the	  host	  molecular	  events	  involved	  in	  PMT	  trafficking	  within	  cells	  [15].	  We	  still	  do	  not	  have	  a	  comprehensive	  model	  on	  how	  the	  cargo	  domains	  of	  PMT	  are	  packaged	  into	  a	  modular	  assembly	  for	  their	  efficient	  cellular	  delivery	  during	  the	  intoxication	  process.	  It	  is	  also	  unclear	  whether	  delivery	  involves	  further	  processing	  of	  the	  toxin	  and/or	  release	  of	  the	  cargo	  after	  translocation.	  To	  this	  date,	  there	  is	  no	  accepted	  mechanism	  of	  the	  translocation	  and	  cargo	  delivery	  process.	  There	  is	  also	  no	  exhaustive	  list	  of	  all	  the	  protein	  and	  cellular	  determinants	  involved	  in	  these	  processes.	  This	  study	  aims	  to	  answer	  lingering	  questions	  regarding	  the	  translocation	  steps	  utilized	  by	  PMT,	  and	  further	  define	  the	  intoxication	  process	  of	  PMT.	  In	  particular,	  we	  strive	  to	  tackle	  specific	  aspects	  of	  translocation,	  such	  as	  the	  structural	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makeup	  of	  the	  cargo	  that	  is	  delivered	  to	  the	  host	  cell	  cytosol,	  the	  cellular	  and	  protein	  determinants	  that	  facilitate	  cargo	  delivery,	  and	  the	  nature	  of	  the	  delivery	  vehicle	  after	  translocation.	  To	  answer	  these	  questions,	  I	  initially	  used	  HA-­‐tagged	  PMT	  (PMT-­‐HA)	  and	  assess	  the	  localization	  as	  well	  as	  the	  translocation	  steps	  by	  using	  subcellular	  fractionation	  and	  Western	  blot	  analysis.	  I	  was	  specifically	  interested	  in	  what	  part	  of	  PMT	  (i.e.	  how	  much	  of	  C-­‐terminus)	  is	  delivered	  into	  cytosol	  and	  how	  it	  is	  delivered.	  Next,	  I	  used	  an	  N-­‐terminal	  mutant	  (residues	  1-­‐568)	  with	  an	  exogenous	  cargo	  (GFP)	  at	  its	  C-­‐terminus	  to	  examine	  toxin	  trafficking	  inside	  host	  cells	  through	  visualization	  by	  fluorescence	  microscopy.	  This	  helped	  us	  examine	  the	  localization	  of	  PMT	  to	  specific	  organelles,	  assessed	  by	  colocalization	  of	  PMT-­‐N-­‐GFP	  with	  organelle	  specific	  markers	  fused	  to	  DsRed.	  In	  addition,	  I	  identified	  the	  location	  where	  PMT	  translocates	  by	  using	  a	  density-­‐gradient	  as	  well	  as	  subcellular	  fractionations.	  This	  helped	  determine	  the	  nature	  of	  the	  translocation	  step,	  and	  whether	  or	  not	  PMT	  is	  capable	  of	  transferring	  exogenous	  cargo	  into	  the	  cytosol.	  Finally,	  I	  studied	  the	  fate	  of	  the	  N-­‐terminus	  after	  translocation.	  Results	  from	  these	  studies	  provided	  insights	  into	  the	  functional	  organization	  and	  processing	  of	  the	  modular	  toxin	  that	  occurs	  during	  cellular	  intoxication.	  
	  
3.2.	  Materials	  and	  Methods	  
3.2.1.	  Plasmid	  Constructs	  Organelle-­‐specific	  cellular	  markers,	  expressed	  as	  DsRed-­‐fusion	  proteins	  (nucleus,	  ER,	  and	  mitochondria),	  were	  obtained	  from	  Clontech.	  The	  signal	  sequence	  for	  the	  early	  endosome	  marker,	  early	  endosome	  antigen-­‐1	  (EEA1)	  was	  generated	  by	  RT-­‐PCR	  of	  the	  corresponding	  signal	  sequences.	  I	  used	  total	  RNA	  obtained	  from	  human	  HEK-­‐293T	  (ATCC#	  CRL-­‐11268)	  cells	  as	  template	  and	  exchanged	  the	  fragment	  into	  the	  pDsRed2-­‐nucleus	  vector.	  The	  primers	  used	  were:	  5’-­‐ctcgaggagaaattgctgtcttagaagcaac-­‐3’	  (forward):	  5’-­‐ctactctagagttgtgataacccgttatccttgc-­‐3’	  (reverse).	  The	  HA	  tag	  was	  introduced	  by	  several	  rounds	  of	  primer	  extension	  and	  incorporated	  into	  a	  pTHC-­‐tox	  vector	  (Invitrogen)	  by	  fragment	  exchange.	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3.2.2.	  Expression,	  Purification	  and	  Quantification	  of	  PMT	  and	  PMT	  Fusion	  Proteins	  The	  genes	  for	  PMT-­‐N	  (PMT	  N-­‐terminal	  fragment	  1-­‐568),	  PMT-­‐N-­‐GFP	  (C-­‐terminal	  GFP-­‐fusion	  protein	  of	  PMT-­‐N),	  and	  PMT-­‐GFP	  (C-­‐terminal	  GFP-­‐fusion	  protein	  of	  full-­‐length	  PMT)	  were	  cloned	  into	  the	  pET21b	  expression	  vector	  (Novagen),	  and	  the	  corresponding	  recombinant	  proteins	  were	  expressed	  in	  E.	  coli	  BL21	  cells	  (Novagen)	  under	  the	  control	  of	  an	  IPTG-­‐inducible	  promoter.	  The	  gene	  for	  PMT-­‐HA	  (HA-­‐tagged	  full-­‐length	  PMT	  (1-­‐1285))	  was	  cloned	  into	  the	  pTrcHisC	  expression	  vector	  (Invitrogen),	  and	  the	  corresponding	  recombinant	  protein	  was	  expressed	  in	  E.	  coli	  TOP10	  cells	  (Invitrogen)	  under	  the	  control	  of	  an	  IPTG-­‐inducible	  promoter.	  All	  recombinant	  proteins	  were	  partially	  purified	  from	  cellular	  extracts	  by	  Ni2+-­‐NTA-­‐agarose	  chromatography	  (Qiagen),	  followed	  by	  FPLC	  using	  a	  HiTrapQ	  anion	  exchange	  column	  (Amersham).	  The	  His6-­‐tag	  was	  removed	  by	  using	  Thrombin	  Cleavage	  Capture	  Kit	  (Novagen),	  and	  the	  protein	  was	  further	  purified	  by	  FPLC	  using	  a	  HiTrapQ	  anion	  exchange	  column.	  The	  toxin-­‐containing	  fractions	  were	  then	  concentrated	  by	  using	  Centricon	  filter	  units	  (Millipore,	  MWCO	  =	  30	  kDa	  for	  the	  truncated	  mutants	  and	  100	  kDa	  for	  the	  full-­‐length	  toxins)	  and	  desalted	  by	  a	  PD-­‐10	  column	  (Amersham)	  using	  phosphate-­‐buffered	  saline	  (PBS,	  10	  mM	  phosphate,	  137	  mM	  NaCl,	  2.7	  mM	  KCl,	  pH	  7.4)	  containing	  10%	  glycerol.	  Protein	  concentrations	  of	  the	  resulting	  purified	  proteins	  (Figure	  1)	  were	  determined	  by	  quantitative	  digital	  image	  analysis	  using	  NIH	  ImageJ	  software	  of	  SDS-­‐PAGE	  gels	  stained	  with	  Pierce	  GelCode	  Blue	  and	  using	  bovine	  serum	  albumin	  (BSA)	  as	  the	  protein	  standard.	  The	  toxin	  samples	  were	  flash-­‐frozen	  and	  stored	  at	  −80°C	  until	  used.	  Biological	  activity	  of	  purified	  full-­‐length	  PMT	  was	  confirmed	  as	  previously	  described	  [22],	  with	  an	  EC50	  value	  of	  2	  ng/mL.	  	  	  
3.2.3.	  Biotin	  Labeling	  of	  Toxin	  	  Biotin	  labeling	  of	  toxin	  proteins	  was	  performed	  as	  follows.	  Stock	  solutions	  of	  purified	  PMT-­‐GFP,	  PMT-­‐N-­‐GFP	  or	  PMT-­‐N	  were	  diluted	  with	  PBS	  containing	  10%	  glycerol	  to	  obtain	  a	  final	  concentration	  of	  250	  nM,	  to	  that	  we	  added	  0.2	  mg	  of	  NHS-­‐biotin	  (Invitrogen)	  dissolved	  in	  dimethyl	  sulfoxide	  (DMSO)	  up	  to	  25%	  of	  final	  volume.	  The	  mixture	  was	  vortexed	  immediately	  to	  disperse	  the	  reagents	  and	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incubated	  at	  room	  temperature	  for	  at	  least	  1	  hour	  with	  gentle	  shaking,	  followed	  by	  passing	  through	  a	  PD-­‐10	  desalting	  column	  to	  equilibrate	  in	  PBS	  containing	  10%	  glycerol.	  The	  concentration	  of	  the	  resulting	  biotin-­‐labeled	  protein	  was	  determined,	  as	  describe	  above,	  and	  aliquots	  were	  flash-­‐frozen	  and	  stored	  at	  -­‐80°C	  until	  use.	  	  
3.2.4.	  Cell	  Culture	  Swiss	  3T3	  cells	  (ATCC#	  CCL-­‐92)	  were	  cultured	  at	  37°C	  and	  5%	  CO2	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	  (DMEM,	  GIBCO)	  medium,	  supplemented	  with	  10%	  heat-­‐inactivated	  bovine	  growth	  serum	  (BGS,	  HyClone),	  pH	  7.4,	  and	  containing	  100	  units/mL	  penicillin	  G	  and	  100	  µg/mL	  streptomycin.	  For	  transient	  transfection	  experiments,	  cells	  were	  plated	  onto	  6-­‐well	  plates	  at	  70-­‐80%	  confluence	  24	  hrs	  prior	  to	  transfection.	  Transfection	  was	  performed	  using	  TransIT-­‐LT1	  reagent	  (Mirus),	  according	  to	  the	  manufacturer’s	  protocol.	  	  In	  short,	  250	  μL	  of	  serum-­‐free	  Opti-­‐MEM	  was	  mixed	  with	  7.5	  μL	  TransIT-­‐LT1	  Reagent	  by	  pipetting	  gently	  and	  2.5	  μg	  plasmid	  DNA	  was	  added	  to	  the	  mixture	  and	  incubated	  at	  room	  temperature	  for	  15-­‐30	  min.	  During	  the	  incubation,	  the	  medium	  from	  each	  well	  was	  replaced	  with	  fresh	  DMEM	  supplemented	  with	  10%	  BGS,	  and	  the	  TransIT-­‐LT1	  Reagent-­‐DNA	  complex	  was	  added	  to	  the	  cells.	  Medium	  was	  replaced	  after	  24	  hrs.	  Two	  days	  later,	  transfection	  efficiency	  was	  determined	  by	  visualization	  using	  an	  Olympus	  IX-­‐70	  inverted	  fluorescence	  microscope	  equipped	  with	  a	  digital	  camera	  (Olympus	  DP70)	  or	  Zeiss	  Axiovert	  200M	  inverted	  fluorescence	  microscope.	  	  
3.2.5.	  Fluorescence	  Microscopy	  Swiss	  3T3	  cells,	  cultured	  as	  above,	  were	  plated	  onto	  cover	  slips	  placed	  in	  a	  12-­‐well	  plate	  at	  a	  cell	  density	  of	  30–50%	  and	  incubated	  in	  DMEM	  supplemented	  with	  2%	  BGS	  overnight	  at	  37°C	  and	  5%	  CO2.	  Cells	  were	  treated	  with	  the	  indicated	  GFP-­‐fusion	  proteins	  at	  a	  final	  concentration	  of	  685	  nM	  for	  the	  indicated	  times.	  The	  cells	  were	  washed	  three	  times	  with	  PBS	  and	  fixed	  with	  3.7%	  formaldehyde	  in	  DMEM	  supplemented	  with	  10%	  BGS	  for	  15	  min	  at	  room	  temperature,	  followed	  by	  washing	  three	  times	  with	  PBS	  before	  mounting	  on	  slides	  and	  visualization	  using	  fluorescence	  microscopy	  (as	  above)	  or	  confocal	  fluorescence	  microscopy	  (Leica	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Microsystems	  TCS	  SP2	  laser	  scanning	  spectral	  confocal	  fluorescence	  microscope).	  All	  the	  experiments	  shown	  were	  repeated	  independently	  at	  least	  three	  times.	  	  
3.2.6.	  Toxin	  Treatment	  of	  Cells	  Swiss	  3T3	  cells,	  cultured	  as	  above,	  were	  plated	  onto	  6-­‐well	  plates	  at	  a	  density	  of	  0.3	  x	  106	  cells/well	  and	  incubated	  at	  37°C	  and	  5%	  CO2	  for	  two	  days	  prior	  to	  toxin	  treatment.	  Cells	  were	  cooled	  on	  ice	  (4°C),	  and	  medium	  was	  replaced	  with	  fresh	  cold	  DMEM	  supplemented	  with	  10%	  BGS	  containing	  PMT-­‐GFP,	  PMT-­‐N-­‐GFP	  or	  PMT-­‐N,	  or	  GFP	  or	  horseradish	  peroxidase	  (HRP)	  alone	  as	  controls,	  and	  incubated	  on	  ice	  for	  30	  min.	  The	  toxin-­‐treated	  cells	  were	  then	  incubated	  at	  37°C	  for	  the	  indicated	  times.	  	  For	  experiments	  involving	  treatment	  with	  cytochalasin	  D	  (200	  µM	  stock	  solution	  dissolved	  in	  DMSO,	  Sigma,	  C8273),	  and	  bafilomycin	  A1	  (1	  µM	  stock	  solution	  dissolved	  in	  DMSO,	  Enzo	  Life	  Sciences)	  or	  NH4Cl	  (1M	  stock	  solution	  dissolved	  in	  H2O,	  
J.	  T.	  Baker),	  the	  cells	  were	  first	  exposed	  to	  the	  indicated	  reagents	  at	  the	  indicated	  concentrations	  for	  the	  indicated	  times	  prior	  to	  toxin-­‐GFP	  treatment.	  In	  short,	  the	  medium	  was	  replaced	  with	  fresh	  warm	  (37°C)	  DMEM	  supplemented	  with	  10%	  BGS,	  followed	  by	  addition	  of	  the	  reagent.	  The	  cells	  were	  incubated	  at	  37°C	  for	  1	  hour	  (cytochalasin	  D)	  or	  20	  min	  (bafilomycin	  A1	  or	  NH4Cl).	  The	  plate	  was	  then	  removed	  from	  the	  incubator	  and	  placed	  on	  ice.	  The	  toxin	  was	  added	  to	  the	  medium	  and	  the	  cells	  were	  incubated	  on	  ice	  for	  30	  min	  before	  returning	  to	  the	  incubator	  (37°C)	  for	  4	  hours.	  	  For	  experiments	  involving	  pronase	  (Sigma)	  treatment,	  the	  toxin-­‐treated	  cells	  were	  washed	  three	  times	  with	  cold	  PBS	  and	  then	  incubated	  with	  0.5	  mg/mL	  pronase	  in	  cold	  PBS	  for	  5	  min	  on	  ice,	  followed	  by	  three	  washes	  with	  cold	  PBS	  containing	  1	  mM	  benzamidine	  (Fisher),	  1	  mM	  phenylmethanesulfonyl	  fluoride	  (PMSF)	  (Amresco)	  and	  protease	  inhibitor	  cocktail	  (PI,	  Sigma,	  a	  mixture	  consisting	  of	  4-­‐(2-­‐aminoethyl)benzenesulfonyl	  fluoride,	  bestatin,	  pepstatin	  A,	  E-­‐64,	  and	  phosphoramidon).	  	  For	  experiments	  involving	  full-­‐length	  toxin	  (PMT-­‐HA),	  after	  two	  days	  post	  plating,	  the	  medium	  was	  replaced	  with	  fresh	  DMEM	  supplemented	  with	  10%	  BGS	  containing	  PMT-­‐HA	  and	  then	  incubated	  at	  37°C	  for	  4	  hours.	  After	  the	  toxin	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treatment,	  cells	  were	  washed	  twice	  with	  PBS	  (2	  min	  each),	  replaced	  with	  fresh	  DMEM	  supplemented	  with	  10%	  BGS	  without	  toxin,	  incubated	  at	  37°C	  for	  30	  min,	  washed	  three	  times	  with	  PBS	  (2	  min	  each),	  and	  then	  washed	  once	  with	  cold	  PBS	  before	  harvesting	  the	  cells.	  For	  all	  types	  of	  treatments,	  the	  cells	  were	  collected	  and	  analyzed	  using	  a	  subcellular	  fractionation	  method	  (see	  3.2.7.).	  All	  the	  experiments	  shown	  were	  repeated	  independently	  at	  least	  three	  times.	  	  
3.2.7.	  Subcellular	  Gradient	  Fractionation	  Swiss	  3T3	  cells	  were	  cultured,	  plated,	  and	  treated	  as	  described	  above.	  The	  cells	  were	  collected	  in	  cold	  PBS,	  then	  centrifuged	  for	  2-­‐3	  min	  at	  3,000	  x	  g,	  4°C	  to	  pellet	  the	  cells.	  The	  cell	  pellets	  were	  resuspended	  in	  0.5	  mL	  homogenization	  buffer	  (250	  mM	  sucrose,	  0.5	  mM	  EDTA	  containing	  PI)	  and	  homogenized	  at	  4°C	  by	  30	  passages	  through	  a	  263/8-­‐gauge	  needle	  fitted	  using	  a	  1-­‐mL	  plastic	  syringe.	  The	  homogenate	  was	  centrifuged	  for	  10	  min	  at	  800	  x	  g,	  4°C	  to	  separate	  cell	  pellet,	  comprised	  of	  nuclei	  and	  cell	  debris,	  and	  supernatant	  (intracellular	  fraction),	  comprised	  of	  organelles	  and	  cytosolic	  components	  (Axis-­‐Shield).	  Intracellular	  fraction	  was	  then	  applied	  to	  an	  OptiPrep	  (Axis-­‐Shield)	  gradient	  by	  mixing	  the	  fraction	  with	  a	  60%	  stock	  solution	  of	  OptiPrep	  to	  bring	  the	  fraction-­‐containing	  solution	  to	  a	  final	  concentration	  of	  50%.	  The	  mixture	  was	  loaded	  on	  the	  bottom	  of	  the	  gradient	  and	  40,	  30,	  20,	  and	  10%	  solutions	  of	  OptiPrep	  were	  loaded	  sequentially	  on	  top.	  The	  gradient	  mixture	  was	  centrifuged	  for	  18	  hours	  at	  100,000	  x	  g,	  4°C	  using	  a	  SW-­‐40	  rotor.	  Fractions	  (1	  mL	  each)	  were	  collected	  from	  the	  top	  (fraction	  #1,	  low	  density)	  to	  the	  bottom	  (fraction	  #12,	  high	  density),	  and	  200-­‐µL	  portions	  of	  each	  of	  the	  fractions	  were	  used	  for	  trichloroacetic	  acid	  (TCA)	  precipitation	  (final	  concentration	  of	  10%	  TCA	  solution,	  50%	  by	  volume).	  Samples	  were	  resolubilized	  in	  100	  mM	  Tris-­‐HCl	  buffer,	  pH	  9,	  and	  subjected	  to	  SDS-­‐PAGE	  and	  Western	  blot	  analysis	  (see	  3.2.8.).	  	  For	  subsequent	  subcellular	  fractionations,	  the	  intracellular	  fraction	  was	  further	  centrifuged	  for	  1	  hour	  at	  100,000	  x	  g,	  4°C	  using	  a	  TH-­‐660	  rotor	  to	  enrich	  for	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the	  microsomal	  fraction	  (vesicle	  fraction),	  comprised	  of	  organelles	  (Axis-­‐Shield),	  while	  the	  cytosolic	  proteins	  remained	  in	  the	  supernatant	  (cytosolic	  fraction)	  (Axis-­‐
Shield).	  The	  fractions	  (vesicle	  and	  cytosolic)	  were	  then	  further	  subjected	  to	  gradient	  fractionation.	  The	  gradient	  was	  setup	  as	  mentioned	  above	  and	  the	  mixture	  was	  centrifuged	  for	  18	  hours	  at	  100,000	  x	  g.	  Fractions	  (0.4	  mL	  each)	  were	  collected	  from	  the	  top	  to	  the	  bottom,	  and	  each	  of	  the	  fractions	  was	  used	  for	  TCA	  precipitation,	  as	  above.	  Samples	  were	  resolubilized	  and	  subjected	  to	  SDS-­‐PAGE	  and	  Western	  blot	  analysis,	  as	  mentioned	  above.	  All	  the	  experiments	  shown	  were	  repeated	  independently	  at	  least	  three	  times.	  	  
3.2.8.	  Western	  Blot	  Analysis	  Protein	  samples	  from	  above	  were	  separated	  by	  10%	  SDS-­‐PAGE,	  transferred	  to	  polyvinyl	  difluoride	  (PVDF)	  membranes	  (Pall	  Life	  Sciences)	  and	  analyzed	  by	  Western	  blot,	  using	  standard	  procedures.	  The	  following	  primary	  antibodies	  were	  used	  against	  the	  proteins:	  anti-­‐mouse	  monoclonal	  GFP	  (sc9996,	  Santa	  Cruz	  
Biotechnology),	  anti-­‐rabbit	  polyclonal	  EEA1	  (E4156,	  Sigma),	  anti-­‐mouse	  monoclonal	  β-­‐tubulin	  (sc53140,	  Santa	  Cruz	  Biotechnology),	  and	  anti-­‐mouse	  monoclonal	  HA	  (26183,	  Thermo	  Scientific).	  Specific	  protein	  bands	  were	  visualized	  by	  ECL	  Plus	  System	  (GE	  Life	  Sciences)	  using	  appropriate	  HRP-­‐conjugated	  secondary	  antibodies:	  goat	  anti-­‐mouse	  for	  GFP,	  β-­‐tubulin	  and	  HA	  or	  donkey	  anti-­‐rabbit	  for	  EEA1	  (Santa	  
Cruz	  Biotechnology,	  Sigma).	  For	  Swiss	  3T3	  cells	  treated	  with	  the	  resulting	  biotin-­‐labeled	  toxin	  proteins,	  cellular	  extracts	  were	  prepared	  and	  analyzed	  by	  Western	  blot	  using	  anti-­‐mouse	  monoclonal	  GFP	  (sc9996,	  Santa	  Cruz	  Biotechnology)	  or	  StrepTactin-­‐HRP	  conjugate	  antibodies	  (#161-­‐0381,	  Bio-­‐Rad).	  Blots	  were	  scanned	  using	  HP	  Scanjet	  G4050	  scanner,	  and	  images	  were	  trimmed	  using	  Adobe	  Photoshop.	  	  	  
3.2.9.	  GFP	  Emission	  Profiles	  The	  GFP	  emission	  profile	  (λex	  =	  395	  nm,	  λem	  max	  =	  510	  nm)	  of	  each	  subcellular	  fraction	  (200	  µL)	  was	  recorded	  between	  450	  nm	  –	  600	  nm	  using	  a	  fluorescence	  microplate	  reader	  (Spectramax	  M2,	  Molecular	  Devices).	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3.3.	  Results	  	  
3.3.1.	  Translocation	  of	  PMT-­‐C	  into	  Host	  Cell	  Cytosol	  I	  first	  asked	  whether	  the	  entire	  C-­‐terminus	  of	  PMT	  (PMT-­‐C)	  or	  only	  a	  portion	  of	  the	  C-­‐terminus	  gets	  translocated	  and/or	  is	  released	  into	  the	  host	  cell	  cytosol.	  To	  address	  this	  question,	  I	  utilized	  HA-­‐tagged	  PMT	  (PMT-­‐HA)	  to	  examine	  toxin	  trafficking	  within	  cells	  by	  subcellular	  and	  gradient	  fractionation	  and	  Western	  blotting.	  Swiss	  3T3	  cells	  were	  exposed	  to	  PMT-­‐HA	  and	  microsomal	  enrichment	  was	  performed	  to	  separate	  cellular	  extracts,	  initially	  into	  two	  fractions:	  the	  cell	  pellet	  (containing	  nucleus	  and	  large	  organelles	  and	  cellular	  debris)	  and	  the	  supernatant	  (intracellular	  fraction,	  containing	  vesicles	  and	  soluble	  cytosolic	  components).	  The	  intracellular	  fraction	  was	  then	  further	  separated	  into	  a	  microsomal	  pellet	  (vesicle	  fraction,	  comprised	  of	  vesicles)	  and	  the	  supernatant	  (cytosolic	  fraction,	  containing	  soluble	  cytosolic	  components).	  Intact	  full-­‐length	  toxin	  was	  detected	  in	  the	  cell	  pellet	  (not	  shown),	  intracellular	  and	  vesicle	  fractions,	  but	  not	  detected	  in	  the	  cytosolic	  fraction	  (Figure	  2A).	  Instead,	  a	  smaller	  HA-­‐tag-­‐containing	  fragment	  with	  a	  molecular	  size	  of	  ~80-­‐kDa,	  corresponding	  to	  intact	  PMT-­‐C	  (C1-­‐C2-­‐C3)	  with	  a	  C-­‐terminal	  HA-­‐tag,	  was	  observed	  in	  the	  cytosolic	  fraction	  (Figure	  2A).	  Interestingly,	  there	  were	  no	  other	  fragments	  observed	  in	  the	  cytosolic	  fraction,	  including	  any	  corresponding	  to	  the	  C2-­‐C3	  or	  C3	  domains	  alone.	  This	  80-­‐kDa	  fragment	  was	  also	  present	  in	  the	  other	  vesicle-­‐containing	  fractions,	  indicating	  that	  the	  toxin	  gets	  internalized	  and	  processed	  to	  produce	  a	  fragment	  comprised	  of	  PMT-­‐C	  that	  subsequently	  gets	  delivered	  intact	  into	  the	  cytosol.	  Moreover,	  processing	  of	  PMT-­‐HA	  and	  cytosolic	  delivery	  of	  PMT-­‐C-­‐HA	  was	  blocked	  when	  cells	  were	  treated	  with	  NH4Cl	  to	  prevent	  endosomal	  acidification	  (Figure	  2B).	  	  
3.3.2.	  PMT-­‐N-­‐GFP	  Is	  Internalized	  and	  Localizes	  within	  Early	  Endosomes	  	  We	  previously	  showed	  that	  PMT-­‐N	  fused	  with	  GFP	  at	  the	  C-­‐terminus	  (PMT-­‐N-­‐GFP)	  is	  taken	  up	  through	  receptor-­‐mediated	  endocytosis	  and	  localizes	  in	  endosomes	  [15].	  We	  used	  confocal	  fluorescence	  microscopy	  to	  confirm	  this	  by	  examining	  in	  more	  detail	  the	  localization	  and	  trafficking	  of	  PMT-­‐N-­‐GFP	  in	  Swiss	  3T3	  cells	  transfected	  with	  various	  organelle-­‐specific	  fluorescent	  DsRed-­‐fusion	  protein	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markers	  (Figure	  3	  and	  4).	  After	  3	  hours	  of	  exposure,	  the	  majority	  of	  PMT-­‐N-­‐GFP	  appeared	  to	  localize	  to	  early	  endosomes	  (Figure	  3).	  However,	  the	  colocalization	  signal	  decreased	  over	  time,	  such	  that	  by	  24	  hrs	  most	  of	  the	  GFP	  signal	  was	  found	  in	  non-­‐endosomal	  vesicles	  (Figure	  4).	  Localization	  of	  PMT-­‐N-­‐GFP	  to	  other	  organelles	  was	  not	  observed	  (Figure	  4).	  This	  result	  indicates	  that	  PMT	  goes	  through	  the	  endosomes	  at	  earlier	  time	  points	  but	  passes	  through	  the	  endosomes	  and	  localizes	  to	  a	  different	  subcellular	  compartment	  after	  some	  time.	  	  
	  
3.3.3.	  After	  Internalization	  the	  GFP	  Cargo	  Is	  Cleaved	  and	  Delivered	  into	  the	  Cytosol	  I	  next	  asked	  if	  this	  PMT-­‐N-­‐GFP	  fusion	  protein	  could	  deliver	  the	  GFP	  cargo	  into	  the	  cytosol	  of	  host	  cells.	  To	  address	  this,	  I	  examined	  the	  dose-­‐	  and	  time-­‐dependent	  uptake	  of	  PMT-­‐N-­‐GFP	  into	  Swiss	  3T3	  cells	  by	  Western	  blot	  analysis	  of	  cell	  extracts	  separated	  into	  cell	  pellet	  and	  intracellular	  fractions	  (Figure	  5).	  Within	  30	  min	  of	  exposure	  to	  the	  toxin	  a	  stable	  GFP-­‐containing	  protein	  fragment	  with	  molecular	  size	  of	  ~26-­‐kDa	  appeared	  in	  the	  intracellular	  fraction,	  as	  detected	  by	  anti-­‐GFP	  antibody.	  This	  fragment	  accumulated	  over	  time	  (Figure	  5A),	  while	  the	  amount	  of	  full-­‐length	  fusion	  protein	  remained	  relatively	  constant.	  This	  indicated	  that	  a	  fragment	  of	  the	  PMT-­‐N-­‐GFP	  protein	  comprised	  of	  GFP	  accumulated	  inside	  the	  cells.	  These	  results	  were	  also	  dose	  dependent	  (Figure	  5B).	  Uptake	  and	  processing	  of	  PMT-­‐N-­‐GFP	  to	  generate	  the	  GFP-­‐containing	  fragment	  was	  inhibited	  by	  cytochalasin	  D	  (Figure	  5C).	  Uptake	  of	  GFP	  alone	  by	  the	  host	  cells	  was	  also	  possible,	  but	  only	  at	  much	  higher	  concentrations	  (Figure	  5D).	  To	  determine	  the	  subcellular	  localization	  of	  the	  intact	  toxin	  and	  toxin	  fragments,	  the	  intracellular	  fraction	  was	  subjected	  to	  further	  separation	  by	  density	  gradient	  fractionation	  using	  ultracentrifugation,	  followed	  by	  Western	  blot	  analysis	  (Figure	  6).	  The	  gradient	  distribution	  pattern	  of	  the	  intact	  PMT-­‐N-­‐GFP	  and	  the	  smaller	  GFP-­‐containing	  fragment	  revealed	  localization	  of	  the	  proteins	  to	  different	  subcellular	  compartments	  (Figure	  6,	  top	  panels).	  The	  intact	  PMT-­‐N-­‐GFP	  protein	  remained	  confined	  to	  the	  low-­‐density	  vesicle	  fractions,	  as	  evidenced	  by	  colocalization	  with	  EEA1-­‐positive	  fractions	  (Figure	  6,	  bottom	  panels).	  On	  the	  contrary,	  most	  of	  the	  cleaved	  GFP-­‐containing	  fragment	  was	  found	  in	  the	  denser	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cytosolic	  fractions,	  as	  evidenced	  by	  localization	  in	  β-­‐tubulin	  positive	  fractions,	  and	  a	  much	  smaller	  amount	  localized	  to	  the	  vesicle	  fraction.	  Preventing	  endosomal	  acidification	  with	  NH4Cl	  or	  bafilomycin	  A1	  (Figure	  6,	  middle	  panels)	  blocked	  proteolysis	  of	  the	  PMT-­‐N-­‐GFP	  such	  that	  intact	  protein	  remained	  in	  the	  EEA1-­‐positive	  endosomal	  fractions	  and	  in	  turn	  prevented	  delivery	  of	  the	  cleaved	  GFP	  cargo	  into	  the	  β-­‐tubulin-­‐positive	  cytosolic	  fractions	  (Figure	  6,	  bottom	  panels).	  Similar	  results	  were	  obtained	  when	  the	  intracellular	  fraction	  was	  further	  separated	  into	  the	  microsomal	  pellet	  (vesicles)	  and	  supernatant	  (cytosolic)	  fractions	  by	  high-­‐speed	  centrifugation	  prior	  to	  gradient	  fractionation	  (Figure	  7A).	  Control	  GFP	  alone	  also	  could	  be	  taken	  up	  by	  cells	  as	  delivered	  into	  the	  cytosolic	  fraction,	  but	  again	  only	  at	  10-­‐fold	  higher	  concentrations	  (Figure	  7B).	  In	  fact,	  when	  side-­‐by-­‐side	  experiment	  was	  done	  to	  show	  the	  efficient	  delivery	  of	  cargo	  by	  PMT-­‐N-­‐GFP,	  control	  GFP	  alone	  failed	  to	  transport	  GFP	  into	  the	  cytosol	  (Figure	  7C).	  Further	  separation	  of	  the	  vesicle	  and	  cytosolic	  fractions	  by	  density	  gradient	  fractionation	  using	  ultracentrifugation	  revealed	  that	  cytosolic	  fraction	  contained	  only	  GFP-­‐containing	  cleaved	  fragments	  (no	  full-­‐length	  protein).	  On	  the	  other	  hand,	  the	  vesicle	  fraction	  contained	  both	  full-­‐length	  protein	  and	  GFP-­‐containing	  cleaved	  fragments	  (Figure	  8).	  Moreover,	  inhibition	  of	  endosomal	  acidification	  by	  increasing	  concentrations	  of	  NH4Cl	  blocked	  the	  appearance	  of	  cleaved	  GFP-­‐containing	  fragments	  in	  both	  the	  vesicle	  fractions	  and	  the	  cytosolic	  fractions	  (Figure	  7A	  and	  8).	  Unlike	  GFP,	  the	  larger	  HRP	  (~44-­‐kDa)	  remained	  in	  the	  vesicle	  fractions	  and	  was	  not	  found	  in	  the	  cytosolic	  fractions	  when	  introduced	  extracellularly	  (compare	  Figure	  7B	  with	  8,	  bottom	  panels).	  The	  observed	  distribution	  pattern	  also	  did	  not	  change	  when	  the	  cells	  were	  exposed	  briefly	  to	  externally	  applied	  pronase	  after	  toxin	  treatment	  for	  4	  hrs	  (Figure	  9A).	  While	  pronase	  degraded	  the	  toxin	  that	  remained	  extracellularly,	  internalized	  PMT-­‐N-­‐GFP	  protein	  that	  was	  localized	  in	  endosomes	  was	  protected	  in	  large	  part	  from	  the	  protease	  treatment	  (Figure	  9B).	  These	  results	  suggest	  that	  a	  significant	  amount	  of	  toxin	  remains	  bound	  to	  the	  cell	  surface,	  even	  after	  repeated	  washes	  before	  processing,	  but	  is	  removed	  by	  pronase	  treatment.	  These	  results	  also	  indicate	  that	  upon	  cellular	  uptake,	  intact	  toxin	  is	  found	  in	  the	  vesicle	  fractions,	  but	  then	  most	  of	  the	  intact	  toxin	  follows	  the	  endocytic	  pathway	  and	  upon	  lowering	  of	  the	  pH,	  GFP	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is	  cleaved	  and	  delivered	  to	  the	  cytosol,	  where	  it	  accumulates.	  A	  small	  portion	  of	  the	  PMT-­‐N-­‐GFP	  may	  also	  traffic	  to	  lysosomes	  and	  be	  degraded,	  as	  indicated	  by	  the	  presence	  of	  GFP-­‐containing	  fragments	  in	  the	  vesicle	  fractions	  (Figure	  9B).	  	  
	  
3.3.4.	  N-­‐Terminal	  Fragments	  of	  PMT-­‐N-­‐GFP	  Remain	  Inside	  Vesicles	  After	  Translocation	  I	  next	  asked	  what	  happens	  to	  the	  PMT-­‐N	  after	  translocation	  of	  the	  cargo.	  Since	  placing	  an	  HA-­‐tag	  at	  the	  N-­‐terminus	  of	  PMT	  interfered	  with	  binding	  to	  host	  cells	  (data	  not	  shown),	  I	  turned	  to	  utilizing	  PMT-­‐GFP,	  PMT-­‐N-­‐GFP	  and	  PMT-­‐N	  to	  address	  this	  question.	  To	  determine	  the	  fate	  of	  the	  polypeptides	  PMT-­‐GFP,	  PMT-­‐N-­‐GFP,	  PMT-­‐N	  and	  their	  fragments	  after	  the	  translocation	  event,	  they	  were	  labeled	  with	  biotin.	  Swiss	  3T3	  cells	  were	  exposed	  to	  these	  biotinylated	  toxins,	  and	  cellular	  extracts	  were	  subjected	  to	  subcellular	  fractionation	  by	  high-­‐speed	  centrifugation	  into	  cell	  pellet,	  intracellular,	  microsomal	  pellet	  and	  cytosolic	  fractions.	  As	  expected,	  Western	  blot	  analysis	  using	  anti-­‐GFP	  antibody	  detected	  intact	  toxin	  only	  in	  the	  vesicle-­‐containing	  cell	  pellet,	  intracellular	  and	  vesicle	  fractions,	  whereas	  the	  small	  fragment,	  corresponding	  to	  released	  GFP	  cargo,	  was	  present	  in	  all	  fractions,	  but	  mostly	  in	  the	  cytosolic	  fraction,	  indicating	  that	  the	  small	  fragment	  was	  translocated	  to	  the	  cytosol	  (Figure	  10A).	  No	  other	  larger	  or	  smaller	  bands	  were	  detected.	  These	  fractions	  were	  also	  analyzed	  by	  blotting	  with	  StrepTactin-­‐HRP	  conjugate	  for	  visualization	  of	  biotin-­‐labeled	  protein	  fragments	  (Figure	  10B),	  further	  confirming	  the	  delivery	  of	  the	  small	  fragment	  of	  ~26-­‐kDa	  (corresponding	  to	  GFP)	  into	  the	  cytosolic	  fraction	  and	  the	  localization	  of	  PMT-­‐N	  (66-­‐kDa)	  and	  various	  smaller	  PMT-­‐N-­‐related	  fragments	  in	  the	  vesicle-­‐containing	  fractions.	  Full-­‐length	  PMT-­‐GFP	  (175-­‐kDa)	  likewise	  delivered	  GFP	  cargo	  (Figures	  10C,	  D	  and	  E)	  as	  well	  as	  a	  fragment	  corresponding	  to	  the	  80-­‐kDa	  C-­‐terminal	  C1-­‐C2-­‐C3	  domains	  into	  the	  cytosolic	  fraction	  (observed	  upon	  longer	  exposures,	  Figure	  10E).	  Additionally,	  when	  the	  integrity	  of	  GFP	  fluorescence	  of	  each	  fraction	  was	  examined	  using	  a	  fluorescence	  microplate	  reader,	  the	  cytosolic	  fraction	  retained	  significant	  fluorescence	  due	  to	  the	  presence	  of	  intact,	  folded	  GFP	  (Figure	  10F).	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3.4.	  Discussion	  In	  contrast	  to	  some	  well-­‐characterized	  AB	  toxins,	  such	  as	  diphtheria	  toxin	  [6,	  12],	  the	  botulinum	  neurotoxins	  [1,	  4,	  17,	  18],	  cholera	  toxin	  [8],	  pertussis	  toxin	  [9,	  10,	  11],	  and	  the	  anthrax	  toxins	  [7,	  23],	  the	  mechanism	  by	  which	  PMT	  mediates	  delivery	  of	  its	  cognate	  activity	  cargo	  modules	  remains	  largely	  unknown.	  To	  date,	  very	  limited	  biochemical	  information	  is	  available	  for	  the	  N-­‐terminus.	  To	  this	  end,	  I	  sought	  to	  gain	  further	  insight	  about	  the	  cargo	  delivery	  process	  for	  PMT	  by	  asking	  three	  questions:	  (1)	  What	  is	  the	  structural	  makeup	  of	  the	  cargo	  that	  is	  delivered	  to	  the	  host	  cell	  cytosol?	  (2)	  What	  are	  the	  cellular	  and	  protein	  determinants	  that	  facilitate	  cargo	  delivery?	  (3)	  What	  happens	  to	  the	  delivery	  vehicle	  after	  the	  cargo	  is	  delivered?	  To	  address	  the	  first	  question,	  I	  utilized	  an	  HA-­‐tagged	  PMT	  (PMT-­‐HA)	  to	  examine	  the	  subcellular	  localization	  and	  nature	  of	  the	  protein	  after	  internalization	  in	  Swiss	  3T3	  cells	  (i.e.,	  did	  the	  protein	  remain	  intact	  or	  was	  it	  processed	  to	  smaller	  fragments	  and	  where	  were	  those	  smaller	  fragments	  located?).	  I	  find	  that	  during	  intoxication	  processing	  of	  the	  toxin	  occurs	  to	  produce	  a	  smaller	  HA-­‐tagged	  fragment	  that	  was	  subsequently	  translocated	  into	  the	  cytosol,	  while	  intact	  toxin	  remained	  in	  the	  endosomal	  vesicles	  (Figure	  2).	  The	  size	  of	  this	  delivered	  cargo	  was	  approximately	  80-­‐kDa,	  corresponding	  to	  the	  intact	  C-­‐terminus	  of	  PMT	  (PMT-­‐C,	  residues	  569-­‐1285)	  comprised	  of	  all	  three	  activity	  modules	  (C1-­‐C2-­‐C3).	  Noteworthy	  is	  that	  no	  other	  larger	  or	  smaller	  fragments	  with	  the	  HA-­‐tag	  were	  observed.	  Furthermore,	  preventing	  endosomal	  acidification	  blocked	  the	  delivery	  of	  the	  cargo.	  Taken	  together,	  these	  results	  support	  a	  mechanism	  whereby	  after	  internalization	  and	  trafficking	  to	  endosomes	  PMT	  is	  proteolytically	  processed,	  and	  then	  translocates	  and	  releases	  its	  C-­‐terminal	  cargo	  as	  an	  intact	  moiety	  into	  the	  cell	  cytosol.	  This	  delivered	  cargo	  would	  then	  presumably	  target	  the	  plasma	  membrane	  via	  its	  C1	  membrane	  localization	  module	  so	  that	  the	  C3	  glutamine	  deamidase	  domain	  can	  gain	  access	  to	  the	  membrane-­‐bound	  heterotrimeric	  G-­‐protein	  substrate,	  as	  depicted	  in	  Figure	  11.	  To	  address	  the	  second	  question,	  I	  first	  utilized	  a	  recombinant	  fusion	  protein	  of	  PMT-­‐N,	  harboring	  the	  delivery	  vehicle	  module(s),	  with	  GFP	  at	  its	  C-­‐terminus	  (PMT-­‐N-­‐GFP)	  to	  examine	  trafficking	  inside	  Swiss	  3T3	  cells.	  Our	  results	  indicate	  that	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PMT-­‐N-­‐GFP	  traffics	  through	  the	  endosomes	  at	  earlier	  time	  points,	  but	  subsequently	  localizes	  to	  other	  subcellular	  vesicular	  compartments,	  such	  as	  lysosomes,	  as	  evidenced	  by	  the	  colocalization	  of	  the	  toxin	  and	  early	  endosomes	  wanes	  over	  time	  such	  that	  GFP	  signal	  is	  found	  in	  other	  vesicles	  (Figure	  3	  and	  4).	  To	  determine	  if	  the	  GFP	  cargo	  is	  delivered	  after	  internalization	  of	  PMT-­‐N-­‐GFP,	  I	  examined	  the	  subcellular	  localization	  of	  GFP	  in	  cells	  by	  Western	  blot.	  Results	  shown	  in	  Figure	  5	  revealed	  that	  while	  intact	  PMT-­‐N-­‐GFP	  remained	  at	  relatively	  constant	  levels	  in	  vesicle-­‐containing	  fractions,	  a	  fragment	  corresponding	  to	  the	  GFP	  cargo	  accumulated	  inside	  cells	  in	  a	  dose-­‐	  and	  time-­‐dependent	  manner.	  Appearance	  of	  this	  GFP-­‐containing	  fragment	  was	  dependent	  on	  trafficking	  of	  PMT-­‐N-­‐GFP	  to	  early	  endosomes,	  as	  cytochalasin	  D	  blocked	  its	  formation	  while	  not	  interfering	  with	  the	  levels	  of	  intact	  protein	  in	  the	  intracellular	  fraction.	  Moreover,	  when	  the	  cellular	  extracts	  were	  further	  fractionated	  into	  vesicles	  and	  cytosolic	  components,	  the	  majority	  of	  the	  GFP-­‐containing	  fragment	  was	  confined	  to	  the	  cytosolic	  fractions	  (Figure	  7),	  while	  the	  intact	  toxin	  remained	  in	  the	  vesicle	  fractions.	  This	  distribution	  pattern	  did	  not	  change	  when	  the	  cells	  were	  treated	  with	  pronase	  after	  exposure	  to	  PMT-­‐N-­‐GFP	  (Figure	  9).	  Pronase	  treatment	  appeared	  to	  have	  degraded	  protein	  that	  remained	  extracellular,	  while	  internalized	  toxin	  localized	  in	  endocytic	  vesicles	  was	  protected	  from	  the	  proteolysis.	  	  Our	  results	  further	  demonstrate	  that	  upon	  uptake	  into	  endocytic	  vesicles,	  (1)	  the	  intact	  toxin	  or	  toxin-­‐derived	  delivery	  vehicle	  undergoes	  proteolytic	  processing	  and	  (2)	  the	  cargo	  is	  delivered	  into	  the	  cytosol	  (either	  endogenous	  PMT-­‐C	  cargo	  or	  exogenous	  GFP	  cargo,	  respectively).	  Moreover,	  this	  delivery	  process	  involves	  a	  pH-­‐dependent	  translocation	  step,	  as	  the	  appearance	  of	  the	  cleaved	  PMT-­‐C	  fragment	  or	  the	  GFP-­‐containing	  fragment	  decreases	  with	  inhibition	  of	  endosomal	  acidification	  by	  treatment	  with	  bafilomycin	  A1	  or	  NH4Cl.	  These	  results	  are	  consistent	  with	  previous	  studies	  that	  showed	  PMT	  traffics	  to	  late	  endosomes,	  where	  PMT	  translocates	  its	  activity	  cargo	  into	  the	  cytosol	  through	  a	  pH-­‐dependent	  process	  [2,	  3,	  15,	  16].	  The	  presence	  of	  a	  small	  amount	  of	  cleaved	  cargo	  fragments	  in	  vesicle-­‐containing	  fractions	  suggests	  that	  either	  the	  cargo	  is	  processed	  prior	  to	  translocation	  in	  late	  endosomes,	  or	  alternatively,	  a	  portion	  of	  the	  toxin	  is	  trafficked	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to	  lysosomal	  vesicles,	  following	  degradation	  pathway.	  A	  proposed	  model	  for	  these	  trafficking	  events	  is	  depicted	  in	  Figure	  11.	  To	  address	  the	  third	  question,	  I	  examined	  the	  fate	  of	  N-­‐terminus	  of	  biotin-­‐labeled	  PMT-­‐N,	  PMT-­‐N-­‐GFP,	  and	  PMT-­‐GFP	  after	  internalization	  by	  Swiss	  3T3	  cells.	  I	  demonstrated	  that	  while	  most	  of	  the	  cargo	  (GFP,	  PMT-­‐C)	  is	  delivered	  intact	  into	  the	  cytosol	  (Figure	  10),	  the	  N-­‐terminal	  portion	  of	  the	  toxin	  gets	  further	  processed	  into	  multiple,	  smaller	  fragments,	  which	  remain	  associated	  within	  vesicles.	  The	  observation	  that	  these	  smaller	  PMT-­‐N-­‐derived	  fragments	  appear	  to	  be	  relatively	  stable,	  discrete	  entities	  suggests	  that	  they	  may	  correspond	  to	  possible	  subdomains	  of	  the	  toxin	  involved	  in	  cell	  receptor	  binding	  and/or	  translocation	  functions.	  	   In	  summary,	  the	  work	  shown	  here	  further	  define	  the	  trafficking	  pathway	  of	  PMT	  and	  how	  the	  toxin	  delivers	  cargo	  (exogenous	  and	  endogenous)	  into	  the	  host	  cell:	  N-­‐terminal	  PMT	  (1-­‐568)	  is	  capable	  of	  delivering	  a	  cargo	  protein	  (GFP,	  PMT-­‐C)	  into	  host	  cytosol	  and	  the	  N-­‐terminal	  fragment	  of	  the	  toxin	  (1-­‐568)	  is	  sufficient	  for	  the	  delivery.	  Additionally,	  I	  showed	  that	  the	  C-­‐terminal	  domain	  (or	  cargo)	  gets	  delivered	  as	  a	  single	  unit	  and	  does	  not	  get	  further	  processed.	  Upon	  delivery	  of	  the	  C-­‐terminus	  to	  the	  cytosol,	  the	  cargo	  presumably	  localizes	  to	  the	  membrane	  using	  the	  C1	  membrane	  localization	  domain	  to	  bring	  the	  C3	  deamidase	  module	  in	  close	  proximity	  to	  its	  target,	  a	  membrane-­‐bound	  heterotrimeric	  G-­‐protein.	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3.5.	  Figures	  
	  
Figure	  3.1.	  Recombinant	  toxin	  proteins	  used	  in	  this	  study.	  	  (A)	  Schematic	  of	  recombinant	  proteins	  used	  in	  this	  study.	  Black	  bars	  indicate	  where	  His-­‐tags	  were	   introduced.	   Stripe	   box	   indicates	  where	   HA-­‐tag	  was	   introduced.	   (B)	  Representative	  GelCode	  Blue-­‐stained	  10%	  SDS-­‐PAGE	   gels	   of	   purified	   recombinant	  proteins	   used	   in	   this	   study:	   PMT-­‐GFP,	   PMT-­‐HA,	   PMT-­‐N-­‐GFP	   and	   PMT-­‐N	   (where	  N=1-­‐568).	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Figure	   3.5.	   Time	   and	   dose	   dependence	   of	   PMT-­‐N-­‐GFP	   internalization	   and	  
accumulation	  in	  cells.	  	  Shown	   are	   Western	   blots	   using	   anti-­‐GFP	   antibody	   to	   detect	   localization	   of	   GFP-­‐containing	  protein	  bands	   in	   cellular	  pellet	  and	   intracellular	   fractions	   from	  cellular	  extracts	  of	  Swiss	  3T3	  cells	  treated	  with	  the	  indicated	  concentrations	  of	  PMT-­‐N-­‐GFP	  for	   the	   indicated	   length	   of	   time:	   (A)	   Time	   dependence	   of	   PMT-­‐N-­‐GFP	   (250	   nM)	  internalization	  and	  processing.	  (B)	  Dose	  dependence	  of	  PMT-­‐N-­‐GFP	  internalization	  and	   processing	   after	   4	   hours.	   (C)	   Dose-­‐dependent	   inhibition	   of	   PMT-­‐N-­‐GFP	   (250	  nM)	   processing	   to	   smaller	   GFP-­‐containing	   fragments	   by	   cytochalasin	   D	   (µM).	   (D)	  Dose	   dependence	   of	   GFP	   (alone	   as	   control)	   internalization	   after	   4	   hrs.	   Arrows	  indicate	   the	   protein	   bands	   corresponding	   to	   intact	   PMT-­‐N-­‐GFP	   and	   arrowheads	  indicate	  the	  bands	  corresponding	  to	  GFP	  or	  GFP-­‐containing	  cleaved	  fragment.	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Figure	   3.6.	   PMT-­‐N-­‐GFP-­‐mediated	   delivery	   of	   GFP	   cargo	   into	   cytosol	   via	   pH-­‐














Figure	   3.7.	   PMT-­‐N-­‐GFP-­‐mediated	   delivery	   of	   GFP	   cargo	   into	   cytosol	   via	   pH-­‐



















Figure	   3.8.	   PMT-­‐N-­‐GFP-­‐mediated	   delivery	   of	   GFP	   cargo	   into	   cytosol	   via	   pH-­‐































Figure	  3.9.	  Effect	  of	  pronase	  treatment	  on	  the	  subcellular	  distribution	  of	  PMT-­‐

















Figure	  3.10.	  	  
	  
(A,	   B)	   Subcellular	   localization	   of	   biotin-­‐labeled	   PMT-­‐N-­‐GFP,	   PMT-­‐N,	   or	   PMT-­‐

















Figure	  3.10.	  continued	  
	  	  
(C,	   D,	   E,	   F)	   Subcellular	   localization	   of	   biotin-­‐labeled	   PMT-­‐N-­‐GFP,	   PMT-­‐N,	   or	  






























Figure	   3.11.	   Proposed	   model	   of	   PMT-­‐mediated	   delivery	   of	   toxic	   activity	  
modules	  into	  host	  cells.	  	  Shown	   is	   a	   schematic	   diagram	   depicting	   the	   steps	   involved	   in	   PMT	   intoxication:	  binding	   to	   cell	   receptors	   via	   the	   N-­‐terminus,	   entry	   via	   receptor-­‐mediated	  endocytosis,	  trafficking	  through	  endosomes,	  translocation	  of	  intact	  C-­‐terminal	  cargo	  (toxic	   activity	   modules	   or	   other	   cargo)	   upon	   endosomal	   acidification,	   release	   of	  cargo	  into	  cytosol,	  and	  targeting	  of	  the	  deamidase	  activity	  module	  C3	  to	  the	  plasma	  membrane	  via	  C1,	  where	  the	  heterotrimeric	  G-­‐protein	  substrates	  of	  the	  C3	  module	  are	   located.	   During	   the	   intoxication	   process,	   a	   portion	   of	   the	   toxin	   is	   further	  trafficked	   to	   lysosomes,	   where	   further	   degradation	   may	   occur.	   The	   N-­‐terminal	  delivery	  vehicle	  portion	  of	  the	  toxin	  remains	  behind	  in	  the	  endocytic	  vesicle	  and	  is	  perhaps	  recycled	  back	  to	  the	  surface	  or	  further	  degraded,	  presumably	  by	  trafficking	  to	  lysosomes.	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Chapter	  4:	  	  Conclusions	  and	  Future	  Directions	  This	  thesis	  aimed	  to	  investigate	  two	  major	  questions	  concerning	  toxin	  action.	  The	  first	  aim	  was	  to	  dissect	  the	  involvement	  of	  three	  members	  of	  the	  dermonecrotic	  toxin	  family,	  PMT,	  CNF1	  and	  DNT,	  in	  signal	  transduction	  pathways	  involving	  adipogenesis.	  The	  second	  aim	  was	  to	  provide	  further	  insight	  into	  the	  mechanism	  of	  PMT	  intoxication	  by	  examining	  the	  cellular	  and	  protein	  determinants	  involved	  in	  trafficking	  and	  translocation	  of	  cargo	  into	  the	  host	  cell	  cytosol.	  	  
4.1.	  Toxin	  Action	  on	  Adipogenesis	  We	  previously	  demonstrated	  that	  PMT	  blocks	  adipogenesis	  and	  adipocyte	  differentiation	  through	  suppression	  of	  Notch1	  and	  stabilization	  of	  β-­‐catenin	  and	  Pref1/Dlk1	  [1].	  This	  PMT-­‐mediated	  inhibition	  of	  adipogenesis	  does	  not	  occur	  exclusively	  through	  its	  known	  activation	  of	  Gq-­‐PLCβ1-­‐dependent	  calcium	  signaling	  [1].	  In	  this	  thesis,	  I	  focused	  on	  the	  Rho/ROCK	  signaling	  pathway	  as	  an	  alternative	  route	  through	  which	  toxin-­‐mediated	  inhibition	  of	  adipogenesis	  occurs.	  Additionally,	  I	  compared	  PMT	  action	  with	  that	  of	  other	  dermonecrotic	  toxins	  CNF1	  and	  DNT	  to	  further	  characterize	  toxin	  involvement	  in	  this	  pathway.	  Our	  data	  show	  that	  treatment	  with	  any	  one	  of	  the	  dermonecrotic	  toxins	  blocked	  adipogenesis	  (no	  lipid	  accumulation)	  and	  inhibited	  adipocyte	  differentiation	  (downregulation	  of	  adipocyte	  differentiation	  specific	  markers)	  through	  Rho/ROCK-­‐dependent	  pathway,	  suggesting	  an	  important	  role	  of	  the	  Rho/ROCK	  pathway	  in	  the	  regulation	  of	  adipocyte	  differentiation	  and	  adipogenesis.	  Differences	  in	  the	  levels	  of	  Rho/ROCK	  inhibition	  of	  signaling	  by	  each	  of	  the	  toxins	  may	  be	  a	  result	  of	  differences	  in	  their	  cellular	  targets:	  DNT	  and	  the	  CNFs	  act	  directly	  on	  Rho	  proteins,	  while	  PMT	  acts	  on	  heterotrimeric	  G	  proteins	  that	  are	  upstream	  of	  the	  Rho	  proteins.	  As	  shown,	  CNF1-­‐	  and	  DNT-­‐	  mediated	  inhibition	  of	  Rho/ROCK	  signaling	  displayed	  stronger	  effects,	  compared	  to	  that	  of	  PMT,	  suggesting	  that	  additional	  pathways	  mediate	  the	  action	  of	  PMT.	  Knockdown	  studies	  confirm	  that	  PMT-­‐mediated	  downregulation	  of	  Notch1	  does	  not	  occur	  through	  Rho/ROCK	  or	  Gαq	  signaling,	  but	  instead	  occur	  through	  the	  G12/13	  pathway.	  
	  110	  
For	  possible	  directions	  of	  future	  research,	  we	  can	  expand	  our	  study	  to	  the	  remaining	  dermonecrotic	  toxins	  and	  how	  they	  affect	  adipogenesis.	  As	  the	  remaining	  CNFs	  share	  amino	  acid	  sequence	  similarities	  with	  CNF1,	  we	  would	  suspect	  they	  might	  behave	  similarly.	  In	  addition,	  it	  would	  be	  interesting	  to	  examine	  the	  differences	  between	  DNT	  and	  CNFs.	  Though	  they	  share	  the	  same	  intracellular	  targets,	  the	  entry	  and	  trafficking	  pathway	  is	  different:	  cell	  surface	  receptors	  and	  uptake	  mechanisms	  are	  different.	  More	  importantly,	  the	  translocation	  step	  could	  involve	  either	  a	  pH-­‐independent	  or	  a	  pH-­‐dependent	  pathway.	  Additionally,	  the	  fact	  that	  disruption	  of	  trafficking	  pathways	  by	  commercially	  available	  drugs	  leads	  to	  differential	  toxin	  activity	  on	  their	  targets	  indicates	  they	  have	  distinct	  mechanisms	  [32].	  	   Results	  from	  these	  experiments	  will	  help	  us	  gain	  a	  better	  understanding	  of	  adipogenesis	  and	  adipocyte	  differentiation,	  in	  particular	  a	  better	  definition	  of	  the	  role	  of	  Rho/ROCK	  signaling	  pathway.	  In	  addition,	  this	  will	  also	  help	  us	  delineate	  the	  role	  of	  Rho	  proteins	  in	  contrast	  to	  heterotrimeric	  G	  proteins	  in	  the	  adipogenesis	  pathway.	  Furthermore,	  it	  will	  also	  help	  us	  gain	  better	  understanding	  of	  Rho/ROCK	  signaling	  contribution	  to	  mitogenic	  pathways	  and	  the	  molecular	  dynamics	  of	  these/certain	  cellular	  processes	  in	  cells.	  	  	  
4.2.	  Toxins	  as	  Carcinogens	  The	  data	  presented	  in	  this	  thesis	  add	  to	  the	  accumulating	  evidence	  that	  exposure	  to	  toxin-­‐producing	  bacteria	  might	  predispose	  infected	  individuals	  to	  possible	  long-­‐term	  adverse	  outcomes,	  including	  cancer.	  Pathways	  that	  we	  examined	  here	  (i.e.	  Wnt/β-­‐catenin,	  Pref1/Dlk1	  and	  Notch1	  signaling	  pathways)	  are	  strongly	  linked	  to	  cancer	  predisposition	  [14,	  30,	  34],	  neurological	  and	  immunological	  dysfunctions	  [4,	  13,	  43],	  and	  fat	  and	  bone	  developmental	  disorders	  [31,	  38,	  44].	  Moreover,	  the	  cellular	  effects	  of	  the	  dermonecrotic	  toxins	  have	  been	  implicated	  as	  risk	  factors	  for	  cancer	  development	  [18,	  26,	  27,	  36,	  42]	  because	  of	  their	  effects	  on	  Rho-­‐GTPases	  signaling	  pathways	  and	  the	  induction	  of	  anti-­‐apoptotic	  (Bcl-­‐2)	  and	  pro-­‐inflammatory	  (NF-­‐kB	  and	  COX-­‐2)	  protein	  expression	  [6,	  7,	  17,	  27,	  36].	  Once	  again,	  PMT	  exhibits	  oncogenic	  characteristics	  as	  it	  affects	  mitogenic	  (Erk	  and	  p38	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MAPK)	  and	  anti-­‐apoptotic	  (JAK/STAT	  and	  Akt)	  signaling	  processes	  in	  many	  cell	  types	  [18,	  19,	  26,	  27,	  41,	  42].	  These	  cells	  include	  fibroblasts	  (mouse,	  rat	  and	  human)	  [11,	  26,	  28,	  40],	  preadipocytes	  [1]	  and	  osteoblasts	  [9,	  10,	  22,	  23,	  35].	  Overall,	  this	  evidence	  points	  toward	  a	  role	  of	  chronic	  and/or	  previous	  exposure	  to	  bacterial	  pathogens	  in	  cancer	  predisposition	  [18,	  24,	  37]	  and	  immune	  modulation	  [3].	  Bacterial	  infections	  and	  the	  consequent	  chronic	  exposure	  to	  their	  effector	  proteins/toxins	  directly	  and	  specifically	  disrupt	  normal	  cell	  functions.	  Dysregulation	  of	  cell	  function	  and	  growth	  through	  pathways	  mentioned	  above	  may	  lead	  to	  uncontrolled	  cell	  proliferation.	  Thus,	  studying	  a	  role	  of	  the	  dermonecrotic	  toxins	  in	  these	  pathways	  and	  understanding	  how	  they	  intertwine	  could	  help	  us	  dissect	  the	  possible	  function	  of	  these	  toxins	  with	  respect	  to	  cancer	  development.	  	  
4.3.	  Toxin	  Trafficking	  	  Though	  recent	  studies	  allowed	  us	  to	  begin	  understanding	  the	  trafficking	  pathway	  of	  PMT,	  we	  still	  do	  not	  know	  much	  about	  the	  N-­‐terminus	  of	  PMT.	  In	  this	  study,	  we	  addressed	  specific	  questions	  to	  further	  examine	  the	  toxin	  and	  its	  trafficking	  pathway:	  (1)	  What	  portion	  of	  the	  toxin	  gets	  transported	  into	  the	  host	  cytosol?	  (2)	  What	  cellular	  and/or	  protein	  components	  facilitate	  the	  process?	  (3)	  What	  is	  the	  nature	  of	  the	  toxin	  after	  the	  delivery?	  Our	  data	  presented	  here	  better	  outlined	  the	  trafficking	  pathway	  of	  PMT	  and	  how	  the	  toxin	  delivers	  its	  activity	  domain	  into	  the	  host	  cell:	  Using	  an	  HA-­‐tag	  at	  the	  C-­‐terminus	  of	  PMT	  (PMT-­‐HA),	  the	  subcellular	  localization	  and	  nature	  of	  the	  protein	  after	  internalization	  in	  Swiss	  3T3	  cells	  were	  examined.	  Data	  from	  this	  experiment	  presented	  the	  first	  evidence	  that	  delivery	  of	  C-­‐terminus	  takes	  place	  from	  late	  endosomes	  and	  the	  release	  of	  endogenous	  cargo	  revealed	  an	  intact	  moiety	  corresponding	  to	  the	  entire	  activity	  domain.	  Investigation	  of	  toxin	  trafficking	  using	  the	  N-­‐terminus	  of	  PMT	  (1-­‐568)	  as	  a	  fusion	  with	  exogenous	  cargo	  (GFP)	  elucidated	  early	  steps	  of	  trafficking:	  initial	  localization	  to	  early	  endosomes	  and	  subsequent	  localization	  to	  other	  subcellular	  vesicular	  compartments	  such	  as	  lysosomes.	  Furthermore,	  PMT-­‐N-­‐GFP	  delivery	  of	  the	  GFP	  cargo	  inside	  cells	  was	  dose-­‐	  and	  time-­‐dependent.	  Moreover,	  upon	  the	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delivery	  of	  cargo,	  N-­‐terminal	  toxin	  remained	  in	  the	  vesicle.	  Both	  full-­‐length	  and	  N-­‐terminal	  toxins	  transferred	  most	  of	  the	  cargo	  (GFP,	  PMT-­‐C)	  intact	  into	  the	  cytosol	  (Chapter	  3,	  Figure	  10),	  and	  the	  N-­‐terminal	  portion	  of	  the	  toxin	  gets	  further	  processed	  into	  multiple,	  smaller	  fragments,	  which	  remain	  associated	  within	  vesicles.	  	  The	  results	  support	  a	  mechanism	  whereby	  after	  internalization	  and	  trafficking	  to	  the	  endosomes,	  PMT	  proteolytically	  gets	  processed,	  and	  subsequently	  translocates	  to	  release	  its	  C-­‐terminal	  cargo	  (endogenous	  or	  exogenous	  cargo)	  as	  an	  intact	  moiety	  into	  the	  cell	  cytosol.	  This	  delivered	  cargo	  would	  then	  presumably	  target	  the	  plasma	  membrane	  via	  its	  C1	  membrane	  localization	  module	  to	  bring	  the	  C3	  glutamine	  deamidase	  module	  to	  the	  membrane-­‐bound	  heterotrimeric	  G-­‐protein	  substrate	  (Chapter	  3,	  Figure	  11).	  Since	  the	  C1	  domain,	  harboring	  a	  membrane-­‐targeting	  motif	  [15],	  was	  shown	  to	  recruit	  the	  rest	  of	  the	  C-­‐terminal	  portion	  of	  PMT	  to	  the	  plasma	  membrane	  using	  a	  four	  helical	  bundle	  (residues	  590-­‐670)	  [8,	  15],	  this	  translocation	  model	  further	  corroborates	  the	  current	  model.	  This	  thesis	  enabled	  us	  to	  answer	  some	  of	  the	  important	  questions	  about	  the	  trafficking	  pathway,	  specifically	  the	  translocation	  step.	  However,	  the	  overall	  picture	  of	  how	  PMT	  gains	  access	  to	  host	  cells,	  how	  the	  translocation	  step	  is	  initiated	  (besides	  the	  requirement	  of	  proteolytic	  event),	  and	  how	  the	  cargo	  is	  delivered	  into	  the	  cytosol	  is	  sill	  not	  complete.	  I	  believe	  that	  in	  future	  studies,	  the	  elucidation	  of	  the	  exact	  cleavage	  site	  would	  be	  key.	  As	  the	  proteolytic	  event	  seems	  to	  be	  important,	  introduction	  of	  a	  mutation	  to	  block	  the	  process	  should	  prevent	  PMT	  from	  intoxicating	  the	  host.	  It	  would	  also	  be	  exciting	  to	  study	  how	  PMT	  delivers	  its	  cargo	  into	  the	  cytosol.	  As	  many	  of	  other	  known	  AB	  toxins	  seem	  to	  go	  through	  partial	  unfolding	  event	  to	  transport	  their	  activity	  moiety,	  exploring	  the	  difference	  between	  their	  mechanism	  versus	  PMT	  would	  be	  challenging	  but	  might	  open	  up	  the	  door	  to	  an	  entirely	  new	  field.	  Moreover,	  I	  envision	  addressing	  the	  nature	  of	  the	  cargo,	  as	  well	  as	  characterizing	  the	  N-­‐terminus	  that	  remains	  associated	  with	  vesicles	  after	  the	  delivery	  of	  the	  cargo	  into	  the	  host	  cytosol.	  Since	  we	  still	  do	  not	  know	  the	  binding	  and	  translocation	  domains	  of	  PMT,	  delineating	  that	  aspect	  of	  toxin	  action	  will	  help	  us	  gain	  better	  understanding	  of	  the	  binding	  and	  translocation	  process.	  It	  would	  also	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be	  interesting	  to	  examine	  other	  types	  of	  cargos	  and/or	  non-­‐cleavable	  GFP	  cargo	  as	  an	  alternative.	  Since	  the	  GFP	  fusion	  toxin	  seemed	  to	  get	  processed	  before	  the	  translocation,	  we	  can	  examine	  the	  translocation	  process	  better	  if	  we	  use	  non-­‐cleavable	  version	  of	  GFP	  or	  a	  form	  of	  GFP	  that	  cannot	  traverse	  membranes	  on	  its	  own.	  Other	  types	  of	  cargos	  that	  we	  can	  examine	  are	  antibodies	  and	  other	  fluorescent	  molecules	  (examples	  discussed	  in	  section	  4.4).	  Furthermore,	  other	  GFP	  variants	  could	  be	  considered.	  GFP	  has	  been	  explored	  as	  a	  cargo	  and	  shown	  to	  be	  capable	  of	  crossing	  plasma	  membrane	  when	  mutated	  as	  a	  “supercharged”	  protein	  [21].	  Although	  we	  did	  not	  use	  supercharged	  GFP,	  it	  seems	  GFP	  alone	  can	  get	  across	  plasma	  membrane	  when	  higher	  concentrations	  of	  protein	  are	  used.	  Therefore,	  we	  could	  try	  other	  fluorescent	  proteins	  as	  alternative	  cargos.	  In	  addition,	  we	  would	  like	  to	  make	  our	  current	  GFP	  to	  be	  non-­‐cleavable	  so	  that	  we	  can	  ask	  questions	  regarding	  the	  process	  of	  translocation.	  	  
4.4.	  Toxins	  as	  a	  Delivery	  Vehicle	  Over	  the	  past	  few	  decades,	  researchers	  have	  begun	  to	  exploit	  modular	  toxins	  for	  therapeutic	  applications	  as	  delivery	  vehicles	  for	  various	  therapeutic	  cargos.	  For	  instance,	  the	  catalytic	  and	  translocation	  domains	  of	  diphtheria	  toxin	  linked	  to	  antibodies	  directed	  against	  specific	  cell	  surface	  antigens	  are	  currently	  used	  as	  immunotoxins	  to	  treat	  certain	  cancers	  [29].	  The	  anthrax	  toxins	  and	  diphtheria	  toxin	  are	  currently	  being	  explored	  as	  vehicles	  for	  delivery	  of	  antigenic	  epitopes	  into	  host	  cells	  to	  stimulate	  cell-­‐mediated	  immune	  responses	  [2],	  while	  others	  such	  as	  cholera	  toxin,	  E.	  coli	  heat-­‐labile	  enterotoxin,	  and	  pertussis	  toxin	  are	  being	  tested	  as	  immunomodulatory	  adjuvants	  in	  mucosal	  vaccines	  [20].	  We,	  as	  well	  as	  others	  have	  demonstrated	  the	  utility	  of	  using	  botulinum	  neurotoxins	  as	  delivery	  vehicles	  for	  various	  therapeutic	  cargos	  [5,	  12,	  25,	  39].	  Results	  from	  our	  studies	  here	  provide	  additional	  insights	  into	  the	  modular	  nature	  of	  multi-­‐domain-­‐containing	  toxins,	  such	  as	  PMT,	  and	  how	  various	  activity	  cargos	  that	  are	  packaged	  as	  modular	  assemblies	  for	  cellular	  delivery	  during	  infection	  can	  be	  exploited	  for	  delivery	  of	  other	  types	  of	  cargo.	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4.5.	  Nature	  of	  Cargo	  Since	  the	  use	  of	  toxin	  as	  a	  potential	  therapeutic	  application	  has	  been	  examined,	  we	  cannot	  simply	  rule	  out	  the	  discussion	  about	  the	  importance	  of	  the	  nature	  of	  the	  cargo	  in	  facilitating	  delivery	  into	  the	  cytosol.	  Here,	  we	  chose	  our	  non-­‐native	  cargo	  molecule	  to	  be	  a	  GFP	  variant	  due	  to	  its	  stability	  and	  easy	  detection.	  The	  area	  of	  protein-­‐based	  therapeutics	  is	  now	  gaining	  more	  attention	  and	  importance	  because	  of	  the	  specificity	  and	  compatibility	  that	  they	  possess.	  The	  first	  requirement	  for	  intracellular	  cargo	  delivery	  is	  uptake	  by	  the	  host.	  We	  also	  need	  to	  be	  able	  to	  detect	  the	  cargo	  intracellularly	  to	  ascertain	  successful	  transport.	  Hence,	  incorporation	  of	  GFP	  gave	  us	  a	  useful	  means	  of	  detection.	  It	  enabled	  us	  to	  visualize	  the	  localization	  of	  the	  molecule	  and	  assess	  the	  retention	  of	  activity	  (i.e.,	  whether	  or	  not	  the	  protein	  was	  folded	  correctly).	  Though	  accumulating	  evidence	  on	  GFP	  as	  a	  molecular	  cargo	  gives	  us	  a	  promising	  outcome,	  we	  now	  must	  step	  closer	  to	  the	  goal	  of	  this	  area	  of	  research;	  start	  considering	  alternatives	  such	  as	  inhibitors	  to	  toxin	  or	  toxin	  activity	  to	  combat	  the	  disease	  outcome.	  This	  study	  helps	  us	  gain	  better	  knowledge	  about	  bacterial	  toxin	  entry	  mechanisms,	  which	  in	  turn	  will	  help	  us	  understand	  the	  molecular	  dynamics	  of	  cellular	  processes	  in	  cells.	  It	  also	  aids	  us	  in	  designing	  inhibitors	  to	  block	  intoxication	  by	  these	  toxins,	  as	  well	  as	  exploring	  further	  possibility	  of	  using	  them	  as	  delivery	  vehicles	  to	  transport	  new	  therapeutics	  into	  targeted	  cells.	  	  
4.6.	  Conclusion	  Overall,	  this	  thesis	  helped	  us	  better	  understand	  the	  dermonecrotic	  toxin	  action	  on	  cell	  signal	  transduction	  pathways	  and	  the	  trafficking	  pathway	  utilized	  by	  PMT	  to	  deliver	  its	  toxic	  cargo.	  The	  knowledge	  gained	  through	  this	  study	  helps	  us	  further	  our	  efforts	  in	  developing	  new	  therapeutics,	  hence	  contributing	  to	  scientific	  advancement.	  This	  study	  extended	  our	  current	  knowledge	  of	  the	  PMT	  action	  on	  adipogenesis	  to	  other	  members	  of	  the	  dermonecrotic	  toxin	  family	  and	  demonstrated	  that	  similar	  to	  PMT,	  DNT	  and	  CNF1	  downregulate	  key	  players	  of	  adipocyte	  differentiation,	  blocking	  adipogenesis.	  CNF1/DNT-­‐mediated	  inhibition	  of	  Rho/ROCK	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signaling	  was	  stronger	  because	  of	  Rho	  being	  the	  direct	  target	  of	  the	  toxins.	  On	  the	  other	  hand,	  PMT-­‐mediated	  inhibition	  of	  Rho/ROCK	  signaling	  was	  less	  prominent,	  pointing	  toward	  additional	  pathways	  mediating	  the	  action	  of	  PMT.	  In	  addition,	  we	  successfully	  characterized	  the	  pathway	  PMT	  uses	  to	  block	  adipogenesis:	  PMT	  uses	  activation	  of	  the	  G12/13	  pathway	  and	  not	  Rho/ROCK	  or	  Gαq	  signaling	  to	  downregulate	  notch1.	  This	  thesis	  also	  addressed	  an	  important	  aspect	  of	  the	  intoxication	  process	  and	  contributed	  to	  knowledge	  about	  the	  trafficking	  pathway	  of	  PMT:	  PMT	  traffics	  through	  early	  endosomes	  to	  late	  endosomes,	  where	  translocation	  of	  its	  C-­‐terminus	  takes	  place.	  PMT	  activity	  is	  sensitive	  to	  pH;	  lowering	  of	  pH	  is	  essential	  for	  successful	  delivery	  of	  the	  C-­‐terminus	  into	  the	  cytosol.	  We	  demonstrated	  that	  the	  N-­‐terminus	  remains	  in	  vesicles	  after	  the	  delivery	  of	  an	  intact	  C-­‐terminus.	  In	  summary,	  this	  thesis	  helped	  delineate	  the	  intracellular	  trafficking	  pathway	  for	  PMT	  delivery	  of	  its	  cargo.	  As	  mentioned	  above,	  to	  generate	  effective	  therapies	  for	  combatting	  diseases,	  we	  first	  need	  to	  understand	  what	  effects	  toxins	  have	  on	  the	  host	  as	  well	  as	  how	  they	  carry	  out	  those	  effects.	  The	  more	  we	  understand	  the	  specific	  and	  detailed	  mechanism	  by	  which	  toxins	  exploit	  cellular	  processes,	  the	  easier	  it	  would	  be	  to	  design	  new	  therapeutics.	  We	  can	  rationally	  design	  drugs	  that	  target	  specific	  areas	  or	  steps	  of	  the	  intoxication	  process,	  as	  we	  would	  need	  different	  therapies	  for	  different	  purposes,	  such	  as	  blocking	  entry,	  blocking	  translocation,	  or	  blocking	  activity.	  Toxin-­‐based	  therapy	  is	  already	  implemented	  in	  the	  area	  of	  cancer	  treatment	  [16,	  33].	  Knowledge	  of	  binding	  and	  entry	  is	  critical	  for	  generating	  novel	  therapeutics.	  This	  immunotoxin	  approach	  has	  advantages	  over	  other	  types	  of	  therapy	  due	  to	  its	  specificity	  in	  binding	  and	  entry	  into	  different	  cell	  types.	  PMT	  has	  been	  proven	  to	  be	  a	  health	  problem	  especially	  in	  agriculture,	  and	  now	  is	  implicated	  as	  a	  contributor	  to	  other	  diseases	  such	  as	  cancer.	  This	  study	  may	  have	  a	  great	  impact	  on	  laying	  the	  groundwork	  for	  designing	  therapeutics	  to	  prevent	  PMT-­‐induced	  diseases.	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